MRGPRX2 antagonists for the treatment of pseudoallergic reactions
By developing anti-allergic compounds with a fused ring structure, the shortcomings in the prior art for non-IgE-mediated pseudo-allergic diseases are solved, and effective prevention and treatment of pseudo-allergic reactions are achieved.
Patent Information
- Application Number
- CN202210608467.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-05-31
- Filing Date
- 2022-05-31
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-05-31
AI Technical Summary
The prior art lacks effective selective drugs to treat non-IgE-mediated pseudo-allergic diseases, and existing drugs are mainly symptomatic treatments, and cannot prevent or treat the underlying causes of pseudo-allergic reactions.
A synthetic compound as an antiallergic agent has two ring moieties containing a fused ring structure for the preparation of antiallergic drugs and pharmaceutical preparations, for prevention or Treatment of pseudoallergic diseases.
This compound can effectively inhibit the degranulation of mast cells and activation of MRGPRX2, reduce the release of inflammatory mediators, and provides a prevention and treatment plan for pseudo-allergic diseases.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Field of the Invention
[0001] The present invention is generally in the field of synthetic compounds and their use as antiallergic agents. Background Art
[0002] Allergic diseases are prevalent throughout the world and are common in all age groups. For example, in the United States, allergies are the sixth leading cause of chronic disease, affecting more than 50 million Americans and costing $18 billion annually. Allergic diseases are reported to be a rapidly growing disease with a high burden on the pediatric population. Pseudoallergy is an allergic reaction characterized by systemic and local symptoms similar to allergies. However, the MC activation mechanism of pseudoallergy is different from that of immunoglobulin E (IgE). Pseudoallergy, also known as non-IgE-mediated hypersensitivity, is usually triggered by an allergen or the first dose of a drug and results in local and systemic hypersensitivity reactions. Pseudoallergy does not induce an antigen-specific immune response, but causes histamine release, complement system activation, atypical synthesis of eicosanoids, and cytokine release. The signs and symptoms of pseudoallergy are virtually identical to those mediated by IgE, such as skin flushing, headache, edema, hypotension, angioedema, urticaria, bronchospasm, and gastrointestinal signs. Two-thirds of hypersensitivity reactions are pseudoallergic reactions; however, the lack of systematic research into the etiology and mechanisms is a major challenge in diagnosing and treating these reactions.
[0003] Mast cells (MCs) are tissue-resident innate immune cells, with the vast majority found primarily in external environmental barriers such as the skin and respiratory tract. MCs are known for their dense secretory granules, which contain several presynthesized mediators such as proteases and histamine. MC granules also release de novo synthesized mediators such as prostaglandins (PGs), chemokines, and cytokines. MCs can be rapidly activated by allergens, infectious agents, toxins, and drugs to release these mediators. The MC activation mechanism is cross-linking of the high-affinity immunoglobulin E (IgE) receptor (FcεRI); however, MCs can be activated by non-IgE pathways such as GPCRs, especially antibodies against the IgE receptor. Mas-related G protein-coupled receptor (GPCR) X2 (MRGPRX2) has been identified as a GPCR responsible for non-IgE-mediated allergic and inflammatory diseases. It has been reported that some endogenous peptides, allergens, infectious agents, toxins, and FDA-approved drugs (e.g., fluoroquinolone antibiotics, neuromuscular blockers, icatibant, opioids, diagnostic agents) induce allergic reactions through MRGPRX2 activation.
[0004] There are currently no selective drugs available to treat this type of allergy, and only symptomatic treatment options are available, including avoidance of allergens or emergency treatment with antihistamines, corticosteroids, and monoclonal antibodies against the IgE receptor. For example, currently available drugs such as epinephrine and antihistamines are strictly symptomatic solutions. In addition, some cases of allergies are not amenable to currently available treatments, and acute to severe allergic reactions cannot be treated. For example, MRGPRX2 can be activated by some ligands, including antibiotics, antimicrobial peptides, neuropeptides, ant venom peptides, and anesthetics. In addition, some endogenous ligands such as cathelicidin LL-37 and neuropeptide substance P can activate MRGPRX2 in response to infection and tissue damage. These ligands can activate MCs through MRGPRX2, induce and amplify inflammation, and play a role in mediating the pathophysiology of chronic diseases such as systemic urticaria, asthma, and rosacea. In addition, exogenous stimuli such as C48 / 80, ant venom peptides, and drugs (fluoroquinolone antibiotic neuromuscular blockers) have been reported to activate MC-MRGPRX2 and induce pseudoallergic reactions and inflammation.
[0005] Few MRGPRX2 antagonists have been reported recently, such as the peptide antagonist QWF, two small molecule compounds, and DNA aptamers. However, they have limitations in both pharmacology and pharmacology. For example, the limitations of QWF and DNA aptamers are plasma degradation and low bioavailability; they are rapidly degraded in plasma. Two small molecule compounds reported by Ogasawara et al. in the Journal of Leukocyte Biology in 2019 only showed in vitro antagonistic activity but failed to show ex vivo and in vivo antagonistic activity. There is no therapeutic strategy to treat the root cause of allergic reactions (mast cell degranulation).
[0006] There remains a need to develop anti-allergic compounds that can prevent or treat non-IgE-mediated pseudoallergy, allergic diseases and / or inflammatory diseases.
[0007] Therefore, an object of the present invention is to provide antiallergic compounds.
[0008] Another object of the present invention is to provide a method for preparing the antiallergic compound.
[0009] Another object of the present invention is to provide methods of using the anti-allergic compounds. Summary of the invention
[0010] Synthetic compounds as antiallergic agents and methods of their preparation and use are described.
[0011] Generally, the compound may have two ring portions, wherein each of the two ring portions contains a fused ring structure. In some forms, the compound may have a structure of Formula I:
[0012]
[0013] (a) wherein n is an integer from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 or ; (b) wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; (c) wherein A' and Z' are independently substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; and (d) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0014] In some forms of Formula I, wherein the compound has the structure:
[0015]
[0016] (a) wherein E' and G' are independently substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl;
[0017] (b) wherein J' is a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, or a substituted or unsubstituted polyheteroaryl group;
[0018] (c) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and
[0019] (d) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0020] In some forms of Formula I, n is zero.
[0021] In some forms of Formula I, A' can have the following structure:
[0022]
[0023] (a) wherein E' and G' are independently substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, or substituted or unsubstituted polyheteroaryl; (b) wherein Y' is independently CR1, O, S, or NR2 at each occurrence, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0024] In some forms of Formula I, A' can have the following structure:
[0025]
[0026] (a) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, and (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0027] In some forms of Formula I, A' can have the following structure:
[0028]
[0029] (a) wherein X' is C, N, O or S; (b) wherein R3 is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxy, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0030] In some forms of Formulas Va and Vb, (a) wherein X' is C or N; (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl, or halogen; and (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide, or oxo.
[0031] In some forms of formula Va and Vb, (a) wherein X' is C or N; (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxy, heterocyclyl, And R5 to R 10 (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0032] In some forms of Formulas Va and Vb, (a) wherein X' is C or N; (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, oxo, hydroxyl or carboxyl; and (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amido or oxo.
[0033] In some forms of Formula I, Z' can have the following structure:
[0034]
[0035] (a) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphonyl, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; (b) wherein J' is substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; and (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0036] In some forms of Formula I, Z' can have the following structure:
[0037]
[0038] (a) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, and (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0039] In some forms of Formula I, Z' can have the following structure:
[0040]
[0041] (a) wherein R4 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0042] In some forms of Formula IX, (a) wherein R4 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxy, heterocyclyl, And R5-R 10 (a) wherein the substituents are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino or halogen; and (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0043] In some forms of Formula IX, (a) wherein R4 at each occurrence is independently hydrogen, and R5 to R8 are independently hydrogen or substituted or unsubstituted alkyl; and (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0044] In some forms, the compound may have the following structure:
[0045]
[0046] Disclosed are pharmaceutical compositions and pharmaceutical preparations suitable for delivering the compound in unit dosage form and their preparation. In general, the pharmaceutical composition or preparation contains one or more compounds and a suitable pharmaceutically acceptable excipient. The amount of the compound in the pharmaceutical composition or preparation can be an amount that effectively prevents or treats pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease in a subject in need thereof or treats or alleviates one or more symptoms associated with pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease. In some forms, in addition to the compound, the pharmaceutical composition or preparation may also contain one or more active agents, such as one or more additional antiallergic agents or one or more additional anti-inflammatory agents or a combination thereof.
[0047] The method for preparing a compound disclosed herein may include: (i) mixing a reactant mixture with a catalyst to form a reaction mixture, wherein the reactant mixture comprises a first reactant, a second reactant, and a solvent; and (ii) heating the reaction mixture at a suitable temperature for a period of time sufficient to form a product comprising the compound, wherein step (i) may be performed before step (ii) or simultaneously with step (ii).
[0048] In some forms of the method, the first reactant may have the following structure:
[0049]
[0050] (a) wherein a is an integer from 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 or 1; (b) wherein R' and R" are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphonyl, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; (c) wherein A' is substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; (d) wherein R 11 is a halogen or has the following structure:
[0051]
[0052] Where R 12 is independently hydrogen or substituted or unsubstituted alkyl at each occurrence; and (e) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxy, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0053] In some forms of the method, the second reactant may have the following structure:
[0054]
[0055] (a) wherein b is an integer from 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 or 1; (b) wherein R' and R" are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; (c) wherein Z' is substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; (d) wherein R 13 is trifluoromethanesulfonate ("OTf") or has the structure of Formula XIV; and (e) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amido, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0056] In some forms of the method, the solvent used in step (i) can be water, dioxane, dimethoxyethane, 2-methyltetrahydrofuran, cyclopentyl methyl ether, tetrahydrofuran, tert-butyl methyl ether or dichloromethane or a combination thereof. In some forms of the method, the catalyst can be PdCl2(dppf), PdCl2(dppf)DCM complex, Tetrakis, PdCl2(PPh3)2, XPhos Pd G3 and Pd(OAc)2 / PPh3 and a combination thereof.
[0057] In some forms of the method, in step (ii), the reaction mixture can be heated at a temperature in the range of 50°C to 150°C, 60°C to 150°C, 70°C to 150°C, 80°C to 150°C, 50°C to 140°C, 50°C to 120°C, 70°C to 120°C, 80°C to 120°C, such as about 100°C, for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 8 hours, at least 10 hours, up to 20 hours, up to 18 hours, up to 16 hours, a time in the range of 1 hour to 18 hours, 2 hours to 16 hours, or 2 hours to 15 hours to form a product containing the compound.
[0058] In some forms, the method further comprises mixing the first reactant, the second reactant, and the solvent to form a reactant mixture prior to step (i), purging the reactant mixture with an inert gas prior to step (ii), stirring the reaction mixture during step (ii) and / or purifying a product containing the compound.
[0059] The method of using the compound in a subject in need for preventing or treating pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease or treating or alleviating one or more symptoms associated with pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease may include administering a pharmaceutical preparation comprising one or more compounds to the subject. The administration step may be performed once or multiple times. The subject is typically a mammal, such as a human. In some forms of the method, the pharmaceutical preparation may be administered orally, parenterally, by inhalation, by mucosal administration, by topical use, or a combination thereof.
[0060] In some forms of the methods, following a single administration or more than one administration of the pharmaceutical formulation to the subject, an effective amount of a compound is administered to the subject to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage and / or prevent or reduce MC degranulation in the subject.
[0061] In some forms, the method further comprises administering to the subject a second active agent, optionally more than one second active agent, before, during and / or after step (i). The second active agent may be an anti-allergic agent or an anti-inflammatory agent or a combination thereof.
[0062] Also disclosed is a method of treating mast cells in a subject in need thereof. The method may include: (i) administering to the subject a pharmaceutical formulation containing one or more compounds, wherein step (i) is performed one or more times.
[0063] In some forms of the methods, an effective amount of a compound is administered to a subject to inhibit MC degranulation, inhibit MRGPRX2 activation, reduce calcium cations ("Ca 2+") in MCs, following a single administration or more than one administration of the drug formulation to the subject, compared to cells in a control not treated with the compound tested under the same conditions. 2+ ”) flux and / or reduction in the release of inflammatory chemokines and / or cytokines. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1A is a 3D representation of genistein at the binding site showing the N-terminal amino acid residue of MRGPRX2. Figure 1B is a 3D amino acid interaction map showing the interaction of genistein at the binding site of the N-terminal amino acid residue of MRGPRX2. Figure 1Cis a 3D representation of the pharmacophore developed from the genistein binding site on MRGPRX2.
[0065] Figure 2A is the Ramachandran plot, indicating that 98.8% of the amino acid residues are in the favorable region, while there are three residues in the outlier region. Figure 2B is a schematic diagram showing a 2D receptor-drug interaction view of ZINC72453573 with MRGPRX2. The receptor amino acid residues are represented as circles with the amino acid name and number, with ZINC72453573 at the center. The negatively charged residues GLU164 and ASP184 are highlighted with arrows. Figure 2C is a schematic diagram showing a 2D receptor-drug interaction view of the C48 / 80 and MRGPRX2 models.
[0066] Figures 3A-3H Is to show genistein ( Figure 3A )、C48 / 80( Figure 3B ) and the small molecule antagonist GE0117 ( Figure 3C )、GE0118( Figure 3D )、GE0119( Figure 3E )、GE1109 ( Figure 3F )、GE1110( Figure 3G ) and GE1111( Figure 3H ) Schematic diagram of the 3D and 2D binding postures and amino acid interaction map of MRGPRX2.
[0067] Figure 4A It is a bar graph showing the antagonistic effect of small molecule compound antagonists on MC degranulation. Figure 4B is a bar graph showing the antagonistic effect of small molecule compound antagonists on MRGPRX2 activation. Figure 4C is a graph showing the dose response curve of C48 / 80 by MC degranulation. Figure 4D is a graph showing the dose response curve of C48 / 80 by MRGPRX2 activation assay. In the MC degranulation and MRGPRX2 activation assay, the EC of C48 / 80 50 The EC values of C48 / 80 were 4.61 μM and 2.85 μM, respectively. 90 It is ~10μM. Figure 4E is a bar graph showing MC degranulation in the absence of C48 / 80. Figure 4F is a bar graph showing MRGPRX2 activation assay in the absence of C48 / 80. Data are presented as mean ± SEM of three independent experiments, ****P < 0.0001 compared to control (C48 / 80).
[0068] Figure 5A-5G It is to show the antagonistic activity and IC of small molecule antagonists 50 The dose response curve (DRC) was performed by MC degranulation assay. Human LAD-2 MC was treated with graded concentrations of the small molecule compound antagonist GE0117 ( Figure 5A )、GE0118( Figure 5B )、GE0119( Figure 5C )、GE1109( Figure 5D )、GE1110( Figure 5E )、GE1111( Fig. 5F ) and genistein (also referred to herein as "lead") ( Figure 5G ) and then treated with EC 90 The cells were treated with C48 / 80 at 10 μM concentration. Figure 5H is a graph showing human LAD-2 MCs treated with graded concentrations of small molecule compound antagonists and genistein alone. Each data represents the mean ± SEM of four to six independent experiments.
[0069] Figures 6A-6G The IC values of small molecule antagonists determined by the MRGPRX2 Tango assay are shown. 50 For IC 50 DRC was evaluated. HTLA cells transfected with MRGPRX2-Tango were treated with graded concentrations of small molecule antagonists and then treated with EC 90 Concentration (10 μM) of C48 / 80, GE0117 ( Fig. 6A )、GE0118( Figure 6B )、GE0119 ( Figure 6C )、GE1109( Fig.6D )、GE1110( Fig. 6E )、GE1111( Fig. 6F ) and genistein ( Figure 6G )deal with. Figure 6H The results showed that the antagonist was treated with graded concentrations of a small molecule compound followed by EC 90 Graph of Mock transfected HTLA cells (non-MRGPRX2 plasmid) treated with C48 / 80 at different concentrations (10 μM). Each data represents the mean ± SEM of four to six independent experiments.
[0070] Figure 7: is a bar graph showing the effect of small molecule compound antagonists on MC calcium influx response. Small molecule compound antagonists GE0117, GE0118, GE0119, GE1109, GE1110, GE1111 and genistein show C48 / 80 (EC 90 The data are presented as the mean ± SEM of five to six independent experiments. Compared with the basal calcium influx, #### P<0.0001, compared with the control (C48 / 80), *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0071] Figures 8A-8B It is shown that the MC degranulation assay ( Fig. 8A ) and MRGPRX2 activation assay ( Figure 8B ) The EC values of small molecule antagonists against C48 / 80 were determined 50 and E max The concentration of all small molecule antagonists and genistein was 10 μM.
[0072] Figures 9A-9B It is to show that small molecule compound antagonists (GE0117, GE1109 and GE1111) and genistein have an effect on C48 / 80-induced monocyte chemoattractant protein-1 (MCP-1) ( Fig.9A ) and prostaglandin D-2 (PGD-2) release from human MC ( Fig. 9B ). Data are presented as mean ± SEM of three independent experiments (N = 3). Compared with the basal level of MCP-1 / PGD-2, #### P<0.0001, and compared with the control (C48 / 80), *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
[0073] Figures 10A-10B is a bar graph showing the in vivo effects of small molecule compound antagonists (GE0117, GE1109 and GE1111) and genistein on Evans blue paw extravasation in a pseudoallergic / localized allergy mouse model. Fig. 10A Shown is the quantification of the % paw thickness increase 15 minutes after C48 / 80 injection (30 μg / ml). Fig. 10B Quantification of Evans blue leakage 15 min after C48 / 80 injection (30 μg / ml) is shown. Data are presented as mean ± SEM of 6 to 8 mice / group, compared with saline. ###p<0.001, and compared with C48 / 80, *P<0.05, **P<0.01, ***P<0.001.
[0074] Fig.11 is a bar graph showing the quantification of Evans blue leakage into the ear 15 min after 30 μg / ml C48 / 80 injection using a pseudoallergic / local allergy mouse model. Data are presented as mean ± SEM of 6 to 8 mice / group, compared to saline. ### p<0.001, and compared with C48 / 80, *P<0.05, **P<0.001, ***P<0.0001.
[0075] Figures 12A-12B It is a graph showing the in vivo effects of small molecule compound antagonists (GE0117, GE1109 and GE1111) and genistein on C48 / 80-induced systemic hypersensitivity. Fig. 12A shows the effect of intraperitoneal injection of 8 mg / kg C48 / 80 on changes in body temperature. Fig. 12B The effect of intraperitoneal injection of 8 mg / kg C48 / 80 on systemic anaphylaxis symptom scores is shown. Data are presented as mean ± SEM of 6 to 8 mice / group, compared with vehicle control. #### P < 0.0001, and **P < 0.01 compared with C48 / 80 control.
[0076] Fig.13 Figure 2 shows the quantitative assessment of degranulated MCs in different experimental groups obtained from 20x magnified tissue sections. Paraffin-embedded skin sections from different mouse groups were stained with H&E to assess tissue morphology and inflammation, and with toluidine blue to detect in vivo MC degranulation. Data represent the percentage of degranulated MCs in 6 to 8 mice / group (mean ± SEM). Compared with vehicle, #### p<0.0001, **P<0.01, ****P<0.0001 compared with vehicle+C48 / 80. DETAILED DESCRIPTION
[0077] I. Definitions
[0078] It is to be understood that unless otherwise specified, the disclosed compounds, compositions and methods are not limited to specific synthetic methods, specific analytical techniques or specific reagents and are therefore variable. It is also to be understood that the terminology used herein is for the purpose of describing particular forms and embodiments only and is not intended to be limiting.
[0079] As used herein, "substituted" refers to all permissible substituents of the compounds or functional groups described herein. In the broadest sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. Illustrative substituents include, but are not limited to, halogen, hydroxyl, or any other organic group containing any number of carbon atoms, preferably containing 1-14 carbon atoms in a straight chain, branched or cyclic structure and optionally containing one or more heteroatoms such as oxygen, sulfur or nitrogen groups. Representative substituents include substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, halogen, hydroxy, alkoxy, phenoxy, aryloxy, silyl, thiol, alkylthio, substituted alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, substituted or unsubstituted carbonyl, carboxyl, amino, amide, oxo, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, amino acid. Such substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, halogen, hydroxy, alkoxy, phenoxy, aryloxy, silyl, thiol, alkylthio, substituted alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, substituted or unsubstituted carbonyl, carboxyl, amino, amide, oxo, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl and amino acid may be further substituted.
[0080] Heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible organic compound substituents as described herein that satisfy the valence states of the heteroatoms. It should be understood that "substitution" or "substituted" includes the implicit condition that such substitution is in accordance with the permissible valence states of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e., a compound that does not spontaneously undergo transformations due to, for example, rearrangement, cyclization, elimination, etc.
[0081] As used herein, "alkyl" refers to a saturated aliphatic group, including straight chain alkyl, branched chain alkyl and cycloalkyl (alicyclic). In some forms, a straight chain or branched chain alkyl has 30 or fewer (e.g., C1 to C2 for a straight chain) in its backbone. 30 For the branched chain, C3 to C 30), 20 or less, 15 or less or 10 or less carbon atoms. Alkyl includes methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, etc. Similarly, cycloalkyl is a non-aromatic carbon-based ring composed of at least three carbon atoms, such as a non-aromatic monocyclic or non-aromatic polycyclic ring containing 3 to 30 carbon atoms, 3 to 20 carbon atoms or 3 to 10 carbon atoms in its ring structure, and has 5, 6 or 7 carbons in the ring structure. Cycloalkyl containing a polycyclic system may have two or more non-aromatic rings, wherein two or more carbons are shared by two adjacent rings (i.e., "fused cycloalkyl ring"). Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc.
[0082] As used throughout the specification, examples and claims, the term "alkyl" is intended to include both "unsubstituted alkyl" and "substituted alkyl", wherein the latter refers to an alkyl moiety having one or more substituents replacing hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents may be any of the substituents described above, for example, halogen (such as fluorine, chlorine, bromine or iodine), hydroxy, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), thiocarbonyl (such as thioester, thioacetate or thioformate), aryl, alkoxy, aralkyl, phosphonium, phosphino, phosphono, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, oxo, sulfhydryl, thiol, alkylthio, silyl, sulfinyl, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aromatic or heteroaromatic moieties. -NRR', wherein R and R' are independently hydrogen, alkyl or aryl, and wherein the nitrogen atom is optionally quaternized; -SR, wherein R is phosphonyl, sulfinyl, silyl, hydrogen, alkyl or aryl; -CN; -NO2; -COOH; carboxylate; -COR, -COOR or -CON(R)2, wherein R is hydrogen, alkyl or aryl; imino, silyl, ether, haloalkyl (such as -CF3, -CH2-CF3, -CCl3); -CN; -NCOCOCH2CH2; -NCOCOCHCH; and -NCS; and combinations thereof. The term "alkyl" also includes "heteroalkyl".
[0083] Those skilled in the art will appreciate that the moiety substituted on the hydrocarbon chain may itself be substituted, if appropriate. For example, the substituents of substituted alkyl groups may include halogen, hydroxyl, nitro, thiol, amino, aralkyl, azido, imino, amide, phosphonium, phosphino, phosphoryl (including phosphonates and phosphinates), oxo, sulfonyl (including sulfates, sulfonamido, sulfamoyl and sulfonates) and silyl as well as ethers, alkylthio, carbonyl (including ketones, aldehydes, carboxylates and esters), haloalkyl, -CN, etc. Cycloalkyl groups may be substituted in the same manner.
[0084] As used herein, unless otherwise specified, "lower alkyl" means an alkyl group as defined above but having one to ten carbons, more preferably one to six carbons, in its backbone structure. Similarly, "lower alkenyl" and "lower alkynyl" have similar chain lengths.
[0085] As used herein, "heteroalkyl" refers to a linear or branched or cyclic carbon-containing alkyl group or a combination thereof containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. For example, the term "heterocycloalkyl" is a cycloalkyl group as defined above in which at least one ring carbon atom is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0086] As used herein, the term "alkenyl" is a hydrocarbon group of 2 to 24 carbon atoms having a structural formula containing at least one carbon-carbon double bond. Alkenyl groups include straight chain alkenyls, branched alkenyls, and cycloalkenyls. Cycloalkenyls are non-aromatic carbocyclic rings consisting of at least three carbon atoms and at least one carbon-carbon double bond, such as non-aromatic monocyclic or non-aromatic polycyclic rings containing 3 to 30 carbon atoms and at least one carbon-carbon double bond, 3 to 20 carbon atoms and at least one carbon-carbon double bond, or 3 to 10 carbon atoms and at least one carbon-carbon double bond in their ring structure, and having 5, 6 or 7 carbons and at least one carbon-carbon double bond in their ring structure. Cycloalkenyl groups containing polycyclic ring systems may have two or more non-aromatic rings and contain at least one carbon-carbon double bond, wherein two or more carbons are common to two adjacent rings (i.e., "fused cycloalkenyl rings"). Asymmetric structures such as (AB)C=C(C'D) are intended to include E and Z isomers. This can be inferred from the structural formulas herein where an asymmetric olefin is present or can be explicitly indicated by the bond symbol C. The term "alkenyl" as used throughout the specification, examples and claims is intended to include "unsubstituted alkenyl" and "substituted alkenyl", the latter referring to alkenyl moieties having one or more substituents on one or more carbons on the hydrocarbon backbone. The term "alkenyl" also includes "heteroalkenyl".
[0087] The term "substituted alkenyl" refers to an alkenyl moiety having one or more substituents replacing one or more hydrogens on one or more carbons of the hydrocarbon backbone. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, oxo, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl and combinations thereof.
[0088] As used herein, "heteroalkenyl" refers to a linear or branched or cyclic carbon-containing alkenyl group or combinations thereof containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. For example, the term "heterocycloalkenyl" is a cycloalkenyl group in which at least one ring carbon atom is replaced by a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0089] As used herein, the term "alkynyl" is a hydrocarbon group of 2 to 24 carbon atoms having a structural formula containing at least one carbon-carbon triple bond. Alkynyl groups include straight chain alkynyls, branched chain alkynyls, and cycloalkynyls. Cycloalkynyls are non-aromatic carbocyclic rings consisting of at least three carbon atoms and at least one carbon-carbon triple bond, such as non-aromatic monocyclic or non-aromatic polycyclic rings containing 3 to 30 carbon atoms and at least one carbon-carbon triple bond, 3 to 20 carbon atoms and at least one carbon-carbon triple bond, or 3 to 10 carbon atoms and at least one carbon-carbon triple bond in their ring structure, and having 5, 6 or 7 carbons and at least one carbon-carbon triple bond in the ring structure. Cycloalkynyl groups containing polycyclic ring systems may have two or more non-aromatic rings and contain at least one carbon-carbon triple bond, wherein two or more carbons are common to two adjacent rings (i.e., "fused cycloalkynyl rings"). Asymmetric structures such as (AB)C≡C(C"D) are intended to include both E and Z isomers. This may be inferred from formulae herein where an asymmetric alkyne is present or may be explicitly indicated by the bond symbol C. The term "alkynyl" as used throughout the specification, examples and claims is intended to include "unsubstituted alkynyl" and "substituted alkynyl", the latter referring to alkynyl moieties having one or more substituents replacing hydrogen on one or more carbons of the hydrocarbon backbone. The term "alkynyl" also includes "heteroalkynyl".
[0090] The term "substituted alkynyl" refers to an alkynyl moiety having one or more substituents replacing one or more hydrogens on one or more carbons of the hydrocarbon backbone. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl and combinations thereof.
[0091] As used herein, "heteroalkynyl" refers to a linear or branched or cyclic carbon-containing alkynyl group or combinations thereof containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen, phosphorus, and sulfur atoms are optionally oxidized, and the nitrogen heteroatom is optionally quaternized. For example, the term "heterocycloalkynyl" is a cycloalkynyl group in which at least one ring carbon atom is replaced by a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus.
[0092] As used herein, the term "aryl" is any C5 to C 26 A carbon-based aromatic group, a heteroaromatic group, a fused heteroaromatic group or a fused heteroaromatic group. For example, as used herein, "aryl" may include 5-, 6-, 7-, 8-, 9-, 10-, 14-, 18- and 24-membered monocyclic aromatic groups, including but not limited to benzene, naphthalene, anthracene, phenanthrene, , pyrene, cyclopentene, coronene, etc. "Aryl" also encompasses polycyclic systems having two or more rings, wherein two or more carbons are common to two adjacent rings (i.e., "fused aromatic rings"), wherein at least one ring is aromatic, for example, the other ring or rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl and / or heterocyclic. Aryl may be substituted with one or more groups, including but not limited to alkyl, alkynyl, alkenyl, aryl, halide, nitro, amino, ester, ketone, aldehyde, hydroxyl, carboxylic acid or alkoxy.
[0093] The term "substituted aryl" refers to an aryl group in which one or more hydrogen atoms on one or more aromatic rings are replaced by one or more substituents. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, carbonyl (e.g., ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl (e.g., CF3, -CH2-CF3, -CCl3), -CN, aryl, heteroaryl, and combinations thereof.
[0094] "Heterocycle" and "heterocyclyl" are used interchangeably and refer to cyclic groups attached through ring carbon atoms or ring nitrogen atoms of a non-aromatic monocyclic or polycyclic ring containing 3 to 30 ring atoms, 3 to 20 ring atoms, 3 to 10 ring atoms, or 5 to 6 ring atoms, wherein each ring contains carbon and one to four heteroatoms each selected from the group consisting of non-peroxide oxygen, sulfur, and N(Y), wherein Y is absent or is H, O, C1 to C2 10 Alkyl, phenyl or benzyl, and optionally containing 1 to 3 double bonds, and optionally substituted with one or more substituents. The definition of heterocyclic group is different from that of heteroaryl. Heterocycle can be heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, etc., such as piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, dihydrofuran [2,3-b] tetrahydrofuran, morpholinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyranyl, 2H-pyrrolyl, 4H-quinolinazinyl, quinuclidinyl, tetrahydrofuranyl, 6H-1,2,5-thiadiazinyl. The heterocyclic group can be optionally substituted with one or more substituents defined above for alkyl and aryl.
[0095] The term "heteroaryl" refers to a C5 to C 30The term "heteroaryl" refers to a 5-, 6-, 7-, 8-, 9-, 10-, 14-, 18- and 24-membered monocyclic aromatic group that may contain one to four heteroatoms, such as pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine. Heteroaryl may also be referred to as "aryl heterocycle" or "heteroaromatic group". "Heteroaryl" also includes a polycyclic system with two or more rings, wherein two or more carbon atoms are shared by two adjacent rings (i.e., "fused ring"), wherein at least one ring is heteroaromatic, for example, another ring or multiple rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocycle or a combination thereof. Examples of heteroaryl rings include, but are not limited to, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiothiophenyl, benzoxazolyl, benzoxazolinyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carlinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindololinyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, naphthyridinyl, octahydroisoquinolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolinyl, oxazolyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, and xanthenyl.One or more rings may be substituted as defined below for "substituted heteroaryl".
[0096] The term "substituted heteroaryl" refers to a heteroaryl in which one or more hydrogen atoms on one or more heteroaromatic rings are replaced by one or more substituents. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, carbonyl (e.g., ketone, aldehyde, carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, imino, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl (e.g., CF3, -CH2-CF3, -CCl3), -CN, aryl, heteroaryl, and combinations thereof.
[0097] The term "polyaryl" includes chemical moieties of two or more aryls, heteroaryls and combinations thereof. Aryls, heteroaryls and combinations thereof are fused or connected by single bonds, ethers, esters, carbonyls, amides, sulfonyls, sulfonamides, alkyls, azos and combinations thereof. For example, a "polyaryl" can be a polycyclic system with two or more rings, wherein two or more carbons are common to two adjacent rings (i.e., "fused aromatic rings"), wherein two or more rings are aromatic. When two or more heteroaryls are involved, a chemical moiety can be referred to as a "polyheteroaryl".
[0098] The term "substituted polyaryl" refers to a polyaryl in which one or more aryl, heteroaryl groups are substituted with one or more substituents. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof. When two or more heteroaryls are involved, the chemical moiety may be referred to as a "substituted polyheteroaryl".
[0099] The term "ring" refers to a substituted or unsubstituted monocyclic ring or a substituted or unsubstituted polycyclic ring (such as those formed by a monocyclic ring system or a fused ring system), for example, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted cycloalkenyl, a substituted or unsubstituted cycloalkynyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted heteroaryl, and a substituted or unsubstituted polyheteroaryl, such as when geometric constraints allow, having 3 to 30 carbon atoms. Substituted cycloalkyl, cycloalkenyl, cycloalkynyl and heterocyclyl are substituted as defined above for alkyl, alkenyl, alkynyl, heterocyclyl, aryl, heteroaryl, polyaryl and polyheteroaryl, respectively.
[0100] As used herein, the term "aralkyl" is an aryl or heteroaryl group having an alkyl, alkynyl or alkenyl group as defined above attached to an aromatic group (eg, aryl, heteroaryl, polyaryl or polyheteroaryl). An example of an aralkyl group is benzyl.
[0101] The terms "alkoxyl" or "alkoxy", "aroxy" or "aryloxy" generally describe an alkyl radical of the formula -OR v The compound shown, wherein R v Including but not limited to substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclic radical, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted assorted alkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted alkylheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, phosphonium, phosphino, phosphono, sulfinyl, silyl, mercaptan, amide and amino. Exemplary alkoxy includes methoxy, ethoxy, propoxy, tert-butoxy etc. " low alkoxy " is the alkoxy containing one to six carbon atoms. " ether " is two functional groups covalently linked by oxygen as defined below. Thus, the substituents of the alkyl group which make the alkyl group an ether to form an alkoxy group or an alkoxy-like group may be, for example, a substituent represented by one of the following: -O-alkyl, -O-alkenyl, -O-alkynyl, -O-aryl, -O-heteroaryl, -O-polyaryl, -O-polyheteroaryl, -O-heterocyclyl, etc.
[0102] The term "substituted alkoxy" refers to an alkoxy group having one or more substituents replacing one or more hydrogens on one or more carbons of the alkoxy backbone. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, oxo, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof.
[0103] As used herein, the term "ether" is a 2 OA 1 Indicates that A 2 and A 1 It may independently be a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a phosphonium group, a phosphino group, a phosphono group, a sulfinyl group, a silyl group, a thiol group, a substituted or unsubstituted carbonyl group, an alkoxy group, an amide group or an amino group as defined above.
[0104] As used herein, the term "polyether" is represented by the formula:
[0105]
[0106] Among them A 3 , A 2 and A 1 It may independently be a substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, phosphonium, phosphino, substituted or unsubstituted carbonyl, alkoxy, amide or amino group as defined above; g may be a positive integer from 1 to 30.
[0107] The term "phenoxy" is art-recognized and refers to a radical of the formula -OR v A compound wherein R v (ie, -O-C6H5). Those skilled in the art will recognize that phenoxy is a type of aryloxy.
[0108] The term "substituted phenoxy" refers to a phenoxy group as defined above having one or more substituents replacing one or more hydrogen atoms on one or more carbons of a benzene ring. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof.
[0109] As used interchangeably herein, the terms "aroxy" and "aryloxy" are represented by -O-aryl or -O-heteroaryl, wherein aryl and heteroaryl are as defined above.
[0110] As used interchangeably herein, the terms "substituted aroxy and substituted aryloxy" refer to -O-aryl or -O-heteroaryl groups as defined herein having one or more substituents replacing one or more hydrogen atoms on one or more ring atoms of the aryl and heteroaryl groups. Such substituents can be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0111] As used herein, the term "amino" includes the following groups:
[0112] (primary amino group), (Secondary amino group),
[0113] (tertiary amino group) and (quaternary amino group),
[0114] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein R is independent of E, x , R xi and R xii Each independently represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aralkyl group (e.g., a substituted or unsubstituted alkylaryl group, a substituted or unsubstituted arylalkyl group), a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, a substituted or unsubstituted heterocyclic group, a hydroxyl group, an alkoxy group, a phosphonium group, a phosphino group, a phosphono group, a sulfinyl group, a silyl group, a thiol group, an amide group, an amino group, or -(CH2) m -R"'; R"' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted cycloalkenyl group, a substituted or unsubstituted heterocyclyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, a substituted or unsubstituted polyheteroaryl group, an alkoxy group, a phosphonium group, a phosphino group, an amide group or an amino group; and m is 0 or an integer in the range of 1 to 8. The term "quaternary amino group" also includes the following groups: wherein nitrogen, R x , R xi and R xii N + Completion is a heterocyclyl or heteroaryl group having from 3 to 14 atoms in the ring structure.
[0115] The terms "amide" or "amido" are used interchangeably to refer to both "unsubstituted amide" and "substituted amide" and are represented by the following general formula:
[0116]
[0117] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heterocyclyl, wherein R and R' independently of E each independently represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, phosphono, sulfinyl, silyl, Thiol, amide, amino or -(CH2) m -R"', or R and R' together with the N atom to which they are attached complete a heterocycle having 3 to 14 atoms in the ring structure; R"' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8. In some forms, when E is oxygen, a carbamate is formed.
[0118] As used herein, "carbonyl" is art-recognized and includes moieties such as those represented by the following formula:
[0119]
[0120] wherein X is a bond or represents oxygen or sulfur, and R represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, amide, amino, or -(CH2) m-R" or a pharmaceutically acceptable salt; E" is absent or E" is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl; R' represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, amide, amino or -(CH2) m -R"; R" represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8. When X is oxygen and R is as defined above, the moiety is also referred to as a carboxyl group. When X is oxygen and R is hydrogen, the formula represents a "carboxylic acid". When X is oxygen and R' is hydrogen, the formula represents a "formate". When X is oxygen and R or R' is not hydrogen, the formula represents an "ester". Generally, when the oxygen atom of the above formula is replaced by sulfur, the formula represents a "thiocarbonyl". When X is sulfur and R or R' is not hydrogen, the formula represents a "thioester". When X is sulfur and R is hydrogen, the formula represents a "thiocarboxylic acid". When X is sulfur and R' is hydrogen, the formula represents a "thioformate". When X is a bond and R is not hydrogen, the above formula represents a "ketone". When X is a bond and R is hydrogen, the above formula represents an "aldehyde".
[0121] The term "substituted carbonyl" refers to a group wherein R, R' or is attached to:
[0122] The carbonyl group as defined above in which one or more hydrogen atoms in the group are independently replaced. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof.
[0123] The term "carboxyl" is as defined above for carbonyl, and more specifically is a radical of the formula -R iv COOH definition, where R iv is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl or substituted or unsubstituted heteroaryl.
[0124] The term "substituted carboxyl" refers to a group in which R iv One or more hydrogen atoms in the carboxyl group as defined above are replaced. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl and combinations thereof.
[0125] The term "phosphino" is represented by the formula:
[0126]
[0127] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein R is independent of E,vi and R vii Each independently represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphino, phosphono, sulfinyl, silyl, thiol, amide, amino or -(CH2) m -R"', or R vi and R vii Together with the P atoms to which they are attached, they complete a heterocycle having 3 to 14 atoms in the ring structure; R'' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8.
[0128] The term "phosphonium" is represented by the following formula:
[0129]
[0130] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, wherein R is independent of E, vi , R vii and R viii Each independently represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (for example, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphino, phosphono, sulfinyl, silyl, thiol, amide, amino or -(CH2) m -R"', or R vi , R vii and R viii The P to which they are attached+ The atoms together complete a heterocycle having 3 to 14 atoms in the ring structure; R'' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8.
[0131] The term "phosphono" is represented by the formula:
[0132]
[0133] wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, oxygen, alkoxy, aryloxy, or substituted alkoxy or substituted aryloxy, wherein, independently of E, R vi and R vii are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic, hydroxy, alkoxy, phosphonium, phosphino, phosphono, sulfinyl, silyl, thiol, amide, amino, or -(CH2) m -R"', or R vi and R vii Together with the P atoms to which they are attached, they complete a heterocycle having 3 to 14 atoms in the ring structure; R'' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8.
[0134] The term "substituted phosphoryl" refers to a phosphonyl group wherein E, R vi and R viiSuch substituents can be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphite, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl and combinations thereof.
[0135] The term "phosphoryl" defines a phosphonyl group wherein E is absent, oxygen, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy, as defined above and independently of E, R vi and R vii is independently hydroxy, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy as defined above. As will be appreciated by those skilled in the art, when E is oxygen, the phosphoryl group cannot be attached to another chemical species, for example to form an oxygen-oxygen bond or other unstable bond. vi and R vii When substituted, the substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphoryl, phosphate, phosphonate, phosphite, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0136] The term "sulfinyl" is represented by the formula:
[0137]
[0138] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, wherein R, independently of E, represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, Phosphonium, phosphine, phosphonyl, silyl, thiol, amide, amino or -(CH2) m -R"', or E and R together with the S atom to which they are attached complete a heterocyclic ring having 3 to 14 atoms in the ring structure; R"' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8.
[0139] The term "sulfonyl" is represented by the formula:
[0140]
[0141] wherein E is absent or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, wherein R, independently of E, represents hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclyl, hydroxy, alkoxy, phosphonium, phosphino, amide, amino, or -(CH2) m-R"', or E and R together with the S atom to which they are attached complete a heterocycle having 3 to 14 atoms in the ring structure; R"' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8.
[0142] The term "substituted sulfonyl" refers to a sulfonyl group in which E, R or both are independently substituted. Such substituents may be any of the substituents described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (e.g., thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (e.g., quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl, polyaryl, polyheteroaryl, and combinations thereof.
[0143] The term "sulfonic acid" refers to a sulfonyl group as defined above wherein R is hydroxy and E is absent or E is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, or substituted or unsubstituted heteroaryl.
[0144] The term "sulfate" refers to a sulfonyl group as defined above as follows: wherein E is absent, oxygen, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy, as defined above, and R is independently hydroxy, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy, as defined above. As will be appreciated by those skilled in the art, when E is oxygen, the sulfate cannot be attached to another chemical species, for example to form an oxygen-oxygen bond or other unstable bond.
[0145] The term "sulfonate" refers to a sulfonyl group as defined above: wherein E is oxygen, alkoxy, aryloxy, substituted alkoxy or substituted aryloxy as defined above, and R is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted amino, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, -(CH2) m -R'', R'' represents a hydroxyl group, a substituted or unsubstituted carbonyl group, an aryl group, a cycloalkyl ring, a cycloalkenyl ring, a heterocyclic ring, an amide group, an amino group or a polycyclic ring; and m is 0 or an integer in the range of 1 to 8. As will be appreciated by those skilled in the art, when E is oxygen, the sulfonate cannot be attached to another chemical species, for example to form an oxygen-oxygen bond or other unstable bonds.
[0146] The term "sulfamoyl" refers to a sulfonamide or a sulfonamide of the formula:
[0147]
[0148] wherein E is absent, or E is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted cycloalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, wherein, independently of E, R and R' each independently represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbonyl, substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted heterocyclic group, hydroxyl, alkoxy, phosphonium, phosphino, amide, amino or -(CH2) m -R"', or R and R' together with the N atom to which they are attached complete a heterocyclic ring having 3 to 14 atoms in the ring structure; R"' represents hydroxy, substituted or unsubstituted carbonyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, alkoxy, phosphonium, phosphino, amide or amino; and m is 0 or an integer in the range of 1 to 8.
[0149] As used herein, the term "silyl" is represented by the formula -SiRR'R", wherein R, R' and R" can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted carbonyl, phosphonium, phosphino, phosphono, sulfinyl, thiol, amide, amino, alkoxy or oxo as defined above.
[0150] The term "thiol" is used interchangeably and is represented by -SR, wherein R can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl (e.g., substituted or unsubstituted alkylaryl, substituted or unsubstituted arylalkyl, etc.), substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted carbonyl, phosphonium, phosphino, amide, amino, alkoxy, oxo, phosphono, sulfinyl, or silyl as defined above.
[0151] The term "alkylthio" refers to an alkyl group as defined above to which a sulfur group is attached. The "alkylthio" portion is represented by -S-alkyl. Representative alkylthio groups represent methylthio, ethylthio, and the like. The term "alkylthio" also includes cycloalkyl groups to which a sulfur group is attached.
[0152] The term "substituted alkylthio" refers to an alkylthio having one or more substituents replacing one or more hydrogen atoms on one or more carbon atoms of the alkylthio backbone. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof.
[0153] The term "phenylthio" is art-recognized and refers to -S-C6H5, ie, a phenyl group attached to a sulfur atom.
[0154] The term "substituted phenylthio" refers to a phenylthio group as defined above having one or more substituents replacing hydrogen on one or more carbons of the phenyl ring. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclic, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof.
[0155] "Arylthio" means an -S-aryl or -S-heteroaryl group in which aryl and heteroaryl are as defined above.
[0156] The term "substituted arylthio" means -S-aryl or -S-heteroaryl having one or more substituents replacing hydrogen atoms on one or more ring atoms of aromatic and heteroaromatic rings as defined above. Such substituents include, but are not limited to, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, carbonyl (such as carboxyl, alkoxycarbonyl, formyl or acetyl), silyl, ether, ester, thiocarbonyl (such as thioester, thioacetate or thioformate), alkoxy, phosphonium, phosphino, phosphoryl, phosphate, phosphonate, phosphinate, amino (such as quaternized amino), amide, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, alkylaryl, haloalkyl, -CN, aryl, heteroaryl and combinations thereof.
[0157] The terms "hydroxyl" and "hydroxy" are used interchangeably and are represented by -OH.
[0158] The term "oxo" refers to a =0 bonded to a carbon atom.
[0159] The terms "cyano" and "nitrile" are used interchangeably to refer to -CN.
[0160] The term "nitro" refers to -NO2.
[0161] The term "phosphate" refers to -O-PO3.
[0162] The terms "azide" or "azido" are used interchangeably to refer to -N3.
[0163] The disclosed compounds and substituent groups can independently have two or more groups listed above. For example, if the compound or substituent is a straight chain alkyl, one of the hydrogen atoms of the alkyl can be substituted by a hydroxyl, an alkoxyl group, etc. Depending on the selected group, the first group can be incorporated into the second group, or alternatively, the first group can be side-joined (i.e., attached) to the second group. For example, for the phrase "an alkyl group comprising an ester group", the ester group can be incorporated into the main chain of the alkyl. Alternatively, an ester can be attached to the main chain of the alkyl. The characteristics of the selected group will depend on whether the first group is embedded in or attached to the second group.
[0164] The compounds and substituents may be independently substituted with substituents as described above in the definition of "substituted".
[0165] II. Composition
[0166] Synthetic compounds (also referred to herein as "compounds") having antiallergic properties have been developed. These compounds have broad antiallergic properties and should be suitable for preventing and / or treating various types of allergies, allergic diseases and / or inflammatory diseases, and / or alleviating the symptoms of various types of allergies, allergic diseases and / or inflammatory diseases. Specifically, these compounds are antagonists with antagonistic activity to Mas-related G protein-coupled receptor (GPCR) X2 (MRGPRX2) and are suitable for preventing and / or treating non-IgE-mediated pseudoallergy, allergic diseases and / or inflammatory diseases.
[0167] In general, the compound contains two ring parts, each of which contains a fused ring structure, which is optionally substituted with one or more functional groups. These compounds can bind to MRGPRX2, block the receptor, and thus prevent MC activation. Without being limited by any theory, the overall structure of these compounds allows them to interact with multiple amino acids (such as at least 7 amino acids, at least 8 amino acids, at least 9 amino acids, or at least 10 amino acids) in the binding pocket of MRGPRX2 located in the N-terminal region, and thus bind to the binding pocket with high affinity, for example, according to the docking method described in the embodiment, for example, with a binding affinity of less than -9kcal / mol, less than -10kcal / mol, less than -10.5kcal / mol, less than -11 kcal / mol, or less than -11.5kcal / mol, between -9kcal / mol and -12.1kcal / mol, -10 kcal / mol and -12.1kcal / mol, or -10.5kcal / mol and -12.1kcal / mol.
[0168] Typically, the compound meets at least two of Lipinski's five rules for evaluating oral drugs, i.e., molecular weight ≤ 500 Dalton, LogPo / w ≤ 5, hydrogen bond donors ≤ 5, and hydrogen bond acceptors ≤ 10. In some forms, the compound meets all of Lipinski's five rules.
[0169] Also disclosed are a pharmaceutical composition and a pharmaceutical preparation containing the compound.
[0170] A. Compounds
[0171] 1. Compound structure
[0172] The compound may have the structure of Formula I:
[0173]
[0174] wherein n can be an integer from 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 or 1; wherein R' and R" can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphonyl, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; wherein A' and Z' can independently be substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl.
[0175] When R', R", A' and / or Z' are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol or a combination thereof.
[0176] In some forms of Formula I, wherein the compound has the structure:
[0177]
[0178] (a) wherein E' and G' are independently substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl;
[0179] (b) wherein J' is a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, or a substituted or unsubstituted polyheteroaryl group;
[0180] (c) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and
[0181] (d) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0182] In some forms of Formula I, n is zero.
[0183] In some forms of Formula I, A' can have a structure of Formula II:
[0184]
[0185] wherein E' and G' may independently be substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, or substituted or unsubstituted polyheteroaryl; wherein Y' is independently CR1, O, S, or NR2 at each occurrence, wherein R1 and R2 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; and wherein the substituents may be any of the substituents described above for Formula I.
[0186] In some forms of Formula II, R1 and R2 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl or halogen.
[0187] In some forms of Formula II, R1 and R2 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxyl, or halogen.
[0188] In some forms of Formula II, when E', G', R1 and / or R2 are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo or a combination thereof.
[0189] In some forms of Formula I, A' can have a structure of Formula III:
[0190]
[0191] wherein Y' may be as defined above for Formula II, and wherein at least one Y' is O, S or NR2, and R2 is as defined above for Formula II.
[0192] In some forms of Formula I, A' can have a structure of Formula IVa or Formula IVb:
[0193]
[0194] wherein Y' may be as defined above for Formula II, and wherein at least one Y' is O, S or NR2, and R2 is as defined above for Formula II.
[0195] In some forms of Formula I, A' can have a structure of Formula Va or Vb:
[0196]
[0197] wherein X' may be C, N, O or S, wherein R3 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and wherein the substituents may be any of the substituents described above for Formula I.
[0198] In some forms of Formula Va or Formula Vb, X' can be C or N, and R3 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl, or halogen.
[0199] In some forms of Formula Va or Formula Vb, X' can be C or N, and each occurrence of R3 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxyl or halogen.
[0200] In some forms of Formula Va or Formula Vb, when R3 is a substituted functional group, the substituent may be a substituted or unsubstituted alkyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted polyheteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted carbonyl, a substituted or unsubstituted alkoxy, a halogen, a hydroxyl, an amino, an amide or an oxo or a combination thereof.
[0201] In some forms of Formula I, Z' can have a structure of Formula VI:
[0202]
[0203] wherein Y' may be as defined above for Formula II, and J' may be a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted polyaryl, or a substituted or unsubstituted polyheteroaryl.
[0204] In some forms of Formula VI, Y' at each occurrence can be CR1 or NR2, and R1 and R2 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl or halogen.
[0205] In some forms of Formula VI, Y' at each occurrence may be CR1 or NR2, and R1 and R2 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amide, amino, sulfonyl, oxo, hydroxyl or halogen.
[0206] In some forms of Formula VI, when J', R1 and / or R2 are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo or a combination thereof.
[0207] In some forms of Formula I, Z' can have a structure of Formula VII:
[0208]
[0209] wherein Y' may be as defined above for Formula II and Formula VI.
[0210] In some forms of Formula I, Z' can have a structure of Formula VIII:
[0211]
[0212] wherein Y' may be as defined above for Formula II and Formula VI.
[0213] In some forms of Formula I, Z' can have a structure of Formula IX:
[0214]
[0215] wherein R4 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; and wherein the substituents may be any of the substituents described above for Formula I.
[0216] In some forms of Formula IX, R4 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl, or halogen.
[0217] In some forms of Formula IX, each occurrence of R4 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxyl, or halogen.
[0218] In some forms of Formula IX, when R4 is a substituted functional group, the substituent may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo, or a combination thereof.
[0219] In some forms, the compound may contain A' of any one of Formulas II, III, IVa, IVb, Va, and Vb and Z' of any one of Formulas VI, VII, VIII, and IX.
[0220] In some forms, the compound may have a structure of Formula Xa or Formula Xb:
[0221]
[0222] wherein Y' may be as defined above for Formula II and Formula VI.
[0223] In some forms, the compound may have the structure of Formula XIa or Formula XIb:
[0224]
[0225] wherein X' may be C, N, O or S, wherein R3 and R4 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and wherein the substituents may be any of the substituents described above for Formula I.
[0226] In some forms of Formula XIa or Formula XIb, X' may be C or N, and R3 and R4, at each occurrence, may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl or halogen.
[0227] In some forms of Formula XIa or Formula XIb, X' may be C or N, and R3 and R4 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amide, amino, sulfonyl, oxo, hydroxyl or halogen.
[0228] In some forms of Formula XIa and Formula XIb, when R3 and / or R4 are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo or a combination thereof.
[0229] In some forms, the compound may have the structure of Formula XIIa or Formula XIIb:
[0230]
[0231] wherein X' may be C, N, O or S, wherein R3 and R4 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and wherein the substituents may be any of the substituents described above for Formula I.
[0232] In some forms of Formula XIIa or Formula XIIb, X' may be C or N, and R3 and R4, at each occurrence, may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl or halogen.
[0233] In some forms of Formula XIIa or Formula XIIb, X' may be C or N, and R3 and R4 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amide, amino, sulfonyl, oxo, hydroxyl or halogen.
[0234] In some forms of Formula XIIa and Formula XIIb, when R3 and / or R4 are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo or a combination thereof.
[0235] In some forms of Formula XIa, XIb, XIIa and XIIb, X' may be C or N, R3 and R4 may each independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxyl, heterocyclic group, And R5 to R 10 It may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino or halogen.
[0236] In some forms of Formula XIa, XIb, XIIa and XIIb, X' may be C or N, and R3 and R4 may each independently be hydrogen, substituted or unsubstituted alkyl, oxo, hydroxyl, And R5 to R8 may independently be hydrogen or a substituted or unsubstituted alkyl group.
[0237] In some forms of Formula XIa, XIb, XIIa and XIIb, X' may be C or N, R3 may be independently hydrogen, substituted or unsubstituted alkyl, oxo, hydroxyl or carboxyl at each occurrence, R4 may be independently hydrogen, And R5 to R8 may independently be hydrogen or a substituted or unsubstituted alkyl group.
[0238] For any of Formulas I, II, III, IVa, IVb, Va, Vb, VI, VII, VIII, IX, Xa, Xb, XIa, XIb, XIIa, and XIIb, the alkyl group may be a straight chain alkyl group, a branched chain alkyl group, or a cyclic alkyl group (either monocyclic or polycyclic). Exemplary alkyl groups include straight chain C1-C 30 Alkyl, branched C4-C 30 Alkyl, cyclic C3-C 30 Alkyl, straight chain C1-C 20 Alkyl, branched C4-C 20 Alkyl, cyclic C3-C 20 Alkyl, straight chain C1-C 10 Alkyl, branched C4-C 10 Alkyl, cyclic C3-C 10 Alkyl, straight chain C1-C6 alkyl, branched chain C4-C6 alkyl, cyclic C3-C6 alkyl, straight chain C1-C4 alkyl, cyclic C3-C4 alkyl, such as straight chain C1-C 10 , C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 alkyl, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkyl, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkyl.
[0239] For any of Formulas I, II, III, IVa, IVb, Va, Vb, VI, VII, VIII, IX, Xa, Xb, XIa, XIb, XIIa, and XIIb, the alkenyl group may be a straight chain alkenyl group, a branched chain alkenyl group, or a cyclic alkenyl group (either monocyclic or polycyclic). Exemplary alkenyl groups include straight chain C1-C 30 Alkenyl, branched C4-C 30 Alkenyl, cyclic C3-C 30Alkenyl, straight chain C1-C 20 Alkenyl, branched C4-C 20 Alkenyl, cyclic C3-C 20 Alkenyl, straight chain C1-C 10 Alkenyl, branched C4-C 10 Alkenyl, cyclic C3-C 10 alkenyl, straight-chain C1-C6 alkenyl, branched-chain C4-C6 alkenyl, cyclic C3-C6 alkenyl, straight-chain C1-C4 alkenyl, cyclic C3-C4 alkenyl, such as straight-chain C1-C 10 , C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 alkenyl, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkenyl, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkenyl.
[0240] For any of Formulas I, II, III, IVa, IVb, Va, Vb, VI, VII, VIII, IX, Xa, Xb, XIa, XIb, XIIa, and XIIb, the alkynyl group can be a straight chain alkynyl group, a branched chain alkynyl group, or a cyclic alkynyl group (either monocyclic or polycyclic). Exemplary alkynyl groups include straight chain C1-C 30 Alkynyl, branched C4-C 30 Alkynyl, cyclic C3-C 30 Alkynyl, straight chain C1-C 20 Alkynyl, branched C4-C 20 Alkynyl, cyclic C3-C 20 Alkynyl, straight chain C1-C 10 Alkynyl, branched C4-C 10 Alkynyl, cyclic C3-C 10 Alkynyl, straight chain C1-C6 alkynyl, branched chain C4-C6 alkynyl, cyclic C3-C6 alkynyl, straight chain C1-C4 alkynyl, cyclic C3-C4 alkynyl, such as straight chain C1-C 10 , C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 alkynyl, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkynyl, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 alkynyl.
[0241] It is understood that any of the exemplary alkyl, alkenyl, and alkynyl groups may be heteroalkyl, heteroalkenyl, and heteroalkynyl groups, respectively. For example, an alkyl group may be a straight chain C2-C 30Heteroalkyl, branched C4-C 30 Heteroalkyl, cyclic C3-C 30 Heteroalkyl (i.e., heterocycloalkyl), straight chain C1-C 20 Heteroalkyl, branched C4-C 20 Heteroalkyl, cyclic C3-C 20 Heteroalkyl, straight chain C1-C 10 Heteroalkyl, branched C4-C 10 Heteroalkyl, cyclic C3-C 10 heteroalkyl, linear C1-C6 heteroalkyl, branched C4-C6 heteroalkyl, cyclic C3-C6 heteroalkyl, linear C1-C4 heteroalkyl, cyclic C3-C4 heteroalkyl, such as linear C1-C 10 , C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 heteroalkyl, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkyl, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkyl.
[0242] For any of Formulas I, II, III, IVa, IVb, Va, Vb, VI, VII, VIII, IX, Xa, Xb, XIa, XIb, XIIa and XIIb, the alkenyl group may be a linear C2-C 30 Heteroalkenyl, branched C4-C 30 Heteroalkenyl, cyclic C3-C 30 Heteroalkenyl (i.e., heterocycloalkenyl), straight chain C1-C 20 Heteroalkenyl, branched C4-C 20 Heteroalkenyl, cyclic C3-C 20 Heteroalkenyl, straight chain C1-C 10 Heteroalkenyl, branched C4-C 10 Heteroalkenyl, cyclic C3-C 10 heteroalkenyl, straight-chain C1-C6 heteroalkenyl, branched-chain C4-C6 heteroalkenyl, cyclic C3-C6 heteroalkenyl, straight-chain C1-C4 heteroalkenyl, cyclic C3-C4 heteroalkenyl, such as straight-chain C1-C 10 , C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 heteroalkenyl, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkenyl, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkenyl.
[0243] For any of Formulas I, II, III, IVa, IVb, Va, Vb, VI, VII, VIII, IX, Xa, Xb, XIa, XIb, XIIa and XIIb, the alkynyl group may be a straight chain C2-C 30 Heteroalkynyl, branched C4-C 30 Heteroalkynyl, cyclic C3-C 30 Heteroalkynyl (i.e., heterocycloalkynyl), straight chain C1-C 20 Heteroalkynyl, branched C4-C 20 Heteroalkynyl, cyclic C3-C 20 Heteroalkynyl, straight chain C1-C 10 Heteroalkynyl, branched C4-C 10 Heteroalkynyl, cyclic C3-C 10 heteroalkynyl, straight-chain C1-C6 heteroalkynyl, branched-chain C4-C6 heteroalkynyl, cyclic C3-C6 heteroalkynyl, straight-chain C1-C4 heteroalkynyl, cyclic C3-C4 heteroalkynyl, such as straight-chain C1-C 10 , C1-C9, C1-C8, C1-C7, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2 heteroalkynyl, branched C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkynyl, or cyclic C3-C9, C3-C9, C3-C8, C3-C7, C3-C6, C3-C5, C3-C4 heteroalkynyl.
[0244] For any of Formulas I, II, III, IVa, IVb, Va, Vb, VI, VII, VIII, IX, Xa, Xb, XIa, XIb, XIIa and XIIb, the aryl group may be C5-C 30 Aryl, C5-C 20 Aryl, C5-C 12 Aryl, C5-C 11 Aryl, C5-C9 aryl, C6-C 20 Aryl, C6-C 12 Aryl, C6-C 11 It should be understood that the aryl group may be a heteroaryl group, such as a C5-C 30 Heteroaryl, C5-C 20 Heteroaryl, C5-C 12 Heteroaryl, C5-C 11 Heteroaryl, C5-C9 heteroaryl, C6-C 30 Heteroaryl, C6-C 20 Heteroaryl, C6-C 12 Heteroaryl, C6-C 11 Heteroaryl or C6-C9 heteroaryl. Polyaryl can be C 10 -C30 Polyaryl, C 10 -C 20 Polyaryl, C 10 -C 12 Polyaryl, C 10 -C 11 Polyaryl or C 12 -C 20 It should be understood that the aryl group may be a polyheteroaryl group, such as C 10 -C 30 Polyheteroaryl, C 10 -C 20 Polyheteroaryl, C 10 -C 12 Polyheteroaryl, C 10 -C 11 Polyheteroaryl or C 12 -C 20 Polyheteroaryl.
[0245] Compounds may contain one or more chiral centers or may otherwise exist as multiple stereoisomers. These may be pure (single) stereoisomers or may be mixtures of stereoisomers, such as enantiomers, diastereomers, and mixtures in enantiomeric or diastereomeric excess. Compounds may exist as geometric isomers. Therefore, it is to be understood that the present invention includes pure geometric isomers or mixtures of geometric isomers.
[0246] 2. Exemplary compounds
[0247] Exemplary compounds are described below.
[0248]
[0249] 3. Pharmaceutically acceptable salts
[0250] The compound may be neutral, or may be one or more pharmaceutically acceptable salts, crystalline forms, non-crystalline forms, hydrates or solvates or combinations thereof. References to compounds may refer to the neutral molecule and / or those additional forms, whether collectively or individually from the context. Pharmaceutically acceptable salts of a compound include acid addition salts and base salts thereof.
[0251] Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include acetate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hyaluronate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, saccharate, stearate, succinate, tartrate, toluenesulfonate, and trifluoroacetate.
[0252] Suitable base salts are formed from bases which form non-toxic salts. Examples include ammonium, arginine, benzathine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts.
[0253] Hemisalts of acids and bases can also be formed, for example, hemisulphate and hemicalcium salts.
[0254] B. Pharmaceutical Compositions
[0255] Disclosed are pharmaceutical compositions and pharmaceutical preparations (also referred to herein as "pharmaceutical preparations") suitable for delivering unit dosage forms of compounds thereof and their preparation. In general, a pharmaceutical composition or pharmaceutical preparation contains a compound described herein and / or a pharmaceutically acceptable salt of the compound and a pharmaceutically acceptable excipient. The term "pharmaceutically acceptable excipient" is used herein to describe any ingredient in a preparation other than the compound described herein. A pharmaceutical composition or pharmaceutical preparation may contain an effective amount of one or more compounds of any structural formula described herein and / or a pharmaceutically acceptable salt thereof for preventing or treating pseudoallergic reactions, pseudoallergic diseases, or pseudoinflammatory diseases in a subject in need thereof, or for treating or alleviating one or more symptoms associated with pseudoallergic reactions, pseudoallergic diseases, or pseudoinflammatory diseases, including any one or any combination of compounds of the structural formula described herein and / or pharmaceutically acceptable salts thereof. It should be understood that a combination and / or mixture of compounds and / or pharmaceutically acceptable salts thereof may be included in a composition or preparation.
[0256] In some forms, the pharmaceutical composition or formulation may contain one or more active agents in addition to the compound, such as one or more additional anti-allergic agents.
[0257] Any one or more of the compounds provided herein may be expressly included or expressly excluded from the pharmaceutical compositions, dosage units, and / or methods of use or methods of treatment disclosed herein.
[0258] 1. Oral preparations
[0259] The compounds and / or pharmaceutically acceptable salts thereof may be administered orally. Oral administration may involve swallowing, whereby the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed, whereby the compound enters the bloodstream directly from the mouth.
[0260] Formulations suitable for oral administration include solid preparations such as tablets, capsules containing granules, liquids, powders, lozenges (including liquid-filled lozenges), chewables, multi- and nanoparticles, gels, solid solutions, liposomes, films, ovules, sprays, and liquid preparations.
[0261] Liquid preparations include suspensions, solutions, syrups and elixirs. Such preparations can be used as fillers in soft or hard capsules and typically contain carriers, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose or suitable oils and one or more emulsifiers and / or suspending agents. Liquid preparations can also be prepared by solid compounding (e.g., compounding from a drug package).
[0262] The compounds and / or pharmaceutically acceptable salts thereof may also be used in fast dissolving, fast disintegrating dosage forms, such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 11(6), 981-986, (2001).
[0263] For tablet or capsule dosage forms, depending on the dose, the compound and / or its pharmaceutically acceptable salt may account for 1% to 80% by weight of the dosage form, more typically 5% to 60% by weight of the dosage form. In addition to the compounds described herein, tablets typically contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, crospovidone, polyvinyl pyrrolidone, methylcellulose, microcrystalline cellulose, lower alkyl substituted hydroxypropyl cellulose, starch, pregelatinized starch and sodium alginate. In general, the disintegrant will account for 1% to 25% by weight of the dosage form, preferably 5% to 20% by weight.
[0264] Binders are generally used to impart cohesiveness to tablet formulations. Suitable binders include microcrystalline cellulose, gelatin, sugar, polyethylene glycol, natural and synthetic gums, polyvinyl pyrrolidone, pregelatinized starch, hydroxypropyl cellulose and hypromellose. Tablets may also contain diluents such as lactose (e.g., monohydrate, spray-dried monohydrate, or anhydrous form), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch, and dibasic calcium phosphate dihydrate.
[0265] Tablets or capsules may also optionally contain surfactants such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surfactants may comprise 0.2% to 5% by weight of the tablet, and glidants may comprise 0.2% to 1% by weight of the tablet.
[0266] Tablets or capsules also typically contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and a mixture of magnesium stearate and sodium lauryl sulfate. Lubricants typically account for 0.25 to 10% by weight of the tablet, preferably 0.5 to 3% by weight.
[0267] Other possible ingredients include glidants (eg, talc or colloidal anhydrous silica, about 0.1 wt % to about 3 wt %), antioxidants, coloring agents, flavoring agents, preservatives, and taste masking agents.
[0268] Exemplary tablets contain up to about 80% of one or more compounds described herein, about 10% to about 90% by weight of a binder, about 0% to about 85% by weight of a diluent, about 2% to about 10% by weight of a disintegrant, and about 0.25% to about 10% by weight of a lubricant.
[0269] Tablets or capsule blends can be compressed directly or by rollers to form tablets. Alternatively, tablet or capsule blends or partial blends can be wet granulated, dry granulated, or melt granulated, melt condensed, or extruded before tableting. The final formulation can contain one or more layers and can be coated or uncoated; it can even be encapsulated.
[0270] Solid preparations for oral administration can be formulated as immediate release and / or sustained release. Sustained release preparations include delayed release preparations, sustained release preparations, pulsed release preparations, controlled release preparations, targeted release preparations, and programmed release preparations.
[0271] 2. Parenteral Preparations
[0272] The compound and / or its pharmaceutically acceptable salt can also be directly administered into the blood, into the muscle or into the internal organ. Suitable routes for such parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, epidural, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous delivery. Suitable devices for parenteral administration include needle (including microneedle) syringes, needle-free syringes and infusion techniques.
[0273] Parenteral preparations are usually aqueous solutions which may contain excipients such as salts, sugars and buffers (preferably at pH 3 to 9), but for some applications they may be more suitably formulated as sterile non-aqueous solutions or in dry form for use with a suitable vehicle (e.g. sterile pyrogen-free water).
[0274] The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may be carried out using standard pharmaceutical techniques well known to those skilled in the art.
[0275] The solubility of compounds used in the preparation of parenteral formulations may be increased using appropriate formulation techniques such as the incorporation of solubility enhancers.
[0276] Preparations for parenteral administration can be formulated as immediate release and / or sustained release. Sustained release preparations include delayed release preparations, sustained release preparations, pulse release preparations, controlled release preparations, targeted release preparations and programmed release preparations. Therefore, the compound can be formulated as a solid, semisolid or thixotropic fluid to be used as an implant reservoir, providing a sustained release of the active compound. The example of such preparations includes a stent coated with a drug and poly (dl-lactic acid-co-glycolic acid) (PGLA) microspheres.
[0277] 3. Pulmonary and mucosal preparations
[0278] The compound and / or its pharmaceutically acceptable salt can be formulated for pulmonary or mucosal administration. The administration can include delivering the composition to the pulmonary, nasal, oral (sublingual, buccal), vaginal or rectal mucosa.
[0279] For example, the compound can also be administered intranasally or by oral inhalation, usually in the form of a dry powder in a dry powder inhaler (either alone, or as a mixture, for example as a dry blend with lactose, or as a mixed component particle, for example mixed with a phospholipid (such as phosphatidylcholine)), or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably using an electrohydrodynamic atomizer to generate a fine mist) or nebulizer (nebuliser) with or without a suitable propellant (such as water, ethanol-water mixture, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane). For intranasal or oral inhalation use, the powder may contain a bioadhesive, for example, chitosan or cyclodextrin. As used herein, the term aerosol refers to any particle fine mist formulation, which may be in the form of a solution or suspension, whether or not it is prepared using a propellant. Aerosols can be prepared using standard techniques, such as ultrasound or high pressure treatment.
[0280] A pressurized container, pump, spray, atomizer or nebulizer contains a solution or suspension of one or more compounds, which solution or suspension comprises, for example, ethanol, ethanol in water or a suitable alternative agent for dispersing, solubilizing or prolonging the release of the active ingredient, a propellant as a solvent, and optionally a surfactant, such as sorbitan trioleate, oleic acid or oligolactic acid.
[0281] Prior to use in dry powder or suspension formulations, the drug product is micronized to a size suitable for delivery by inhalation (usually less than 5 microns). This can be achieved by suitable comminution methods such as spiral jet milling, fluidized bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization or spray drying.
[0282] Capsules (e.g., made of gelatin or hypromellose), blisters and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of a compound described herein, a suitable powder base such as lactose or starch, and a performance modifier such as l-leucine, xylitol or magnesium stearate. Lactose may be anhydrous or may be in the form of a monohydrate, the latter being preferred. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
[0283] Solution formulations suitable for use in atomizers that use electrohydrodynamics to generate fine mist may contain 1 μg to 20 mg of one or more compounds per actuation, and the actuation volume may vary from 1 μl to 100 μl. Typical formulations may contain one or more compounds described herein, propylene glycol, sterile water, ethanol, and sodium chloride. Alternative solvents that can be used to replace propylene glycol include glycerol and polyethylene glycol.
[0284] Suitable flavors (such as menthol and levomenthol) or sweeteners (such as saccharin or saccharin sodium) may be added to those formulations intended for inhaled / intranasal administration.
[0285] Formulations for inhaled / intranasal administration can be formulated as immediate release and / or sustained release using, for example, PGLA. Sustained release formulations include delayed release formulations, sustained release formulations, pulsed release formulations, controlled release formulations, targeted release formulations, and programmed release formulations.
[0286] In the case of dry powder inhalers and aerosols, the dosage unit is determined by a valve that delivers a metered amount. The unit of the compound is usually set to administer a metered amount or "puff". The total daily dose will be administered in a single dose, or more often as divided doses throughout the day.
[0287] In some forms, the compound and / or its pharmaceutically acceptable salt can be formulated for pulmonary delivery, such as intranasal administration or oral inhalation. Carriers for pulmonary preparations can be divided into those for dry powder preparations and those for application as solutions. Aerosols for delivering therapeutic agents to the respiratory tract are known in the art. For administration by the upper respiratory tract, the preparation can be formulated into an aqueous solution, such as water or buffered or unbuffered isotonic saline, or as an aqueous suspension, for intranasal administration as drops or as a spray. Such aqueous solutions or suspensions can be isotonic relative to nasal secretions, and have approximately the same pH, for example, in the range of about pH 4.0 to about pH 7.4 or pH 6.0 to pH 7.0. Buffer should be physiologically compatible, and include phosphate buffer (illustration only). Those skilled in the art can easily determine the suitable saline content and pH of the non-toxic aqueous solution suitable for nasal and / or upper respiratory tract administration.
[0288] In some forms, the aqueous solution is water, a physiologically acceptable aqueous solution containing salt and / or a buffer (e.g., phosphate buffered saline (PBS)) or any other aqueous solution acceptable for administration to animals or humans. Such solutions are well known to those skilled in the art, including but not limited to distilled water, deionized water, pure water or ultrapure water, saline, phosphate buffered saline (PBS). Other suitable aqueous solvents include but are not limited to Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents (e.g., cellulose derivatives, sodium alginate, polyvinyl pyrrolidone and tragacanth) and wetting agents (e.g., lecithin). Preservatives suitable for aqueous suspensions include ethyl p-hydroxybenzoate and n-propyl p-hydroxybenzoate.
[0289] In some forms, solvents that are low toxic organic (i.e., non-aqueous) Class 3 residual solvents (e.g., ethanol, acetone, ethyl acetate, tetrahydrofuran, ether, and propanol) can be used for the formulation. The solvent is selected based on its ability to easily aerosolize the formulation. The solvent should not react harmfully with the compound. An appropriate solvent should be used to dissolve the compound or form a suspension of the compound. The solvent should be volatile enough to form an aerosol of the solution or suspension. Additional solvents or aerosol agents, such as freon, can be added as needed to increase the volatility of the solution or suspension.
[0290] In certain forms, the pharmaceutical composition may contain a small amount of polymers, surfactants or other excipients known to those skilled in the art. In this context, "small amount" means that there is no excipient that may affect or mediate cellular uptake of the compound, and the excipient present in this amount does not adversely affect cellular uptake of the compound.
[0291] Dry lipid powder can be directly dispersed in ethanol due to its hydrophobic properties. For lipids stored in organic solvents such as chloroform, the required amount of solution is placed in a vial and the chloroform is evaporated under a stream of nitrogen to form a dry film on the surface of the glass vial. When compounded with ethanol, the film is easy to swell. In order to fully disperse the lipid molecules in the organic solvent, the suspension is sonicated. Non-aqueous lipid suspensions can also be prepared in anhydrous ethanol using a reusable PARI LC Jet+ nebulizer (PARI Respiratory Equipment, Monterey, California).
[0292] 4. Topical preparations
[0293] The compound and / or its pharmaceutically acceptable salt can be applied directly to the external surface of the skin or mucosa (including the surface membranes of the nose, lungs and mouth) so that the compound and / or its pharmaceutically acceptable salt crosses the external surface of the skin or mucosa and enters the underlying tissue.
[0294] Formulations for topical administration generally contain a dermatologically acceptable carrier that is suitable for application to the skin, has good aesthetic properties, is compatible with the active agent and any other ingredients, and does not raise any undesirable safety or toxicity issues.
[0295] The carrier can have a variety of forms. For example, emulsion carriers including but not limited to oil-in-water, water-in-oil, water-in-oil-in-water and silicone-in-water-in-oil emulsions are available in this article. These emulsions can cover a wide range of viscosities, for example, from about 100 cps to about 200,000 cps. These emulsions can also be delivered in the form of sprays using mechanical pump containers or pressurized aerosol containers using conventional propellants. These carriers can also be delivered in the form of mousses or transdermal patches. Other suitable topical carriers include anhydrous liquid solvents, such as oils, alcohols and silicones (e.g., mineral oil, ethanol-isopropanol, dimethicone, cyclomethicone, etc.); water-based single-phase liquid solvents (e.g., water-alcohol solvent systems, such as mixtures of ethanol and / or isopropanol and water); and thickened forms of these anhydrous and water-based single-phase solvents (e.g., by adding appropriate glues, resins, waxes, polymers, salts, etc. to increase the viscosity of the solvent to form a solid or semi-solid). Examples of topical carrier systems that can be used in the present formulations are described in the following four references, all of which are incorporated herein by reference in their entirety: "Sun Products Formulary" Cosmetics & Toiletries, Vol. 105, pp. 122-139 (December 1990); Sun Products Formulary" Cosmetics & Toiletries, Vol. 102, pp. 117-136 (March 1987); U.S. Pat. No. 5,605,894 issued to Blank et al.; and U.S. Pat. No. 5,681,852 issued to Bissett.
[0296] Preparations for topical administration can be formulated as immediate release and / or sustained release. Sustained release preparations include delayed release preparations, sustained release preparations, pulse release preparations, controlled release preparations, targeted release preparations, and programmed release preparations. Therefore, the compound can be formulated as a solid, semisolid, or thixotropic fluid to be used as an implant reservoir, providing a sustained release of the active compound. Examples of such preparations include stents coated with drugs and poly (dl-lactic acid-co-glycolic acid) (PGLA) microspheres.
[0297] 5. Additional active agents
[0298] In some forms, the pharmaceutical composition or pharmaceutical formulation may contain one or more additional active agents, such as one or more additional anti-allergic and / or anti-inflammatory agents. Antiallergic and anti-inflammatory agents that can be included in pharmaceutical compositions or formulations are known, for example, see WebMD, “Allergy Medications” and “Anti-inflammatory Drugs,” available at https: / / www.webmd.com / allergies / allergy-medications and https: / / www.webmd.com / arthritis / anti-inflammatory-drugs; Barnes, Nature, 402(6760): 31-38 (1999); Rainsford, Inflammation in the pathogenesis of chronic diseases 3: 27 (2007); Chinose, Antiallergic drugs, D. Spina, C. Page, W. Metzger, & B. O'Connor (Eds.), Drugs for the Treatment of Respiratory diseases, 119-123, Cambridge: Cambridge University Press. Press (Cambridge University Press) and Assanasen, Clin. Allergy Immunol., 17: 101-139 (2002).
[0299] Exemplary anti-allergic and anti-inflammatory drugs that may be included in the pharmaceutical composition or pharmaceutical formulation include, but are not limited to, epinephrine, antihistamines, corticosteroids, nonsteroidal drugs, and antibodies, such as (S)-carbinoxamine maleate, 2',4,4',6'-tetrahydroxychalcone, 2',4,4',6'-tetrahydroxychalcone (1-), 6'-O-acetylpeonidin, 7-epiclusianone, trans-rhubarb glycoside, acroptil, alcaftadine, amiloxanol, aspirin-induced resolvin D1, astemizole, azatidine, azatidine maleate, azelastine, azelastine hydrochloride, bepotastine, bepotastine besylate, Breo Ellipta, brompheniramine, brompheniramine maleate, capsaicin esters, carbinoxamine, carbinoxamine maleate, cetirizine, Chlorpheniramine, cinnarizine, clemastine, clemastine fumarate, cortisol, cyproheptadine, cyproheptadine hydrochloride, davidigenin, desloratadine, dexbrompheniramine, dexbrompheniramine maleate, dichotomoside D, diphenhydramine, diphenhydramine hydrochloride, diphenhydramine salicylate, dithiadene, allergy-resistant, emedastine, emedastine difumarate, epinastine, fexofenadine, fluticasone, fluticasone furoate, fluticasone propionate, fucodiphloroethol G, ginsenoside CK, hydrangea phenol, cyanidin, methapyrine, methapyrine hydrochloride, mometasone, mometasone furoate, myricetin, nedocromil, beeswax, prednisolone sodium phosphate, promethazine, promethazine hydrochloride, rhinacanthin D, rhodiocyanoside A, fusanotoxin, hematoxylin, strychnine, tixocortol pivalate, torososide B, tranilast, triamcinolone, triamcinolone acetonide, Δ9-tetrahydrocannabinolic acid, β-lapachone, β-myricene, (-)-anthophan, (-)-piperidin, (-)-larreatricin, (-)-syringaresinol O,O'-di(β-D-glucoside), (+)-α- Grapevine, (+)-conocarpan, (+)-schisandrin, (+)-subersic acid, (10E,12Z,15Z)-9-hydroxy-10,12,15-octadecatrienoic acid methyl ester, (13R,14S)-dihydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid, (18R)-resolvin E3, (18S)-resolvin E1, (18S)-resolvin E2, (1R,5R,6S,7R,8S,10R)-8-hydroxy-4-oxopseudoguaiac-2(3),11(13)-diene-12,6-lactone, (1R,5R,6S,7S,8S,10R,11S)-6-hydroxy-4-oxopseudoguaiac-2(3)-ene-12,8-lactone, (1S,2R,5R,6S,7R,8S,10R)-6-acetoxy-2-methoxy-4-oxopseudoguaiac-11(13)-ene-12,8-lactone, (1S,2R,5R,6S,7S,8S,10R)-6- Hydroxy-2-ethoxy-4-oxopseudoguaiac-11(13)-ene-12,8-lactone, (1S,2R,5R,6S,7S,8S,10R)-6-hydroxy-2-methoxy-4-oxopseudoguaiac-11(13)-ene-12,8-lactone, (1S,2S,5R,6S,7R,8S,10R)-6-acetoxy-2-methoxy-4-oxopseudoguaiac-11(13)-ene-12,8-lactone, (1S,5R,6S,7S,8S,10R,11R)-6- Hydroxy-4-oxopseudoguaiac-12,8-lactone, (1S,5S,7R,8S,10R)-14-acetoxy-4-oxopseudoguaiac-11(13)-ene-12,8-lactone, (2S,3S)-2,3-dihydro-3-hydroxymethyl-2-(4-hydroxyphenyl)-5-(E)-propenylbenzofuran, (4Z,7Z,10S,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosahexaenoic acid, (4Z,7Z,10Z,12E,14R,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, (4Z,7Z,10Z,12E,14S,16Z,19Z)-14,22-dihydroxydocosahexaenoic acid, (4Z,7Z,10Z,13Z,15E,19Z)-17-oxodocosahexaenoic acid, (5Z)-5-(quinoxalin-6-ylmethylene)-1,3-thiazolidine-2,4-dione, (5Z,11Z,14Z)-eicosatrienoic acid, (7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid, (7R,14S)-dihydroxy-(8E,10E,12Z,16Z,19Z)-docosapentaenoic acid, (E)-2,3,5,4'- Tetrahydroxystilbene-2-O-β-D-glucoside, (E,E)-germazine, (R)-lisofylline, (RS)-mallotophilippen E, (S)-colchicine, 1,3,7,9-tetramethyluric acid, 1-O-3,4-dimethoxy-5-hydroxyphenyl-(6-O-3,5-dimethoxygalloyl)-β-D-pyranoglucoside, 1-O-3,4-dimethoxy-5-hydroxyphenyl-(6-O-vanillyl)-β-D-pyranoglucopyranoside, 10-PAHSA, 10-PAHSA(1-), 11(R)-HEPE, 11(R)-HEPE(1-), 11-PAHSA, 11-PAHSA(1-), 12-PAHSA, 12-PAHSA(1-), 13,14(S)-dihydroxy-(7Z,9E,11E,16Z,19Z)-docosapentaenoic acid, 13-PAHSA, 13-PAHSA(1-), 14(S),21-dihydroxy-(7Z,10Z,12E,16Z,19Z)-docosapentaenoic acid, 15(R)-HEPE, 15(R)-HEPE(1-), 16(S)-HETE, 16,23,29-trihydroxy-3- Oxo-angelica-12-ene-28-acid, 17-defuranyl-17-oxo-azido-salanlin (azido-salanlin), 18(R)-HEPE, 18(R)-HEPE(1-), 18(S)-HEPE, 19α-hydroxy-madecassic acid, 2α,3α,23-trihydroxyangelica-12-ene-28-acid, 2α,3β-dihydroxyangelica-13(18)-ene-28-acid, 2α-acetoxy-4α,6α-dihydroxy-1β,5αH-guaiac-9(10),11(13)-diene-12,8α-lactone, 2',4,4',6'-tetrahydroxychalcone, 2',4,4',6'-tetrahydroxychalcone(1-), 2'-Hydroxychalcone, 2'-Hydroxydaidzein, 2'-Hydroxydaidzein (1-), 2'-Hydroxyformononetin, 2,4-dihydroxy-6-methylbenzaldehyde, 2-(β-D-pyranoglucopyranosyloxy)benzoic acid, 2-(2,4-dihydroxyphenyl)-5-(E)-propenylbenzofuran, 2-(2-hydroxy-4-methoxyphenyl)-5-(3-hydroxypropyl)benzofuran, 2-(4-hydroxyphenyl)-5-(E)-propenylbenzofuran, 2-acetaminophen, 22-hydroxyprotectin D1, 3β,6β,23-trihydroxyangelica-12-ene-28- Acid, 3β,6β,23-trihydroxy angelica-12-ene-28-acid 28-O-β-D-pyranoglucopyranoside, 3,4'-dimethyl kaempferol, 3-O-[2,3-di-O-acetyl-α-L-arabinopyranosyl]-hederagenin 28-O-α-L-rhamnopyranosyl-(1→4)-β-D-pyranoglucopyranosyl-(1→6)-β-D-pyranoglucopyranoside, 3-O-[3,4-di-O-acetyl-α-L-arabinopyranosyl] hederagenin 28-O-α-L-rhamnopyranosyl-(1→4)-β-D-pyranoglucopyranosyl-(1→6)-β-D-pyranoglucopyranoside, 3-deacetyl neem salanlin (salannin), 4β,10α-dihydroxy-5αH-guaiac-1(2),11(13)-diene-12,8α-lactone, 4',6,7-trihydroxyisoflavone, 4'-hydroxychalcone, 4-epiisoinuviscolide, 4-hydroxycordoin, 4-terpineol, 5-(3-hydroxypropyl)-2-(2-methoxy-4-hydroxyphenyl)benzofuran, 5-PAHSA, 5-PAHSA(1-), 6'-O-acetylpeonidin, 6,7-dihydroxy-4-methylcoumarin, 7α-hydroxydehydroepiandrosterone, 7-deacetylgedunin, 7-epiclusianone, 7-oxo-10α-cucurbitadienol, 7-PAHSA, 7-PAHSA(1-), 8-epihelenalin, 8-epiinuviscolide, 8-oxo-resolvone D1, 8-PAHSA, 8-PAHSA(1-), 9-PAHSA, 9-PAHSA(1-), 9E,11E-octadecadienoic acid, all-trans-retinoic acid, aloe C-glucosylchromone, epi-maslinic acid, meso-3,3'-didemethoxynectandrin B, meta-zeaxanthin, N-arachidonoyl serotonin, racemic lisofylline, rel-2α,3α,23- rel-2α,3α,23-trihydroxy-19-oxo-18,19-seco-urs-11,13(18)-dien-28-oic acid, rel-2α,3β,23-trihydroxy-19-oxo-18,19-seco-urs-11,13(18)-dien-28-oic acid, rel-2α,3β,23-trihydroxy-19-oxo-18,19-seco-12,17-diene-28-norursane17-dien-28-norursane), trans-rhubarb glycoside, wormwood, verbascoside, afudamidin, acanthoside, antrocapmphin A, aromatic helianthin, ascidiathiazone A, ascidiathiazone B, aspirin-induced protectin D1, aspirin-induced resolvin D1, aspirin-induced resolvin D2, aspirin-induced resolvin D3, aspirin-induced resolvin D4, aspirin-induced resolvin D5, aspirin-induced resolvin D6, astilbin, astragaloside IV, azadirachtin, baicalin, bauhinoxepin F, bauhinoxepin I, BAY 60-6583, berapute, berapute sodium, betamethasone phosphate, betulin, betulinic acid, carmine, bowdichione, brazilian oxyde, brazilian oxyde, bufotoxin, burrodin, butrin, cafestol, camostat, camostat mesylate, cannabidiol, capsaicin, carlinoside, carnosic acid, scutellarin, castanospermine, cenicriviroc, CGP-42112A, CGS-21680, chrysin, chrysophanol, clarinoside, scutellarin A, dihydroanemyl angelate, ferulol A, ferulol B, confertin, CORM 3, coumestrol, crassumolide A, quinolones, fennel alkaloids, cudraflavone B, cudraflavone A, curcumin, L-His-L-Pro, cyclomontanin A, cyclomontanin C, cyclomontanin D, decane-1,2-diol, decanoic acid, dehydroconiferyl alcohol, demethoxycurcumin, norzelaminaldehyde, trisulphuric acid, diinsinin, diinsinol, diosgenin, (-)-β-caryophyllene, (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propionic acid, (E)-3-toluenesulfonyl acrylonitrile, (S)-ketorolac, 4-(methylamino)antipyrine, 4-aminoantipyrine, O- Methyl salicylic acid, [5-fluoro-1-(4-isopropylbenzylidene)-2-methylindan-3-yl]acetic acid, acetylclofenac, acemetacin, acetosyringone, acetylsalicylic acid, adapalene, alclofenac, alminoprofen, almotriptan, almotriptan maleate, amfenac, amfenac sodium hydrate, aminopyrine, amiloxanol, amodiaquine, ampiroxicam, antipyrine, azapropazone, apigenin 7-O-β-D-glucoside, apigenin 7-O-β-D-glucoside (1-), apocynin, apremilast, arasertaconazole, baicalin, balsalazide, balsalazide disodium, benzyldacic acid, Benoxaprofen, benzydamine, biphenyl-4-acetic acid, bromfenac, bromfenac sodium salt, bromfenac sodium salt sesquihydrate, bufenac, bumadizone, bumadizone calcium, bumadizone calcium hemihydrate, Carprofen, cimicoxib, clofazimine, clonixin, clonixin lysine, corilagin, crisaborole, deracoxib, dexibuprofen, dexketoprofen, diclofenac, bifenpyramide, diflunisal, dithiosalicylic acid, droxicam, eletriptan, eletriptan hydrobromide, enprophylline, etodolac, etoricoxib, bifenbutrazole, fendosal, fenoprofen, fenoprofen calcium, firocoxib, flufenamate, flufenamic acid, flunixin, flunixin meglumine, flunoprofen, flurbiprofen, garefoxac, glafenine, ibufenac and ibuprofen and combinations thereof.
[0300] 6. Effective amount
[0301] The effective amount of the compound contained in the pharmaceutical composition or pharmaceutical preparation depends on many factors, including the indication to be treated, the route of administration, the co-administration with other therapeutic compositions, and the overall condition of the patient. An exemplary effective amount of the compound contained in the pharmaceutical preparation (in unit dosage form) may be 0.01 mg to 1500 mg, 0.1 mg to 1500 mg, 1 mg to 1500 mg, 10 mg to 1500 mg, 20 mg to 1500 mg, 0.01 mg to 1000 mg, 0.1 mg to 1000 mg, 1 mg to 1000 mg, 10 mg to 1000 mg, 20 mg to 1000 mg, 0.01 mg to 700 mg, 0.1 mg to 700 mg, 1 mg to 700 mg, 10 mg to 700 mg, 20 mg to 700 mg, 50 mg to 700 mg, 0.01 mg to 500 mg. From about 1 to about 100 mg, from about 200 mg to about 500 mg, from about 100 mg to about 500 mg, from about 200 mg to about 500 mg, from about 500 mg to about 500 mg, from about 0.01 mg to about 100 mg, or from about 0.1 mg to about 100 mg.
[0302] In some forms, the total concentration of one or more compounds in the pharmaceutical formulation is about 0.05% to about 20% by weight, about 0.1% to about 20% by weight, about 0.1% to about 15% by weight, about 0.2% to about 20% by weight, about 0.1% to about 10% by weight, about 0.5% to about 20% by weight, about 0.5% to about 15% by weight, about 0.5% to about 10% by weight, about 0.5% to about 5% by weight, about 0.1% to about 5% by weight, or about 0.1% to about 1% by weight. The term "total concentration of one or more compounds in a pharmaceutical formulation" refers to the total weight of the one or more compounds relative to the weight of the pharmaceutical formulation.
[0303] III. Preparation Method
[0304] A method for preparing a compound is disclosed. In general, the method may include: (i) mixing a reactant mixture with a catalyst to form a reaction mixture, wherein the reactant mixture includes a first reactant, a second reactant and a solvent; and (ii) heating the reaction mixture at a suitable temperature for a time sufficient to form a product of a compound comprising any one of formulas I-XIIb. Step (i) may be performed before step (ii) or simultaneously with step (ii). In some forms, the reactant mixture further includes a base, such as sodium carbonate, potassium carbonate, cesium carbonate, tripotassium phosphate, sodium bicarbonate or sodium hydroxide or a combination thereof.
[0305] In some forms, the first reactant may have the structure of Formula XIII:
[0306]
[0307] wherein a may be an integer from 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 or 1; wherein R' and R" may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; wherein A' may be substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; and wherein R 11 Can be a leaving group.
[0308] In some forms of Formula XIII, n is 0.
[0309] In some forms of Formula XIII, R 11 It may be a halogen (such as fluorine, bromine, chlorine or iodine), dinitrogen, dialkyl ether, perfluoroalkyl sulfonate, toluene sulfonate, mesylate, sulfonate, alcohol, nitrate, phosphate, inorganic ester, thioether, amino, carboxylate, phenoxide, hydroxide, alkoxy, amide, hydride, arsenide, alkanide or a structure having Formula XIV:
[0310]
[0311] Where R 12 Each occurrence may independently be hydrogen or substituted or unsubstituted alkyl, such as substituted or unsubstituted C1-C 15 Alkyl, substituted or unsubstituted C1-C 12 Alkyl, substituted or unsubstituted C1-C 10 Alkyl, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C5 alkyl, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C3 alkyl or substituted or unsubstituted C1-C2 alkyl, such as methyl or ethyl.
[0312] In some forms of Formula XIII, R 11 It may be a halogen, such as bromine. In some forms of Formula XIII, R 11 Can have the structure of Formula XIV:
[0313] When R', R", A' and / or R 12When it is a substituted functional group, the substituent may be a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted polyheteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted carbonyl, a substituted or unsubstituted alkoxy, a halogen, a hydroxyl, a phenoxy, an aryloxy, an alkylthio, a phenylthio, an arylthio, a cyano, an isocyano, a nitro, a carboxyl, an amino, an amide, an oxo, a silyl, a sulfinyl, a sulfonyl, a sulfonic acid, a phosphonium, a phosphino, a phosphoryl, a phosphonyl or a thiol or a combination thereof.
[0314] In some forms, the first reactant may have the structure of Formula XV:
[0315]
[0316] wherein E' and G' are independently substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, or substituted or unsubstituted polyheteroaryl; wherein Y' is independently CR1, O, S, or NR2 at each occurrence, wherein R1 and R2 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; wherein R 11 may be as defined above for Formula XIII, and wherein the substituents may be any of the substituents described above for Formula I.
[0317] In some forms of Formula XV, R1 and R2 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl or halogen.
[0318] In some forms of Formula XV, R1 and R2 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxyl, or halogen.
[0319] In some forms of Formula XV, when E', G', R1 and / or R2 are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo, or combinations thereof.
[0320] In some forms, the first reactant may have the structure of Formula XVI:
[0321]
[0322] Where Y' and R 11 may be as defined above for Formula XIII, and wherein at least one Y' is O, S or NR2, and R2 is as defined above for Formula XV.
[0323] In some forms, the first reactant may have a structure of Formula XVIIa or Formula XVIIb:
[0324]
[0325] Where Y' and R 11 may be as defined above for Formula XIII, and wherein at least one Y' is O, S or NR2, and R2 is as defined above for Formula XV.
[0326] In some forms, the first reactant may have the structure of Formula XVIIIa or Formula XVIIIb:
[0327]
[0328] wherein X' may be C, N, O or S, wherein R3 at each occurrence may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; wherein R 11 and wherein the substituents may be any of the substituents described above for Formula I.
[0329] In some forms of Formula XVIIIa and Formula XVIIIb, X' can be C or N, and R3 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl or halogen.
[0330] In some forms of Formula XVIIIa and Formula XVIIIb, X' can be C or N, and R3 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxyl or halogen.
[0331] In some forms of Formula XVIIIa and Formula XVIIIb, when R3 is a substituted functional group, the substituent may be a substituted or unsubstituted alkyl, a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted polyaryl, a substituted or unsubstituted polyheteroaryl, a substituted or unsubstituted aralkyl, a substituted or unsubstituted carbonyl, a substituted or unsubstituted alkoxy, a halogen, a hydroxyl, an amino, an amide or an oxo or a combination thereof.
[0332] In some forms of Formula XVIIIa and Formula XVIIIb, X' can be C or N, and R3 can be independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxyl, heterocyclic group, And R5 to R 10 It may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino or halogen.
[0333] In some forms of Formula XVIIIa and Formula XVIIIb, X' can be C or N, and each occurrence of R3 can independently be hydrogen, substituted or unsubstituted alkyl, oxo, hydroxyl, And R5 to R8 may independently be hydrogen or a substituted or unsubstituted alkyl group.
[0334] In some forms of Formula XVIIIa and Formula XVIIIb, X' can be C or N, and R3 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, oxo, hydroxy, or carboxy.
[0335] In some forms, the second reactant may have the structure of Formula XIX:
[0336]
[0337] wherein b may be an integer from 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 or 1; wherein R' and R" may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphonyl, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; wherein Z' may be substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; and wherein R 13 Can be a leaving group.
[0338] In some forms of Formula XIII, n is 0.
[0339] In some forms of Formula XIX, R 13 It can be the above-described 11 A leaving group such as trifluoromethanesulfonate ("OTf"), p-toluenesulfonate, mesylate, or a group having the structure of Formula XIV as defined above.
[0340] In some forms, the second reactant may have a structure of Formula XX:
[0341]
[0342] Wherein Y' may be defined as above for Formula XV, R 13 may be OTf or have the structure of Formula XIV defined above, and J′ may be a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted polyaryl, or a substituted or unsubstituted polyheteroaryl.
[0343] In some forms of Formula XX, Y' at each occurrence may be CR1 or NR2, and R1 and R2 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl, or halogen.
[0344] In some forms of formula XX, each occurrence of Y' may be CR1 or NR2, and R1 and R2 may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxyl or halogen.
[0345] In some forms of Formula XX, when J', R1 and / or R2 are substituted functional groups, the substituents may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo, or combinations thereof.
[0346] In some forms, the second reactant may have the structure of Formula XXI:
[0347]
[0348] wherein Y' may be as defined above for Formula XV, and Formula XX and R13 may be as defined above for Formula XIX.
[0349] In some forms, the second reactant may have the structure of Formula XXII:
[0350]
[0351] wherein Y' may be as defined above for formula XV, and formula XX and R 13 May be as defined above for Formula XIX.
[0352] In some forms, the second reactant may have the structure of Formula XXIII:
[0353]
[0354] wherein R4 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; wherein R 13 may be as defined above for Formula XIX; and wherein the substituents may be any substituents described above for Formula I.
[0355] In some forms of Formula XXIII, R4 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxyl, or halogen.
[0356] In some forms of Formula XXIII, each occurrence of R4 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted carbonyl, amido, amino, sulfonyl, oxo, hydroxy, or halogen.
[0357] In some forms of Formula XXIII, when R4 is a substituted functional group, the substituent may be substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxyl, amino, amide or oxo, or a combination thereof.
[0358] In some forms of Formula XXIII, each occurrence of R4 can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxyl, heterocyclic group, And R5 to R 10 It may independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino or halogen.
[0359] In some forms of Formula XXIII, each occurrence of R4 can independently be hydrogen, substituted or unsubstituted alkyl, oxo, hydroxy, And R5 to R8 may independently be hydrogen or a substituted or unsubstituted alkyl group.
[0360] In some forms of Formula XXIII, each occurrence of R4 can independently be hydrogen, And R5 to R8 may independently be hydrogen or a substituted or unsubstituted alkyl group.
[0361] In some forms, the reactant mixture may contain a first reactant having a structure of any one of Formulas XIII, XV, XVI, XVIIa, XVIIb, XVIIIa, and XVIIIb and a second reactant having a structure of any one of Formulas XIX, XX, XXI, XXII, and XXIII.
[0362] The solvent suitable for forming a reactant mixture depends on the solubility of the first reactant and the second reactant. Generally, the solvent suitable for forming a reactant mixture can dissolve the first reactant and the second reactant. Examples of solvents suitable for forming a reactant mixture include, but are not limited to, water, dioxane, dimethoxyethane, 2-methyltetrahydrofuran, cyclopentyl methyl ether, tetrahydrofuran, tert-butyl methyl ether and dichloromethane and mixtures thereof. In some forms, the solvent suitable for forming a reactant mixture may be a mixed solvent, such as a mixture of two or more solvents described above, such as a mixture of water and dioxane. When the solvent suitable for forming a reactant mixture contains a mixed solvent, each component in the mixed solvent may have a suitable volume ratio. For example, when the solvent suitable for forming a reactant mixture contains a first component (such as water) and a second component (such as dioxane), the volume ratio of water to dioxane may be in the range of 10:1 to 1:10, 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 1:2 or about 1:1 or 4:1.
[0363] The catalyst is mixed with the reactant mixture to form a reaction mixture. Suitable catalysts that can be used to catalyze the reaction between the first reactant and the second reactant include, but are not limited to, PdCl2(dppf), PdCl2(dppf)DCM complex, Tetrakis, PdCl2(PPh3)2, XPhos Pd G3, and Pd(OAc)2 / PPh3 and combinations thereof.
[0364] A reaction mixture containing the first reactant, the second reactant, an optional base, and a catalyst in a solvent can be heated at a suitable temperature and for a time sufficient to form a product containing a compound having the structure of any one of Formulas I-XIIb.
[0365] In some forms, the reaction mixture can be heated at a temperature in the range of 50°C to 150°C, 60°C to 150°C, 70°C to 150°C, 80°C to 150°C, 50°C to 140°C, 50°C to 120°C, 70°C to 120°C, 80°C to 120°C, such as about 100°C, for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 8 hours, at least 10 hours, up to 20 hours, up to 18 hours, up to 16 hours, for a time of 1 hour to 18 hours, 2 hours to 16 hours, or 2 hours to 15 hours, such as about 2 hours, about 15 hours, or about 16 hours.
[0366] In some forms, the method may further include the step of mixing the first reactant, the second reactant, and the solvent to form a reactant mixture prior to step (i). In some forms, the first reactant, the second reactant, the solvent, and the optional base are mixed at room temperature (i.e., a temperature in the range of about 20°C to about 22°C at 1 atm).
[0367] In some forms, the method may further comprise the step of purging the reactant mixture with an inert gas prior to step (ii). Examples of inert gases suitable for purging the reactant mixture are nitrogen, helium, neon, argon, krypton, xenon and radon.
[0368] In some forms, the method may further comprise the step of stirring the reaction mixture during step (ii). Methods for stirring the reaction mixture during the reaction are known, such as using a magnetic stir bar or a mechanical mixer.
[0369] In some forms, the method may also include the step of purifying the product of the compound containing the structure of any one of Formulas I-XIIb. In some forms, the product containing the compound can be purified by filtration, chromatography or its combination. In some forms, the product containing the compound can be purified by filtering and HPLC successively. In some forms, after purification, the purity of the compound in the product is at least 90 % by weight, at least 92 % by weight or at least 95 % by weight. In some forms, the method does not include any purification, and the purity of the compound in the product is at least 90 % by weight, at least 92 % by weight or at least 95 % by weight.
[0370] In some forms, the method may further comprise one or more of the above steps: mixing the first reactant, the second reactant, and the solvent to form a reactant mixture prior to step (i); purging the reactant mixture with an inert gas prior to step (ii); stirring the reaction mixture during step (ii), and purifying the product containing the compound.
[0371] Additional exemplary first and second reactants, as well as more specific methods for synthesizing exemplary compounds, are described in the Examples below.
[0372] IV. How to use
[0373] A. Preventing, treating or alleviating symptoms associated with pseudoallergic reactions, pseudoallergic diseases and / or pseudoinflammatory diseases
[0374] Disclosed are methods of using compounds to prevent or treat pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease in a subject in need thereof, or to treat or alleviate one or more symptoms associated with pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease. Pseudoallergy, pseudoallergic disease and pseudoinflammatory disease may be local or systemic in a subject.
[0375] Pseudoallergic reactions, pseudoallergic diseases and pseudoinflammatory diseases are non-IgE-mediated allergic and inflammatory reactions mediated by MRGPRX2 activation of MCs. The compounds can be used as MRGPRX2 antagonists of MCs. For example, the compounds can target and bind to the binding pocket of MRGPRX2, thereby blocking the receptor, i.e., MRGPRX2, which prevents MC activation and the release of inflammatory and pro-inflammatory mediators.
[0376] In general, the method for preventing or treating pseudoallergic reactions, pseudoallergic diseases and / or pseudoinflammatory diseases in a subject in need thereof or treating or alleviating one or more symptoms associated with pseudoallergic reactions, pseudoallergic diseases and / or pseudoinflammatory diseases comprises administering a pharmaceutical preparation containing one or more compounds disclosed herein to the subject. The pharmaceutical preparation can be administered in an effective amount to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage and / or prevent or reduce MC degranulation in the subject. The step of administering an effective amount of the pharmaceutical preparation can be achieved in a single administration step, or a plurality of steps of administering the pharmaceutical preparation can be used to achieve. The subject can be a mammal in need of treatment, such as a human, dog, cat, rat, monkey, rabbit, guinea pig, etc.
[0377] In some forms of the method, whether inflammation is reduced can be identified by various diagnostic methods known to those skilled in the art, including, but not limited to, observing a reduction in the size of the tissue in which the local allergic reaction occurs, for example, a reduction in the size of the inflamed tissue by greater than 5%, compared to a control tissue not treated with the compound. The control tissue is a tissue in which the same local allergic reaction occurs but is treated with a vehicle such as DMSO or saline instead of the compound.
[0378] In some forms of the method, whether allergic symptoms are reduced can be identified by various diagnostic methods known to those skilled in the art, including, but not limited to, a reduction in the allergy score of a subject treated with the compound compared to a control subject not treated with the compound, wherein the allergy scoring system is as follows: 0, no symptoms; 1, scratching and rubbing around the nose and head; 2, edema around the eyes and mouth, diarrhea, ruffled hair, decreased activity and / or decreased activity with increased respiratory rate; 3, wheezing, dyspnea, cyanosis around the mouth and tail; 4, no activity or trembling, convulsions after stimulation; 5, death. The control subject is a subject who has experienced the same or similar local or systemic allergic reaction but treated with a vehicle such as DMSO or saline, saline without the compound.
[0379] In some forms of the method, whether tissue damage is reduced can be identified by various diagnostic methods known to those skilled in the art, including but not limited to, measuring a reduction in dye extravasation (such as Evans blue extravasation) in tissue undergoing local allergic reactions compared to control tissue not treated with the compound, for example, observing a reduction in dye extravasation (such as Evans blue extravasation) in tissue undergoing local allergic reactions compared to control tissue not treated with the compound by greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45% or greater than 50%.
[0380] In some forms of the method, whether MC degranulation is reduced can be identified by various diagnostic methods known to those skilled in the art, including but not limited to, measuring a decrease in the percentage of degranulated MCs in tissues that undergo local allergic reactions compared to control tissues that have not been treated with the compound, for example, observing a decrease in the percentage of degranulated MCs in tissues that undergo local allergic reactions compared to control tissues that have not been treated with the compound by greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45% or greater than 50%.
[0381] 1. Pseudoallergic reactions, pseudoallergic diseases and / or pseudoinflammatory diseases
[0382] The pseudoallergic reaction, pseudoallergic disease, and pseudoinflammatory disease treated by the disclosed methods can be any allergic reaction, allergic disease, or inflammatory disease mediated by MC activation.
[0383] Suitable pseudoallergic reactions, pseudoallergic diseases and pseudoinflammatory diseases and symptoms associated with pseudoallergic reactions, pseudoallergic diseases and pseudoinflammatory diseases that can be treated by the disclosed methods include, but are not limited to, allergies, anal pruritus, cough, migraine, pain and oral ulcer pain, mastocytosis, mast cell activation syndrome, cholestasis, eczema, atopic eczematous dermatitis, seborrheic dermatitis, atopic dermatitis, contact dermatitis, irritant dermatitis, xerosis (dry skin), psoriasis, fungal infections (including athlete's foot), yeast infections (including diaper rash and vaginal itching), parasitic infections, parasitic infestations (including scabies and lice), lichen planus, lichen planus pilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, lichen simplex, lichen simplex chronicus, lichen sclerosus, itching secondary to drug treatment, senile itch (senile itch ... lichen scle itch), uremia, idiopathic itch, itch associated with cirrhosis, itch associated with inflammation, itch associated with allergies, itch associated with cancer, itch associated with kidney disease, itch associated with hemodialysis, burns, scalds, sunburn, wound healing, insect bites, urticaria, sweat gland abnormalities, bullous pemphigoid, photodermatosis, skin blistering, adult acne, chickenpox, seasonal allergies, Sullliller seasonal relapsing dermatitis, nodular prurigo, paresthesia back pain, cutaneous T-cell lymphoma, dermatitis herpetiformis, X-linked ichthyosis, drug reactions, chronic renal failure and Hodgkin's lymphoma, and combinations thereof.
[0384] 2. Route of administration
[0385] Pharmaceutical formulations containing one or more disclosed compounds and / or pharmaceutically acceptable salts thereof can be administered to a subject by oral administration, parenteral administration, inhalation administration, mucosal administration, topical administration, or a combination thereof.
[0386] For example, a pharmaceutical formulation containing one or more disclosed compounds and / or pharmaceutically acceptable salts thereof can be orally administered to a subject by a healthcare professional or the subject being treated (e.g., self-administration). Pharmaceutical formulations containing one or more disclosed compounds and / or pharmaceutically acceptable salts thereof can be administered as tablets, capsules containing particulate matter, granules, powders, lozenges (including liquid-filled lozenges), chewables, multi- and nanoparticles, gels, or liquids (e.g., solutions or suspensions in aqueous or non-aqueous solvents).
[0387] Optionally, a pharmaceutical formulation containing one or more disclosed compounds and / or pharmaceutically acceptable salts thereof can be administered to a subject by intravenous or intraperitoneal injection. The intravenous or intraperitoneal injection can be performed by a medical professional or the subject being treated (e.g., self-injection).
[0388] Alternatively, pharmaceutical formulations containing one or more disclosed compounds and / or pharmaceutically acceptable salts thereof can be administered to a subject by inhalation (eg, oral inhalation and / or nasal inhalation).
[0389] Optionally, a pharmaceutical formulation containing one or more disclosed compounds and / or pharmaceutically acceptable salts thereof can be administered to a subject by topically applying the compound or pharmaceutical composition or formulation to one or more exposed surfaces of the subject.
[0390] 3. Effective amount
[0391] The step of administering an effective amount of the pharmaceutical preparation can be achieved in a single administration step, or using multiple administration steps. For example, if the unit dosage form contains a compound that is effective in preventing or reducing inflammation, preventing or reducing allergic symptoms, preventing or reducing tissue damage, and / or preventing or reducing MC degranulation in a subject, the method requires only a single administration step. Alternatively, if the unit dosage form contains a compound that is less than the required effective amount for preventing or reducing inflammation, preventing or reducing allergic symptoms, preventing or reducing tissue damage, and / or preventing or reducing MC degranulation in a subject, the method involves at least two steps of administering the pharmaceutical preparation to the subject, optionally more than two steps of administering the pharmaceutical preparation to the subject, until the subject is administered an effective amount of the pharmaceutical preparation for preventing or reducing inflammation, preventing or reducing allergic symptoms, preventing or reducing tissue damage, and / or preventing or reducing MC degranulation in the subject. When multiple administration steps are required to administer an effective amount of the pharmaceutical preparation to the subject, each administration step may involve administering the same dose or different doses of the pharmaceutical preparation to the patient. In some forms, the method involves a single administration of an amount of a pharmaceutical composition effective to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage, and / or prevent or reduce MC degranulation in a subject.
[0392] In some forms of the method, the pharmaceutical preparation administered to the subject has an effective amount, thereby reducing the size of the tissue where local allergies occur compared to control tissues without compound treatment. In some forms of the method, the pharmaceutical preparation administered to the subject has an effective amount, thereby reducing the allergy score of the subject compared to a control without compound treatment. In some forms of the method, the pharmaceutical preparation administered to the subject has an effective amount, thereby reducing the dye exudation (such as Evans blue dye exudation) (which is an indicator of reduced tissue vascular leakage) of the tissue where local allergies occur compared to a control without compound treatment. In some forms of the method, the pharmaceutical preparation administered to the subject has an effective amount, thereby reducing the percentage of degranulated MC in the tissue where local allergies occur compared to a control without compound treatment.
[0393] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an amount effective to reduce the size of tissue experiencing local allergic reactions, the percentage of MCs that have dye extravasation and / or degranulation compared to untreated control tissue, and / or reduce the subject's allergy score compared to an untreated control.
[0394] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an amount effective to reduce the size of tissue experiencing local allergic reaction by at least 5%, at least 10%, at least 15%, or at least 20% compared to control tissue not treated with the compound.
[0395] In some forms of the method, the drug formulation administered to the subject has an effective amount such that the subject's allergy score is reduced by at least 1 point, at least 2 points, at least 3 points, at least 4 points, or 5 points, wherein the allergy scoring system is as follows: 0, no symptoms; 1, scratching and rubbing around the nose and head; 2, edema around the eyes and mouth, diarrhea, ruffled hair, decreased activity and / or decreased activity with increased respiratory rate; 3, wheezing, difficulty breathing, cyanosis around the mouth and tail; 4, no activity or tremors, convulsions after stimulation; 5, death.
[0396] In some forms of the method, the drug formulation administered to the subject is in an effective amount to reduce dye extravasation (such as Evans blue dye extravasation) in tissue undergoing local allergic reaction by greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45%, or greater than 50% compared to control tissue not treated with the compound.
[0397] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an effective amount to reduce the percentage of degranulated MCs in tissue experiencing local allergic reactions by greater than 10%, greater than 15%, greater than 20%, greater than 25%, greater than 30%, greater than 35%, greater than 40%, greater than 45%, or greater than 50%, compared to a control not treated with the compound.
[0398] In some forms, the treatment regimen utilizing the compound comprises administering from about 0.1 mg to about 300 mg of the compound / kg of the recipient's body weight / day in multiple doses or in a single dose. In some embodiments, a suitable dose may be in the range of 0.1 to 300 mg / kg of the recipient's body weight / day, optionally in the range of 6 to 150 mg / kg of body weight / day, optionally in the range of 15 to 100 mg / kg of body weight / day, optionally in the range of 15 to 80 mg / kg of body weight / day, optionally in the range of 15 to 50 mg / kg of body weight / day, optionally in the range of 15 to 30 mg / kg of body weight / day.
[0399] The ideal dose may be presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, in units containing 0.01 mg to 1500 mg, 0.1 mg to 1500 mg, 1 mg to 1500 mg, 10 mg to 1500 mg, 20 mg to 1500 mg, 0.01 mg to 1000 mg, 0.1 mg to 1000 mg, 1 mg to 1000 mg, 10 mg to 1000 mg, 20 mg to 1000 mg, 0.01 mg to 700 mg, 0.1 mg to 700 mg, 1 mg to 700 mg, 10 mg to 700 mg, 20 mg to 700 mg, 50 mg to 700 mg, 0.01 mg to 500 mg, 0.1 mg to 500 mg, 1 mg to 500 mg, 10 mg to 500 mg, The compound is administered in unit dosage forms of 20 mg to 500 mg, 50 mg to 500 mg, 0.01 mg to 100 mg, or 0.1 mg to 100 mg.
[0400] 4. Optional Steps
[0401] a. Administration of additional active agents
[0402] One or more active agents other than the compound may be administered to the subject throughout the method or at various intervals during the method. For example, one or more additional active agents may be administered to the subject before, during, and / or after step (i) of administering a pharmaceutical formulation comprising the compound. In some forms, one or more additional active agents may be included in a pharmaceutical formulation containing the compound and administered to the subject simultaneously with the compound.
[0403] In some forms, the one or more additional active agents are one or more anti-allergic and / or anti-inflammatory agents described above. The amount of the one or more additional anti-allergic and / or anti-inflammatory agents administered will vary from subject to subject as required.
[0404] B. Treatment of mast cells
[0405] In some forms, the compounds can be used in methods of treating mast cells ("MC") in a subject in need thereof.
[0406] The method may follow the method steps described above, for example, administering an effective amount of a pharmaceutical formulation containing one or more compounds to a subject by oral administration, parenteral administration, inhalation administration, mucosal administration, topical administration, or a combination thereof. In some forms, the method may include the additional steps described above. For example, a user may administer one or more additional active agents to a subject before, during, and / or after administering the pharmaceutical formulation to the subject.
[0407] In some forms of the methods, the compound can inhibit MC degranulation and / or MRGPRX2 activation in the subject compared to a control not treated with the compound when tested under the same conditions. Additionally or alternatively, the compound can reduce calcium cations (“Ca 2+”) in the subject’s MCs compared to a control not treated with the compound when tested under the same conditions. 2+ Additionally or alternatively, the compound can reduce the release of inflammatory chemokines and / or cytokines compared to a control not treated with the compound when tested under the same conditions.
[0408] In some forms of the methods, the compound may have an IC lower than that of a positive control compound (e.g., genistein) when tested under the same conditions. 50 IC value 50 Alternatively or additionally, the compound may have an IC value lower than that of a positive control compound (such as genistein) tested under the same conditions. 50 IC value 50 Values inhibit MRGPRX2 activation.
[0409] 1. Inhibition of MC degranulation and / or MRGPRX2 activation
[0410] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an effective amount to inhibit MC degranulation in the subject compared to a control not treated with the compound when tested under the same conditions. "Same conditions" for testing inhibition of MC degranulation are performed using the same assay (e.g., MC degranulation assay), using the same procedures (e.g., same amount of cells and enzymes, same buffer and buffer concentration, same dye and dye concentration, and same incubation time and temperature, etc.).
[0411] MC degranulation is the release of preformed / de novo synthesized mediators and the development of edema and lesions in allergic reactions. MC granules store a potent mixture of preformed inflammatory mediators such as histamine, heparin, serotonin, tryptase and chymase. Some de novo synthesized mediators such as prostaglandins are derived from the precursor molecule arachidonic acid. Therefore, the MC degranulation assay can be used to evaluate the level of MC degranulation by measuring the percentage release of inflammatory mediators (such as the percentage release of β-hexosaminidase).
[0412] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount to inhibit MC degranulation in the subject by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, 30% to 90%, 30% to 80%, 30% to 75%, 35% to 75%, 35% to 75%, 40% to 90%, 40% to 80%, or 40% to 75%, compared to MC in a control not treated with the compound when tested under the same conditions.
[0413] In some forms of the method, the pharmaceutical formulation administered to the subject has an effective amount to inhibit MRGPRX2 activation in the subject compared to cells in a control that was not treated with the compound when tested under the same conditions. The "same conditions" used to test the inhibition of MRGPRX2 activation are performed using the same assay (such as a MRGPRX2 activation assay), using the same procedures (such as the same amount of cells and enzymes, the same buffer and buffer concentration, the same dye and dye concentration, and the same incubation time and temperature, etc.). In some forms, the cells used in the MRGPRX2 activation assay are HTLA cells transfected with MRGPRX2-Tango.
[0414] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount to inhibit MRGPRX2 activation in the subject by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, 30% to 99%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 40% to 99%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 45% to 99%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 45% to 99%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 45% to to 99%, 45% to 95%, 45% to 90%, 45% to 85%, 45% to 80%, 45% to 75% or 45% to 70%.
[0415] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an amount effective to inhibit MC degranulation and MRGPRX2 activation in the subject compared to cells in a control not treated with the compound when tested under the same conditions. In some forms of the methods, the compound may inhibit MC degranulation in a subject by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, 30% to 90%, 30% to 80%, 30% to 75%, 35% to 75%, 35% to 75%, 40% to 90%, 40% to 80%, or 40% to 75%, compared to MCs in a control not treated with the compound when tested under the same conditions, and inhibit MRGPRX2 activation in a subject by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, 30% to 90%, 30% to 80%, 30% to 75%, 35% to 75%, 35% to 75%, 40% to 90%, 40% to 80%, or 40% to 75%, compared to cells in a control not treated with the compound when tested under the same conditions (e.g., MRGPRX2-Tango transfected HTLA cells). At least 65%, at least 70%, at least 75%, 30% to 99%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 40% to 99%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 45% to 99%, 45% to 95%, 45% to 90%, 45% to 85%, 45% to 80%, 45% to 75%, or 45% to 70%.
[0416] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount such that the IC range of less than 30 μM, less than 25 μM, less than 20 μM, less than 15 μM, less than 10 μM, less than 5 μM, between 1 μM and 30 μM, 1 μM and 25 μM, 1 μM and 20 μM, 1 μM and 15 μM, 1 μM and 10 μM, 1 μM and 5 μM, 4 μM and 30 μM, 4 μM and 25 μM, 4 μM and 20 μM, 4 μM and 15 μM, or 4 μM and 10 μM is less than 5 μM, when tested in a MC degranulation assay. 50 Values inhibited MC degranulation in subjects.
[0417] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount so as to have an IC of less than 25 μM, less than 20 μM, less than 15 μM, less than 10 μM, in the range of 1 μM to 25 μM, 1 μM to 20 μM, 1 μM to 15 μM, 1 μM to 10 μM, 5 μM to 25 μM, 5 μM to 20 μM, 5 μM to 15 μM, or 5 μM to 10 μM when tested in a MRGPRX2 activation assay.50 Values inhibit MRGPRX2 activation in subjects.
[0418] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an effective amount so as to produce a drug that is less than the IC of a positive control compound (e.g., genistein) when tested under the same conditions. 50 IC value 50 The value inhibits MC degranulation.
[0419] In some forms of the methods, the pharmaceutical preparation administered to the subject is in an effective amount so that when tested under the same conditions, the IC 50 The value inhibits MC degranulation: This value is higher than the IC value of the positive control compound (such as genistein). 50 The value is at least 10% lower, at least 15% lower, at least 20% lower, at least 25% lower, at least 30% lower, at least 40% lower, at least 50% lower, at least 1-fold lower, at least 2-fold lower, at least 3-fold lower, at least 4-fold lower, or at least 5-fold lower.
[0420] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an effective amount so as to produce a drug compound that is less than the IC of a positive control compound (e.g., genistein) when tested under the same conditions. 50 IC value 50 value, inhibiting MRGPRX2 activation.
[0421] In some forms of the methods, the pharmaceutical preparation administered to the subject is in an effective amount so that when tested under the same conditions, the IC 50 The value inhibits MRGPRX2 activation: This value is higher than the IC value of positive control compounds (such as genistein). 50 The value is at least 10% lower, at least 15% lower, at least 20% lower, at least 25% lower, at least 30% lower, at least 40% lower, at least 50% lower, at least 1 fold lower, at least 2 fold lower, at least 3 fold lower, at least 4 fold lower, or at least 5 fold lower.
[0422] Exemplary compounds tested under specific conditions and exemplary IC values of exemplary known compounds for MC inhibition and MRGPRX2 activation are described in the following examples. 50 value.
[0423] 2. Ca 2+ Reduction in flux
[0424] MRGPRX2 activation leads to intracellular Ca 2+ The rapid increase in flux decays very slowly and is preceded by a decrease in intracellular Ca 2+ Compared with other GPCRs, MRGPRX2 induces a sustained Ca 2+The flux response is unique because most other GPCRs induce transient Ca 2+ The response, due to its rapid desensitization and internalization, returns to baseline almost immediately.
[0425] In some forms of the methods, the compound reduces calcium cations ("Ca2+") in the subject's MCs compared to a control not treated with the compound when tested under the same conditions. 2+ ”) flux. Used to test Ca 2+ "Same conditions" for flux are performed using the same assay (e.g., MC degranulation assay), using the same procedures (e.g., same amount of cells and enzymes, same buffer and buffer concentration, same dye and dye concentration, and same incubation time and temperature, etc.).
[0426] In some forms of the methods, the pharmaceutical formulation administered to the subject is in an amount effective to increase Ca in the subject's MCs compared to MCs in a control not treated with the compound when tested under the same conditions. 2+ The flux is reduced by at least 20%, at least 30%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, 20% to 95%, 20% to 90%, 20% to 85%, 30% to 80%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 40% to 95%, 40% to 90%, 40% to 85%, or 40% to 80%.
[0427] 3. Reduction of inflammatory chemokine and / or cytokine release
[0428] MC activation involves the induction of Ca 2+ The early stages of flux and degranulation and the late stages that induce the production and release of inflammatory chemokines and / or cytokines, such as monocyte chemoattractant protein-1 ("MCP-1") and prostaglandin D-2 ("PGD-2") are discussed.
[0429] In some forms of the method, the compound can reduce the amount of inflammatory chemokines and / or cytokines (such as MCP-1 and / or PGD-2) released from MCs of the subject compared to a control not treated with the compound when tested under the same conditions. "The same conditions" for testing the amount of inflammatory chemokines and / or cytokines released from MCs are performed using the same assay (such as MC degranulation assay), using the same procedures (such as the same amount of cells and enzymes, the same buffer and buffer concentration, the same dye and dye concentration, and the same incubation time and temperature, etc.).
[0430] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount to reduce the amount of inflammatory chemokines and / or cytokines (such as MCP-1) released from the subject's MCs by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, 5% to 50%, 10% to 50%, 5% to 45%, 10% to 45%, 5% to 40%, or 10% to 40%, compared to a control not treated with the compound when tested under the same conditions.
[0431] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount to reduce the amount of inflammatory chemokines and / or cytokines (such as PGD-2) released from the subject's MCs by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, or 30% to 55%, compared to a control not treated with the compound when tested under the same conditions.
[0432] In some forms of the methods, the pharmaceutical formulation administered to the subject has an effective amount to reduce the amount of MCP-1 released from the subject's MCs by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, 5% to 50%, 10% to 50%, 5% to 45%, 10% to 45%, 5% to 40%, or 10% to 40%, and reduce the amount of PGD-2 released from the subject's MCs by at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, or 30% to 55%, compared to a control not treated with the compound when tested under the same conditions.
[0433] The disclosed compounds, methods of use, and methods of preparation can be further understood through the following numbered paragraphs.
[0434] 1. A compound having the following structure:
[0435]
[0436] (a) wherein n is an integer from 0 to 6, 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 or 1;
[0437] (b) wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen;
[0438] (c) wherein A' and Z' are independently substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; and
[0439] (d) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0440] 2. The compound of paragraph 1, wherein the compound has the following structure:
[0441]
[0442] (a) wherein E' and G' are independently substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl;
[0443] (b) wherein J' is a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, a substituted or unsubstituted polyaryl group, or a substituted or unsubstituted polyheteroaryl group;
[0444] (c) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and
[0445] (d) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0446] 3. The compound according to paragraph 1 or 2, wherein n is 0.
[0447] 4. The compound of paragraph 1 or 3, wherein A' has the following structure:
[0448]
[0449] (a) wherein E' and G' are independently substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl or substituted or unsubstituted polyheteroaryl; and
[0450] (b) wherein Y' is independently CR1, O, S or NR2 at each occurrence, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxy or halogen; and
[0451] (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0452] 5. The compound of any one of paragraphs 1 to 4, wherein A' has the following structure:
[0453]
[0454] (a) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and
[0455] (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0456] 6. The compound of any one of paragraphs 1 to 5, wherein A' has the following structure:
[0457]
[0458] (a) wherein X' is C, N, O or S;
[0459] (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amido, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; and
[0460] (c) the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0461] 7. The compound according to paragraph 6,
[0462] (a) wherein X' is C or N;
[0463] (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, thiol, sulfonyl, hydroxy, or halogen; and
[0464] (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0465] 8. The compound according to paragraph 6 or 7,
[0466] (a) wherein X' is C or N;
[0467] (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxyl, heterocyclic group, And R5-R 10 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino or halogen; and
[0468] (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0469] 9. A compound according to any one of paragraphs 6 to 8,
[0470] (a) wherein X' is C or N;
[0471] (b) wherein R3 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, oxo, hydroxy or carboxy; and
[0472] (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0473] 10. The compound of any one of paragraphs 1 or 3 to 9, wherein Z' has the following structure:
[0474]
[0475] (a) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen;
[0476] (b) wherein J' is a substituted or unsubstituted heterocyclyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted polyaryl, or a substituted or unsubstituted polyheteroaryl; and
[0477] (c) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0478] 11. The compound of any one of paragraphs 1 to 10, wherein Z' has the following structure:
[0479]
[0480] (a) wherein Y' is independently CR1, O, S or NR2 at each occurrence, and at least one Y' is O, S or NR2, wherein R1 and R2 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl or halogen; and
[0481] (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0482] 12. The compound of any one of paragraphs 1 to 11, wherein Z' has the following structure:
[0483]
[0484] (a) wherein R4 at each occurrence can independently be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen; and
[0485] (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl or thiol.
[0486] 13. The compound according to paragraph 12,
[0487] (a) wherein R4 at each occurrence is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino, oxo, halogen, hydroxyl, heterocyclic group, And R5-R 10 are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, amino or halogen; and
[0488] (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0489] 14. The compound according to paragraph 12 or 13,
[0490] (a) wherein R4 at each occurrence is independently hydrogen, and R5-R8 are independently hydrogen or substituted or unsubstituted alkyl; and
[0491] (b) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, amino, amide or oxo.
[0492] 15. The compound of any one of paragraphs 1 to 14, having the following structure:
[0493]
[0494] 16. A pharmaceutical preparation comprising
[0495] One or more compounds according to any one of paragraphs 1 to 15;
[0496] a pharmaceutically acceptable excipient,
[0497] One or more compounds are present in an effective amount to prevent or treat pseudoallergy, pseudoallergic disease or pseudoinflammatory disease in a subject, or to treat or alleviate one or more symptoms associated with pseudoallergy, pseudoallergic disease or pseudoinflammatory disease.
[0498] 17. The pharmaceutical formulation of paragraph 16, further comprising a second active agent, optionally including more than one second active agent.
[0499] 18. The pharmaceutical preparation of paragraph 16 or 17, wherein the second active agent is an anti-allergic agent or an anti-inflammatory agent or a combination thereof.
[0500] 19. A method for preparing a compound according to any one of paragraphs 1 to 15, comprising
[0501] (i) mixing a reactant mixture with a catalyst to form a reaction mixture, wherein the reactant mixture comprises a first reactant, a second reactant, and a solvent; and
[0502] (ii) heating the reaction mixture at a suitable temperature and for a period of time sufficient to form a product comprising the compound of paragraph 1,
[0503] Wherein step (i) is performed before step (ii) or simultaneously with step (ii).
[0504] 20. The method of paragraph 19, wherein the first reactant has the following structure:
[0505]
[0506] (a) wherein a is an integer from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 or 1;
[0507] (b) wherein R′ and R″ are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen;
[0508] (c) wherein A' is a substituted or unsubstituted polyaryl group or a substituted or unsubstituted polyheteroaryl group;
[0509] (d) where R 11 is a halogen or has the following structure:
[0510]
[0511] Where R 12 Each occurrence is independently hydrogen or substituted or unsubstituted alkyl; and
[0512] (e) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0513] 21. The method of paragraph 19 or 20, wherein the second reactant has the following structure:
[0514]
[0515] (a) wherein b is an integer from 0 to 6, from 0 to 5, from 0 to 4, from 0 to 3, from 0 to 2, or from 0 or 1;
[0516] (b) wherein R′ and R″ are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, amide, amino, oxo, phosphonium, phosphino, phosphono, silyl, sulfinyl, sulfonyl, thiol, hydroxyl, or halogen;
[0517] (c) wherein Z' is a substituted or unsubstituted polyaryl group or a substituted or unsubstituted polyheteroaryl group;
[0518] (d) where R 13 is triflate ("OTf") or has the structure of Formula XIV; and
[0519] (e) wherein the substituents are independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted polyaryl, substituted or unsubstituted polyheteroaryl, substituted or unsubstituted aralkyl, substituted or unsubstituted carbonyl, substituted or unsubstituted alkoxy, halogen, hydroxy, phenoxy, aryloxy, alkylthio, phenylthio, arylthio, cyano, isocyano, nitro, carboxyl, amino, amide, oxo, silyl, sulfinyl, sulfonyl, sulfonic acid, phosphonium, phosphino, phosphoryl, phosphonyl, or thiol.
[0520] 22. The method of any one of paragraphs 19-21, wherein the solvent is water, dioxane, dimethoxyethane, 2-methyltetrahydrofuran, cyclopentyl methyl ether, tetrahydrofuran, tert-butyl methyl ether or dichloromethane or a combination thereof.
[0521] 23. The method of any one of paragraphs 19-22, wherein the catalyst is PdCl2(dppf), PdCl2(dppf)DCM complex, Tetrakis, PdCl2(PPh3)2, XPhos Pd G3 or Pd(OAc)2 / PPh3 or a combination thereof.
[0522] 24. The method of any of paragraphs 19-24, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 50°C to 150°C, 60°C to 150°C, 70°C to 150°C, 80°C to 150°C, 50°C to 140°C, 50°C to 120°C, 70°C to 120°C, 80°C to 120°C (e.g., about 100°C) for at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, at least 6 hours, at least 8 hours, at least 10 hours, up to 20 hours, up to 18 hours, up to 16 hours, for a period of 1 hour to 18 hours, 2 hours to 16 hours, or 2 hours to 15 hours.
[0523] 25. The method of any of paragraphs 19-24, further comprising mixing the first reactant, the second reactant, and the solvent to form a reactant mixture before step (i), purging the reactant mixture with an inert gas before step (ii), stirring the reaction mixture during step (ii), and / or purifying the product containing the compound.
[0524] 26. A method for preventing or treating pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease, or treating or alleviating one or more symptoms associated with pseudoallergy, pseudoallergic disease and / or pseudoinflammatory disease in a subject in need thereof, comprising:
[0525] (i) administering the pharmaceutical formulation of any one of paragraphs 16-18 to a subject,
[0526] Wherein step (i) is performed once or multiple times.
[0527] 27. The method of paragraph 26, comprising only a single administration of the pharmaceutical formulation, wherein the pharmaceutical formulation comprises an effective amount of the compound to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage and / or prevent or reduce MC degranulation in a subject.
[0528] 28. The method of paragraph 26 or 27, comprising more than one step of administering a pharmaceutical formulation to a subject, wherein after all administration steps, an effective amount of a compound is administered to the subject to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage and / or prevent or reduce MC degranulation in the subject.
[0529] 29. The method of any of paragraphs 26-28, wherein the subject is a mammal.
[0530] 30. The method of any one of paragraphs 26-29, wherein the pharmaceutical preparation is administered by oral administration, parenteral administration, inhalation administration, mucosal administration, topical administration, or a combination thereof.
[0531] 31. The method of any of paragraphs 26-30, further comprising administering a second active agent, optionally more than one second active agent, to the subject before, during and / or after step (i).
[0532] 32. The method of paragraph 31, wherein the second active agent is an anti-allergic agent or an anti-inflammatory agent or a combination thereof.
[0533] 33. A method of treating mast cells ("MC") in a subject in need thereof, comprising
[0534] (i) administering the pharmaceutical preparation of any one of paragraphs 16 to 18 to a subject,
[0535] Wherein step (i) is performed once or multiple times.
[0536] 34. The method of paragraph 33, comprising administering only a single dose of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises an effective amount of a compound, thereby inhibiting MC degranulation, inhibiting MRGPRX2 activation, reducing calcium cations ("Ca 2+") in MCs, as compared to control cells not treated with the compound tested under the same conditions. 2+ ”) flux and / or reduction of inflammatory chemokine and / or cytokine release.
[0537] 35. The method of paragraph 33 or 34, comprising more than one step of administering a pharmaceutical formulation to a subject, wherein after all administration steps, the effective amount of the compound inhibits MC degranulation, inhibits MRGPRX2 activation, reduces Ca in MC, and ... 2+ flux and / or reduction in inflammatory chemokine and / or cytokine release.
[0538] The present invention will be further understood with reference to the following non-limiting examples.
[0539] Example
[0540] Example 1. Synthesis of Exemplary Compounds
[0541] Materials and methods
[0542] Homology and pharmacophore identification of MRGPRX2
[0543] Based on the previous class B hSCTR model development method, the κ-opioid receptor (PDB ID: 6B73) template was used to develop a 3D homology model of MRGPRX2. Three different homology models were developed using both the SWISS-MODEL algorithm and the MODELLER algorithm. The interatomic spatial clashes of the models were further evaluated and screened with the help of Ramachandran in the Rampage server. The homology model was validated by Auto dock vina virtual docking of small molecule compound agonists ZINC72453573 and C48-80 at known binding sites on the receptor. To identify the pharmacophore region, genistein was docked to the MRGPRX2 receptor by Auto Dock vina and visualized by PyMOL, Discovery studio visualization tools, and Schrodinger maestro suite. The amino acid residues were determined and further used to develop a pharmacophore model by Pharmit. The active site predetermined from the MRGPRX2-genistein model was analyzed to locate the interacting amino acid residues. The complex was used as the main structure for designing and screening small molecule antagonists.
[0544] Computer simulation design and screening of potential small molecule antagonists
[0545] Based on the amino acid interaction map and the pharmacophore of genistein, several compounds with different hydrogen bond donors and functional groups (Ar-NH2, alkyl-OH, Ar-OH, alkyl-COOH, alkyl-NH-CO-NH-alkyl, alkyl-S(O)2-NH-alkyl, alkyl-NH-CO-NH-Ar, halogens and heterocyclic amines) were designed. The chemical structures of the compounds were drawn using ACD / ChemSketch software (AdvancedChemistry Development, 2020), saved as MOL files, and optimized using the advanced molecular editing visualization software Avogadro before docking studies. The automatic optimization tool of Avogadro was used to apply the interactive interface, universal force field (UFF) and steepest descent algorithm. All compounds were optimized and saved as PDB files. Molecular docking was performed to select the best hits. Molecular docking simulations were performed using the Broyden-Fletcher-Goldfarb-Shanno (BFGS) retrieval algorithm of Auto Dock Vina. Auto Dock vina was run on a window platform using PyRx dock as an interface. In each round of molecular docking, the best hit compounds were ranked according to their binding affinity and further processed to analyze amino acid interactions. In brief, blind docking was performed for each compound to identify possible binding regions on the MRGPRX2 homology model. Rational docking simulations were then performed to obtain the most accurate binding mode for each compound. First, the entire receptor region was selected by AutoDock Vina with an exhaustiveness of 50 and blind docking was performed. The docking pose of AutoDock Vina was very closely superimposed on the initial pose within the MRGPRX2 active site, with a root mean square deviation (RMSD) of Within acceptable range for successful verification of self-docking In the post-docking analysis, the docking posture and the related ligand binding affinity scores were highly reproducible in AutoDock Vina when performed in four to six independent runs (standard deviation: 0.45-0.9kcal / mol). After the binding site was identified, the focused docking was applied with exhaustiveness set to 50. The binding pocket was further verified using the patch dock / firedock algorithm. The docked compounds were scored according to the binding scores calculated from the docking algorithm. Receptor and protein-ligand interaction visualization was performed by PyMOL, maestro and Discovery studio visualization tools.
[0546] Drug-like properties of novel small molecule antagonists
[0547] The drug-likeness of novel small molecule compounds was measured using the online ADME prediction tool SwissADME (http: / / www.swissadme.ch). The drug-likeness was predicted using the Lipinski rule of five, which is based on the basic laws of the physicochemical properties of small molecule compounds. The rule of five predicts that small molecule compounds with a molecular weight greater than 500 Da, more than 5 hydrogen bond donors, more than 10 hydrogen bond acceptors, and a Log P (MLogP) greater than 5 are likely to have low absorption or low membrane permeability. Therefore, small molecule compounds that do not meet this standard are unlikely to become orally bioavailable drugs.
[0548] Synthesis of small molecule antagonists
[0549] Instruments and Chemicals
[0550] All chemicals and reagents were purchased from Sigma Aldrich, Alfa Aesar, Combi-Blocks, GLR Innovations, Spectrochem, TCI chemicals India and used without further purification. Rf values were determined using pre-coated Merck silica gel 60F254 aluminum sheets (Merck, Germany). Visualization of TLC plates was performed using UV light and iodine vapor. Spectra were recorded on a Bruker Avance-III HD FT-NMR spectrophotometer (Bruker, USA). 1 H NMR (400 MHz) and manual interpretation.
[0551] LC-MS spectra were recorded as detailed below. (a) Water AcquityUPLC H class equipped with PDA and acquity SQ detector; sunfire C18 (150mm x 4.6mm) column, 3.5 μM, mobile phase A was 0.1% formic acid (pH=2.70) in Milli Q water, and mobile phase B was 0.1% formic acid:acetonitrile (10:90) in Milli Q water. For MS, ESI probe and both positive and negative ionization modes were used. (b) Waters 996 photodiode array detector equipped with Waters micromass ZQ detector. Xtimate Welch C18 4.6*150 mm 5.0μM column and 5mM ammonium acetate were used, and 0.1% formic acid (pH=3.50) in milli Q water was used as mobile phase A, while mobile methanol was used as phase B. For MS, ESI probe and both positive and negative ionization modes were used.
[0552] As detailed below, the compound percent purity was determined using HPLC. (a) Agilent Technologies 1260 series, Infinity-II, with PDA detector and sunfire C18 (150 mm x 4.6 mm), 3.5 μM column. Mobile phase A was 0.05% trifluoroacetic acid (pH = 2.2) in milli Q water, and mobile phase B was acetonitrile. The flow rate was 1.0 mL / min, and the total run time was 17 min. (b) Waters Alliance e2695, with 2998 PDA detector, using Atlantis C18 (150 mm x 4.6 mm), 5.0 μM column, or using Welch C18 (150 mm x 4.6 mm), 5.0 μM column. Mobile phase A was 0.1% ammonia (pH = 10.5) in Milli Q water, and mobile phase B was acetonitrile. The flow rate was 1.0 mL / min and the total run time was 17 min. (c) Waters Acquity Ultra High Performance LC, connected to a PDA and equipped with an SQ detector. An XTIMATE 2.1*50 mm 1.8 μM column was used, with mobile phase A being 0.1% formic acid in Milli Q water (pH=2.70) and mobile phase B being 0.1% formic acid in Milli Q water: acetonitrile (10:90). The flow rate was 0.8 mL / min and the sample was run for a total of 4 min.
[0553] Synthesis and characterization of GE0117
[0554] Scheme 1: Upper Scaffold U1: Preparation of methyl 6-(2-methyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)-7-ureido-2-naphthoate
[0555]
[0556] Scheme 2: Lower Scaffold L1: Preparation of methyl 6-(((trifluoromethyl)sulfonyl)oxy)-7-ureido-2-naphthoate
[0557]
[0558] Scheme 3: GE0117: Preparation of methyl 6-(2-methyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)-7-ureido-2-naphthoate
[0559]
[0560] As shown in Scheme 3, the small molecule compound antagonist GE0117 was synthesized by combining the upper scaffold U1 with the lower scaffold L1. According to the reaction scheme shown in Scheme 1, the upper scaffold U1 was synthesized by three steps and two intermediates. Na2CO3 (0.95 g, 0.9 mmol) was added to a stirred solution of U1 (0.1 g, 0.3 mmol) and L1 (0.14 g, 0.35 mmol) in 1,4-dioxane (10 ml) at room temperature. The solution was purged with N2 (gas) for 15 min, followed by the addition of PdCl2 (dppf) (0.02 g, 0.03 mmol); the reaction mixture was stirred at 100 ° C for 16 h. After the reaction was completed by TLC monitoring, the resulting reaction mixture was filtered through a diatomaceous earth bed and washed with ethyl acetate (50 mL). The filtrate was evaporated, and the crude material was purified by reverse phase preparative HPLC purification using 1M HCl / MeCN in water to obtain brown solid GE0117. 1 All intermediates were characterized by H NMR and LCMS. In brief, LCMS confirmed that the upper scaffold U1 showed a molecular weight of 337.15 (M+1). The lower scaffold L1 was synthesized by seven steps according to Scheme 2. In brief, six intermediates (L1A2, L1A3, L1A4, L1A5, L1A6 and L1A7) were synthesized and 1 Characterization was performed by H NMR and LCMS. 1 H NMR and LCMS spectroscopy confirmed the synthesis of the lower scaffold L1.
[0561] Finally, according to Scheme 3, GE0117 was synthesized by fusing the upper scaffold U1 with the lower scaffold L1 in the presence of 1,4-dioxane, Na2CO3 and PdCl2 (dppf). The final product was confirmed by the following characteristic single peaks: 1H NMR spectrum (400MHz, DMSO-d6) δ 8.64-8.53 (m, 6H), 8.03 (d, J = 10, 2H), 7.98-7.85 (m, 3H), 6.56 (s, 1H) 6.60 (s, 1H), 3.93 (s, 3H), 3.45 (s, 3H). LCMS confirmed purity (> 95%) and molecular weight 545.1 (M + 1) (GE0117 retention time in HPLC column is about 1.936 minutes; showing> 95% purity and 454.1 (M + 1) molecular ion peaks; the yield after separation is about 6wt%).
[0562] Synthesis and characterization of GE0118 Scheme 4: Lower scaffold L2: Preparation of dimethyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)naphthalene-2,7-dicarboxylate
[0563]
[0564] Scheme 5: GE0118: Preparation of dimethyl 3-(2-methyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)naphthalene-2,7-dicarboxylate
[0565]
[0566] According to Scheme 5, the small molecule compound antagonist GE0118 was synthesized by combining the upper scaffold U1A2 with the lower scaffold L2. The upper scaffold U1A2 (5-bromo-2-methyl-1H-benzo[de]isoquinoline-1,3(2H)-dione) was previously synthesized as an intermediate and is shown in Scheme 1. 1 The H NMR spectrum shows a characteristic single peak: 1 H NMR (400MHz, CDCl3) δ8.68 (d, J = 1.6 Hz, 1H), 8.62 (d, J = 7.2 Hz, 1H), 8.39 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.80 (t, J = 7.6 Hz, 1H), 3.58 (s, 3H), LCMS showed a mass of 289.9 (M+1). The lower support L2 was synthesized by Scheme 4. Three intermediates (L2A1, L2A2, and L2A3) and L2 were synthesized by four-step reaction, and by 1 H NMR and LCMS characterization. The lower scaffold L2 was characterized by: 1 H NMR (400 MHz, DMSO-d6) δ8.81 (s, 1H), 8.73 (s, 1H), 8.17-8.10 (m, 3H), 3.93 (m, 3H), 3.92 (s, 3H), 3.89 (s, 3H), 1.36 (s, 12H), LCMS showed the molecular mass was: 371.4 (M+1).
[0567] According to Scheme 5, the final reaction to obtain GE0118 is carried out by fusing the upper support U1A2 with the lower support L2 in the presence of 1,4-dioxane, Na2CO3 and PdCl2(dppf). Na2CO3(0.05g, 0.54mmol) was added to a stirred solution of U1A2(0.05g, 0.18mmol) and L2(0.05g, 0.17mmol) in 1,4-dioxane (10ml) at room temperature. N2(gas) was purged for 15min, followed by the addition of PdCl2(dppf) (0.012g, 0.01mmol), and the reaction mixture was stirred at 100°C for 2h. After the reaction was completed by TLC monitoring, the resulting reaction mixture was filtered through a diatomaceous earth bed and washed with ethyl acetate (50mL). The filtrate was evaporated and eluted with 15% ethyl acetate in hexane to obtain an off-white solid compound GE0118. The NMR spectrum of GE0118 showed a characteristic single peak: 1H NMR (400 MHz, DMSO-d6) δ8.89 (s, 1H), 8.82 (s, 1H), 8.55 (t, J = 12 Hz 3H), 8.44 (s, 1H), 8.30 (s, 1H), 8.32-8.16 (m, 2H), 7.94 (t, J = 7.6 Hz, 1H), and LCMS showed a molecular mass of 454.2 (M+1) and >95% purity (the retention time of GE0118 in the HPLC column was about 10.331 minutes; it showed >95% purity and 454.2 (M+1) molecular ion peak; the yield after separation was about 26.5 wt%).
[0568] Synthesis and characterization of GE0119
[0569] Scheme 6: Lower Scaffold L3: Preparation of 5-bromo-2-methyl-1H-benzo[de]isoquinoline-1,3(2H)-dione
[0570]
[0571] Scheme 7: GE0119: Preparation of methyl 3-(2-methyl-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)-7-ureido-2-naphthoate
[0572]
[0573] According to Scheme 7, the small molecule compound antagonist GE0119 was synthesized by combining the upper scaffold U1A2 with the lower scaffold L3. The upper scaffold U1A2 has been previously synthesized and characterized (in Scheme 1 of GE0117), and the lower scaffold L3 was synthesized by Scheme 6. In brief, the chemical reaction includes 8 steps and seven intermediates (L3B2, L3B3, L3B4, L3B5, L3B6, L3B7 and L3B8), which are 1 H NMR and LCMS characterization of intermediate L3 1 The H NMR spectrum showed the following characteristic single peaks: (400 MHz, DMSO-d6) δ 8.89 (s, 1H), 8.28 (s, 1H), 8.09 (s, 1H), 7.92-7.85 (m, 2H), 7.65 (d, J=8.8 Hz, 1H), 6.03 (s, 2H), 3.88 (s, 3H), 1.35 (s, 12H), and LCMS confirmed the molecular weight to be 371.49 (M+H).
[0574] Finally, according to Scheme 7, GE0119 was synthesized by chemical reaction of U1A2 and L3 in the presence of PdCl2 (dppf), Na2CO3 and dioxane: water. Na2CO3 (0.95 g, 0.9 mmol) was added to a stirred solution of U1A2 (0.1 g, 0.3 mmol) and L3 (0.14 g, 0.35 mmol) in 1,4-dioxane (10 ml) at room temperature. N2 (gas) was purged for 15 min, followed by the addition of PdCl2 (dppf) (0.02 g, 0.03 mmol), and the reaction mixture was stirred at 100 ° C for 16 h. After the reaction was completed by TLC monitoring, the resulting reaction mixture was filtered through a diatomaceous earth bed and washed with ethyl acetate (50 mL). The filtrate was evaporated, and the crude material was purified using n-heptane / IPA by a normal phase preparative HPLC purification method to obtain a brown compound GE0119. GE0119 was characterized by the following: 1 H NMR spectrum (400 MHz, DMSO-d6) δ8.38 (s, 1H), 8.52 (s, 3H), 8.40 (d, J = 9.6 Hz 2H), 8.24 (s, 1H) 8.05 (s, 1H), 7.97-7.90 (m, 2H), 7.72 (d, J = 8.0 Hz, 1H), 3.66 (s, 3H), 3.43 (s, 3H), LCMS showed a mass of 454.1 (M+1), >95% purity (the retention time of GE0119 in the HPLC column was about 9.071 minutes; it showed >95% purity, and the M+1 peak was 454.1; the yield after separation was about 6 wt%).
[0575] Synthesis and characterization of GE1109
[0576] Scheme 8: Preparation of upper scaffold U2: 6-bromo-1H-phenazone-1-one
[0577] Scheme 9: GE1109: Preparation of methyl 3-(1-oxo-1H-phenazone-6-yl)-7-ureido-2-naphthoate
[0578]
[0579] According to Scheme 9, the small molecule compound antagonist GE1109 was synthesized by chemical reaction of the upper scaffold U2 and the lower scaffold L3. According to Scheme 8, the upper scaffold U2 was synthesized by 5 chemical reactions; 1 The four intermediates were characterized by both H NMR and LCMS. The upper support U2 shows the characteristics 1 H NMR peak (400MHz, CDCl3) δ 8.68 (dd, J = 7.6Hz, 1H), 8.62 (d, J = 8.4Hz, 1H), 7.90-7.86 (m, 2H), 7.71 (d, J = 10Hz, 1H), 7.56 (d, J = 8.4Hz, 1H), 6.75 (d, J = 8.8Hz, 1H), and LCMS showed a molecular mass of 259.18, 261.2 (M&M+2). The lower support L3 is similar to GE0119 and was previously synthesized as shown in Scheme 6 and characterized as described above.
[0580] Finally, GE1109 was synthesized by combining the upper scaffold U2 with the lower scaffold L3 in the presence of PdCl2(dppf), Na2CO3 and water / dioxane, and 1 H NMR and LCMS were used for characterization. GE1109 showed 1 H NMR spectrum (400 MHz, DMSO-d6) δ8.96 (s, 1H), 8.51-8.48 (m, 2H), 8.26 (s, 1H), 8.10-8.06 (m, 2H), 7.95-7.85 (m, 3H), 7.78 (t, J = 7.6 Hz, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.62 (d, J = 7.2 Hz, 1H), 6.73 (d, J = 9.6 Hz, 1H), 6.06 (s, 2H), 3.43 (s, 3H), and LCMS The molecular mass was shown to be 423.44 (M+1) and the purity was >95% (the retention time of GE1109 in the HPLC column was about 2.062 minutes; it showed >95% purity, and the M+1 peak was 423.44; the yield after isolation was about 20 wt%).
[0581] Synthesis and characterization of GE1110
[0582] Scheme 10: Upper Scaffold U3: Preparation of 5-bromo-9-hydroxy-1-methyl-1H-phenanthene-2-carboxaldehyde
[0583]
[0584] Scheme 11: GE1110: Preparation of dimethyl 3-(2-formyl-9-hydroxy-1-methyl-1H-phenazone-5-yl)naphthalene-2,7-dicarboxylate
[0585]
[0586] According to Scheme 11, the small molecule compound antagonist GE1110 was synthesized by chemical reaction of the upper scaffold U3 with the lower scaffold L2. In brief, the synthesis scheme of the upper scaffold U3 includes 5 chemical reactions and 4 intermediates (Scheme 10). 1 All intermediates were characterized by both HNMR and LCMS. The upper support U3 shows the characteristic 1 H NMR peaks (400MHz, DMSO-d6) δ 10.23 (s, 1H), 9.65 (s, 1H), 8.04 (s, 1H), 7.86-7.66 (m, 3H), 7.24 (d, J = 8.8 Hz, 1H), 4.38 (q, 1H), 1.19 (d, J = 6.8 Hz, 3H), and LCMS showed molecular weights of 303.2 & 305.1 (M & M + 2). The lower scaffold L2 is similar to GE0118 and has been previously synthesized as shown in Scheme 4 and characterized as described above.
[0587] The final synthesis step includes the reaction of the upper scaffold U3 with the lower scaffold L2 in the presence of PdCl2(dppf), Na2CO3 and water / dioxane. A solution of U3 (0.04 g, 0.13 mmol), L2 (0.058 g, 0.15 mmol) and Na2CO3 (0.041 g, 0.39 mmol) in 1,4-dioxane (0.8 mL):H2O (0.2 mL) was purged with N2 (gas) for 5 min. PdCl2(dppf) (0.009 g, 0.013 mmol) was then added to the reaction mixture and stirred at 100 °C for 15 h. After TLC indicated that the reaction was complete, the resulting reaction mixture was filtered through a celite pad and washed with ethyl acetate (30 mL). The filtrate was evaporated and the crude material (0.1 g) was purified by column chromatography (0-5% ethyl acetate in hexane) to obtain a yellow solid compound GE1110. GE1110 shows the characteristics 1H NMR signal (400MHz, DMSO-d6) δ10.17 (s, 1H), 9.68 (s, 1H), 8.84 (s, 1H), 8.70 (s, 1H), 8.22 (s, 1H), 8.19-8.13 (m, 2H), 7.88 (s, 1H), 7.78 (s, 1H), 7.76 (s, 1H), 7.55 (s, 1H) 7.28 (d, J = 8.8 Hz, 1H), 4.44-4.42 (m, 1H), 3.95 (s, 3H), 3.69 (s, 3H), 1.25 (d, J = 9.2 Hz, 3H), and LCMS showed a molecular mass of 467.54 (M+1), >95% purity (the retention time of GE1110 in the HPLC column is about 2.614 minutes; showing >95% purity, and the M+1 peak is 467.54; the yield after separation is about 31.5 wt%).
[0588] Synthesis and characterization of GE1111
[0589] Scheme 12: GE1111: Preparation of methyl 3-(2-formyl-9-hydroxy-1-methyl-1H-phenazone-5-yl)-7-ureido-2-naphthoate
[0590]
[0591] According to Scheme 12, the small molecule compound antagonist GE1111 is synthesized by chemical reaction of the upper scaffold U3 with the lower scaffold L3. The synthesis schemes of the upper scaffold U3 and the lower scaffold L3 are as described in the previous Schemes 10 and 6, respectively. A solution of U3 (0.06 g, 0.19 mmol), L3 (0.08 g, 0.23 mmol) and Na2CO3 (0.041 g, 0.39 mmol) in 1,4-dioxane (1.6 mL):H2O (0.4 mL) was purged with N2 (gas) for 5 min. Subsequently, PdCl2 (dppf) (0.014 g, 0.019 mmol) was added to the reaction mixture and stirred at 100 ° C for 15 h. After TLC indicated that the reaction was complete, the resulting reaction mixture was filtered through a diatomaceous earth pad and washed with ethyl acetate (50 mL). The filtrate was evaporated, and the crude product was purified by normal phase preparative HPLC purification to obtain a yellow solid GE1111. 1 All intermediates were characterized by both H NMR and LCMS. The final synthesis step involved the reaction of the upper scaffold U3 with the lower scaffold L3 in the presence of PdCl2(dppf), Na2CO3 and water / dioxane. The synthesis of GE1111 was characterized by 1H NMR spectrum confirmed: (400MHz, DMSO-d6) δ10.10 (bs, 1H), 9.68 (s, 1H), 8.92 (s, 1H), 8.28 (s, 1H), 8.16 (s, 1H), 7.96-7.91 (m, 2H), 7.81 (s, 1H), 7.75-7.65 (m, 3H), 7.51 (s, 1H), 7.26 (d, J = 8.8 Hz 2H), 6.04 (bs, 2H), 4.44-4.42 (m, 1H), 3.67 (s, 3H), 1.26-1.24 (d, J = 6.8 Hz, 3H), and LCMS showed a molecular weight of 467.59 (M+1), >95% purity (GE1111 on HPLC The retention time in the column was about 2.148 minutes; showing >95% purity, and the M+1 peak was 467.59; the isolated yield was about 15.5 wt%).
[0592] result
[0593] Homology modeling and pharmacophore identification
[0594] To gain a deeper understanding of the 3D structure and ligand binding site of MRGPRX2, a homology model of MRGPRX2 was developed because the crystallographic 3D structure of MRGPRX2 was not available in the RCSB Protein Data Bank. MRGPRX2 is a class A orphan receptor that is structurally similar to opioid GPCRs. Three MRGPRX2 homology models were developed, and among the three developed models, the final selected MRGPRX2 model had 98.8% of the amino acid residues in the focus region or in the allowed region ( Figure 1A ). With the help of Schrodinger Desmond, the energy of the entire receptor structure was minimized in the most thermodynamically stable configuration, and then verified by Ramachandran plot and Auto dock vina molecular docking ( Figure 2A-2C). Experimental data on the structure-function relationship of these ligands as MRGPRX2 agonists are not yet fully established. A cyclized variant of C48 / 80 containing a tetrahydroisoquinoline (THIQ) motif is seven times more potent than C48 / 80 as a MC degranulating agent. The common adjacent THIQ motif and a bulky hydrophobic group with charged nitrogen are a common structure in most known small molecule MRGPRX2 agonists, such as nonsteroidal neuromuscular blocking drugs (NMBDs) and fluoroquinolone antibiotics. MRGPRX2 agonists share a common basic hydrophobic domain structural feature and are collectively referred to as basic secretagogues or cationic-amphiphilic ligands. GPCR-dependent activity of basic secretagogues on MCs has also been reported. Genistein has been used to identify the pharmacophore of ligands and perform structure-based drug design to develop potent small molecule compound MRGPRX2 antagonists. The MRGPRX2 receptor was docked with genistein using Auto Dock vina and visualized using PyMOL, Schrodingermaestro suite, and Discovery studio visualization tools ( Figures 1A-1C ). The active sites pre-determined from the MRGPRX2-genistein model were analyzed to locate the interacting amino acid residues. The complex was used as a structure for designing and screening small molecule compounds. The amino acid interaction map shows the interaction of genistein with the N-terminal extracellular domain of MRGPRX2 through residues Ser96, Ser98, His261, Cys180, Trp179, Cys95, Val88 and Cys180 ( Figure 1B ). The docked MRGPRX2-genistein complex was further evaluated and used to develop a pharmacophore model with the help of Pharmit. Several pharmacophore regions of genistein were identified, showing several contact points of genistein with amino acids in the N-terminal region of the MRGPRX2 binding site. The pharmacophore of genistein has been determined to contain two hydroxyl groups of the chromone ring as hydrogen donors and acceptors, hydroxyl groups of the phenol ring as hydrogen donors, phenol ring as hydrophobic and aromatic pharmacophores, and chromone ( Figure 1C ).
[0595] Design and computer simulation screening of small molecule antagonists
[0596] To select functional groups that can improve the binding affinity of MRGPRX2 antagonists, a computer simulation library of small molecule compounds was designed and screened by molecular docking and post-docking analysis. Blind docking results showed that all molecules were located in pockets similar to the lead compounds with high frequency (data not shown). Rational docking simulation results showed that, assuming similar binding postures, all derivatives were located in the same binding pocket, and their binding affinity to MRGPRX2 was relatively high compared to genistein (data not shown). A hybrid combination of bromobenzo[de]isoquinoline / phenazone-1-one and naphthoate was identified, which significantly improved binding affinity and ligand-amino acid interactions. A series of compounds were designed by replacing several functional groups (such as carboxylic acid, methyl acetate, hydroxyl, amide, methyl and aryl-OH, aryl-COOH, halogen and heterocyclic groups) at different carbon positions. These compounds were tested for MRGPRX2 by performing molecular docking in a similar manner. It was found that replacing the hydrogen atoms at C17 / C18 and C21 / C22 in the naphthoate ring with methyl acetate and amide (as shown in Structures 1 and 2 below) significantly increased the binding affinity and amino acid interactions.
[0597]
[0598] After screening, according to binding affinity and synthetic feasibility, select six kinds of small molecule compounds and check amino acid interactions by docking rear analysis.Compared with genistein, these compounds show significantly high binding affinity and improve the amino acid interactions (table 1) in the binding pocket by some hydrogen bonds, π-σ bonds, π-π stacking bonds, π-π T-shaped bonds, π-alkyl bonds and π-sulfur bonds. Figures 3A-3H The diagram shows the 3D and 2D amino acid interactions of genistein, C48 / 80 and small molecule antagonists with MRGPRX2. Computer simulation results show that these six small molecule compounds bind with high affinity at the same binding site inside the MRGPRX2 binding pocket located in the N-terminal region. Figure 3A As shown, genistein shows one π-σ and two π-π T-bonds with TRP179; one conventional hydrogen bond with HIS261; one conventional hydrogen bond, one van der Waals bond, and two π-alkyl bonds with CYS180; one van der Waals bond with SER96, one conventional hydrogen bond with SER98, and two π-alkyl bonds with VAL88. Figure 3B As shown, compound 48 / 80 shows a π-π T-bond with TRP179; a π-π alkyl bond with CYS180; a π-σ bond with VAL88; a π-alkyl bond with CYS95 and a conventional hydrogen bond and a van der Waals bond with ASN85. Figure 3CAs shown, GE0117 shows one π-σ bond, one π-sulfur bond, and one alkyl bond with MET109; one π-alkyl bond with VAL265; three π-π stacking bonds and one π-alkyl bond with TRP243; one conventional hydrogen bond with ASN85; one conventional hydrogen bond with HIS261; one π-alkyl bond with PHE170; one carbon-hydrogen bond with GLY169, and three π-alkyl bonds with CYS180. Figure 3D As shown in FIG3E , GE0119 shows one π-σ and two π-sulfur bonds with MET109; two π-alkyl bonds with VAL265; three π-π stacking bonds and one π-alkyl bond with TRP243; one conventional hydrogen bond and one π-alkyl bond with HIS261; one π-alkyl bond with VAL88; one π-π stacking bond with TRP179; one conventional hydrogen bond and two π-alkyl bonds with CYS180. As shown in FIG3E , GE0119 shows one π-σ and two π-sulfur bonds with MET109; two π-alkyl bonds with VAL265; three π-π stacking bonds and one π-alkyl bond with TRP243; one conventional hydrogen bond and one π-alkyl bond with HIS261; one π-alkyl bond with VAL88; one π-π stacking bond with TRP179; one π-alkyl bond with CYS180, and one π-sulfur bond with CYS95. Figure 3F As shown, GE1109 shows two π-σ and one π-sulfur bonds with MET109; two π-alkyl bonds with VAL265; three π-π stacking bonds with TRP243; one conventional hydrogen bond with HIS261; one π-alkyl bond with VAL88; one π-alkyl bond with CYS180 and one conventional hydrogen bond with CYS95. Figure 3G As shown, GE1110 shows one π-σ bond, one π-sulfur bond, and one π-alkyl bond with MET109; three π-alkyl bonds with VAL265; two π-π stacking bonds and one carbon-hydrogen bond with TRP243; one π-π stacking bond with TRP179; one conventional hydrogen bond and one π-π T-shaped bond with HIS261; one conventional hydrogen bond and two π-alkyl bonds with VAL88; two π-alkyl bonds and one conventional hydrogen bond with CYS180; one conventional hydrogen bond with SER268; one π-alkyl bond with TYR113, and one π-alkyl bond with PHE239. Figure 3HAs shown, GE1111 shows one π-σ bond, one π-sulfur bond and one π-alkyl bond with MET109; three π-alkyl bonds with VAL265; two π-π stacking bonds and one carbon-hydrogen bond with TRP243; one π-π stacking bond with TRP179; one conventional hydrogen bond and one π-π T-bond with HIS261; one conventional hydrogen bond with VAL88; one π-alkyl bond with CYS180; one conventional hydrogen bond with SER103; one π-alkyl bond with TYR113 and a π-alkyl bond with PHE239.
[0599] Table 1: Binding affinities and interacting amino acid residues of exemplary small molecule compounds and genistein against MRGPRX2.
[0600]
[0601] Drug-like properties of novel small molecule antagonists
[0602] Small molecule antagonists meet all the criteria of Lipinski's five rules and show drug-like molecular properties. According to Lipinski's five rules, orally bioavailable drugs should follow a set of rules (MW ≤ 500; LogP o / w ≤5; hydrogen bond donors ≤5; hydrogen bond acceptors ≤10), and must not violate more than 2 rules. The molecular weight of all small molecule antagonists is less than 500g / mol. Log P values, hydrogen bond (H) donors and acceptors are below the given acceptance criteria (Table 2). The results show the drug-like properties of these small molecule compounds and can be further developed as therapeutic drugs.
[0603] Table 2: Physical characterization of drug-like properties of novel small molecule antagonists
[0604] GE0117 GE0118 GE0119 GE1109 GE1110 GE1111 Molecular weight (g / mol) 453.45 453.44 453.45 422.43 466.48 466.48 <![CDATA[LogP o / w (MLOGP)]]> 3.72 4.3 3.72 3.28 3.74 3.15 Rotatable key 5 5 5 5 6 6 Hydrogen bond donor 2 0 2 2 1 3 Hydrogen bond acceptor 5 6 5 4 6 5
[0605] Synthesis and characterization of novel small molecule antagonists
[0606] The structural similarities and synthetic procedures of all six small molecule antagonists were investigated through PubChem and SciFinder compound libraries. No structurally similar compounds or similar synthetic procedures were identified for these small molecule antagonists.
[0607] Example 2. Compounds show in vitro MRGPRX2 inhibitory activity.
[0608] Materials and methods
[0609] Compound preparation
[0610] All small molecule compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA) and diluted to the desired concentration in buffer, culture medium or saline. For in vitro cell culture experiments, the final DMSO concentration was ≤ 0.1% v / v. For in vivo experiments, the DMSO stock solution of the compound was diluted with normal saline, and DMSO saline was used as a vehicle control.
[0611] Cell lines
[0612] The human mast cell laboratory allergic disease 2 (LAD-2) cell line was grown and maintained in StemPro-34 medium supplemented with 10 ml / L StemPro nutritional supplement, penicillin (1:100), streptomycin (1:100), 2mmol / L glutamine and 100ng / ml human stem cell factor, and incubated at 37°C in a 5% CO2 incubator. The culture medium half-loss and cell proliferation were checked every five days. The HTLA cell line (a HEK293 cell line stably expressing a tTA-dependent luciferase reporter gene and a β-arrestin 2-TEV fusion gene) was grown and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2μg / ml puromycin and 100μg / ml hygromycin B, and incubated at 37°C in a 5% CO2 incubator in a humidified atmosphere.
[0613] β-Hexosaminidase MC degranulation assay
[0614] Human LAD-2 mast cells were cultured at 2×10 4Cells / well / 80 μL were seeded in a 96-well plate. A 10X stock solution of antagonist was prepared in HEPES buffer (HEPES (10 mM), NaCl (137 mM), KCl (2.7 mM), Na2HPO4·7H2O (0.4 mM), glucose (5.6 mM), CaCl2·2H2O (1.8 mM), MgSO4·7H2O (1.3 mM), bovine serum albumin (0.04%), pH 7.4). Antagonist (10 μL, 10X concentration) or buffer was added to the cells and incubated at 37°C in a CO2-free incubator for 30 min. Subsequently, graded concentrations of agonist (10 μL, 10X concentration) or buffer were added to each well and the cells were incubated for another 30 min at 37°C without CO2. The plate was spun at 450 x g for 5 minutes at room temperature and 50 μL of supernatant was aliquoted into a new 96-well plate. The cells were lysed with 100 μL of 0.1% Triton X-100 and 50 μL of the lysate was aliquoted into another 96-well plate. A 1.3 mg / ml solution of the substrate PNAG (4-nitrophenyl N-acetyl-β-D-aminoglucosidoside) was prepared in 0.1 M citric acid / sodium citrate buffer (pH 4.5, 24.087 g / L sodium citrate dihydrate and 3.471 g / L citric acid). 50 μL of PNAG was added to each well of the supernatant and lysate and the cells were incubated at 37°C for 90 min (no CO2). The reaction was stopped by adding 50 μL of 0.4 M glycine buffer. The degree of yellow color was measured at 405 nm using a Victor 4X microplate reader (PerkinElmer), and the percentage of MC degranulation (β-hexosaminidase release) was calculated using the following formula; % MC degranulation:
[0615]
[0616] MRGPRX2 activation assay (PRESTO-Tango assay)
[0617] Activation of MRGPRX2 was measured by the PRESTO-tango assay according to a modification of Kroeze, Wesley K et al. HTLA cells were incubated in DMEM with 10% FBS, 2 μg / ml puromycin and 100 μg / ml hygromycin B in a humidified atmosphere at 37°C in a 5% CO2 incubator. On day 1 of the experiment, HTLA cells were plated at 1×10 6cells / 100 mm cell culture dish for transfection. The next day (day 2), HTLA cells were transfected with Tango MRGPRX2 DNA using a liposomal transfection reagent (Thermo Fischer Scientific). On day 3, Tango MRGPRX2-transfected cells were transferred to 96-well white clear-bottom cell culture plates at a density of 2 x 10 4 Cells / well / 80 μL (PerkinElmer Life Science Improvement). On the 4th day, antagonists (10 μL, 10X concentration) or buffer (10 μL, 20mM HEPES in 1x HBSS, pH 7.4) were added to each well, and the cells were incubated at 37°C in a 5% CO2 incubator for 4 hours. After incubation for 4 hours, graded concentrations of agonists (10 μL, 10X stock solution) or buffer were added to each well, and the cells were incubated at 37°C in a 5% CO2 incubator for another 14 hours. On the 5th day, after removing all culture medium from each well, Bright-Glo solution (Promega) (30 μl / well) was added, and the cells were incubated at room temperature for 5 minutes. Luminescence (relative luminescence unit (RLU)) was measured on a Victor 4X plate luminescence counter (PerkinElmer), and data analysis was performed using Graph Pad Prism.
[0618] Cytotoxicity assay
[0619] Cytotoxicity was determined by trypan blue exclusion assay and MTT assay using modified standard protocols. Human LAD-2MC and HTLA cells were seeded in 96-well plates (2.2 × 10 4Cells / well / 90 μL) were allowed to adhere or balance at 37°C in a 5% CO2 incubator for 24 hours. After 24 hours of incubation, the cells were treated with graded concentrations of antagonists (10 μl, 10x, 0-100 μM) at 37°C in a 5% CO2 incubator for 24 hours. In the trypan blue staining assay, after 24 hours of incubation, the cells were harvested, stained with trypan blue, and live and dead cells were counted using a LUNA automatic cell counter (vector biosystems). For the MTT assay, a 20 μl volume of MTT solution (5 mg / mL in phosphate buffer solution) was added to each well and the cells were incubated at 37°C in a 5% CO2 incubator for 4 hours. For LAD-2 cells, the plate was centrifuged at 500 g for 5 minutes, the culture medium was aspirated, and for HTLA cells, the culture medium was directly aspirated. Formazan crystals were dissolved by adding 150 μL MTT solvent (4 mM HCL + 0.1% NP-40 in isopropanol) to each well and incubated in a 4 ° C shaker for 15 minutes. Finally, the intensity of dissolved formazan crystals (purple) was quantitatively measured at 540 nm using a Victor 4X microplate reader (PerkinElmer). % cell viability was calculated by comparing the OD of drug treatment with control cells and plotted in GraphPad Prism software. Control cells were LAD-2 & HTLA treated with a solvent (DMSO) instead of compounds.
[0620] Intracellular Ca 2+ Flux determination
[0621] Intracellular Ca was measured in human LAD-2 MCs using the Fluo-4 NW calcium assay kit and the manufacturer's protocol (Molecular Probes, Invitrogen, USA). 2+ Briefly, LAD-2 cells were cultured at 1 x 10 5Cells / well / 40 μL density was plated in a 96-well black well plate (SPL Life Sciences) and incubated in a 37°C incubator for 1 h. After 1 h, 40 μL of 2X dye-loaded solution and antagonist or buffer were added to the cells (10 μL, 10X stock solution). The cells were incubated at 37°C in a 5% CO2 incubator for 30 minutes, followed by another 30 minutes. After incubation for 1 hour, graded concentrations of agonist or buffer were added to the cells (10 μL, 10X stock solution). Fluorescence was measured for 150 seconds using a Victor 4X microplate reader (PerkinElmer) at an excitation wavelength of 494 nm and an emission wavelength of 516 nm. ΔF was calculated by subtracting the maximum wavelength (after adding agonist C48 / 80) from the minimum fluorescence (before adding agonist) and plotted using Graph Pad Prism.
[0622] Monocyte chemoattractant protein-1 (MCP-1) and prostaglandin D-2 (PGD2) measurements
[0623] MCP-1 and PGD2 were measured from human LAD2 MCs by a single ELISA kit. Briefly, 1.5 × 10 5 MCs were seeded in complete Stem-Pro 34 medium in 96-well plates at a density of cells / 80 μL / well. MCs were balanced for 1-2 hours and treated with 10 μL 10X small molecule compound antagonists of different concentrations, incubated for 30 minutes at 37°C in a 5% CO2 incubator. For MCP-1 measurements, after 30 minutes, cells were treated with agonist 100 g / ml C48 / 80 (10 μL, 10X stock solution) and incubated for 6 hours at 37°C in a 5% CO2 incubator. Cells were centrifuged to collect supernatants and stored at -80°C until analysis. For PGD2 measurements, after 1 hour of antagonist treatment, cells were treated with agonist 30 g / ml C48 / 80 (10 μL, 10X stock solution) and incubated for 24 hours at 37°C in a 5% CO2 incubator. After 24 hours, cells were centrifuged to discard the culture medium and dissolved by ultrasonic treatment with 0.1 M potassium phosphate. Supernatants of cell lysates were collected and stored at -80°C until analysis. MCP-1 (Abcam, Cambridge, UK) and PGD2 (Cayman Chemicals, MI, USA) were quantified by ELISA according to the manufacturer's instructions.
[0624] result
[0625] Preliminary screening of small molecule antagonists by in vitro MC degranulation and MRGPRX2 activation assays
[0626] MC degranulation is an event that releases preformed / de novo mediators and develops edema and lesions during allergic reactions. MC granules store a potent mixture of preformed inflammatory mediators such as histamine, heparin, serotonin, tryptase, and chymase. In addition, several de novo synthesized mediators such as prostaglandins are derived from the precursor molecule arachidonic acid. To evaluate the antagonistic activity of the new small molecule compound antagonists synthesized, human MCs were subjected to a MC degranulation functional assay (% β-hexosaminidase release) ( Figure 4A ). To evaluate the specific activity of MRGPRX2, the MRGPRX2-Tango-β arrestin recruitment assay was performed on HTLA cells transfected with MRGPRX2-Tango ( Figure 4B For the initial screening, antagonists and vehicle controls (DMSO 1% & 2%) were used at concentrations of 50 μM and 100 μM. In both the MC degranulation and MRGPRX2-Tango activation assays, the MRGPRX2 agonist C48 / 80 was used at a concentration of 10 μM, which is based on the 90% maximal response effective concentration (~EC90) of C48 / 80 ( Figure 4C and 4D Small molecule antagonists have been shown to significantly inhibit MC degranulation at both concentrations ( Figure 4A ) and MRGPRX2 activation (****P<0.001) ( Figure 4B ). There was no significant difference in the activity of DMSO vehicle in C48 / 80-induced MC degranulation and MRGPRX2 activation, indicating that there is no DMSO vehicle activity in these bioassays. Preliminary screening results showed that the antagonistic potential of small molecule compound antagonists is comparable to that of genistein. In addition, to examine the intrinsic antagonistic potential of small molecule compound antagonists, MC degranulation and MRGPRX2 activation assays were performed without treating cells with the agonist C48 / 80. There were no significant changes in MC degranulation and MRGPRX2 activation, indicating that the small molecule compound antagonists have no intrinsic activity ( Figure 4E and 4F ).
[0627] The half maximal inhibitory concentration (IC 50 )
[0628] Although several findings highlight the role of MC-MRGPRX2 activation in the etiology of pseudoallergic diseases, there are currently no specific antagonists available for the prevention or treatment of pseudoallergic reactions. Several natural compounds have been tested for their MRGPRX2 antagonistic activity; however, low potency and poor efficiency are primary issues for drug development. The IC values of synthetic small molecule compound antagonists (GE0117, GE0118, GE0119, GE1109, GE1110, and GE1111) were evaluated using graded concentrations (0–100 μM). 50 , and through MC degranulation ( Figures 5A-5H ) and MRGPRX2 activation assay ( Figures 6A-6H ) to obtain dose response curves. Genistein was used as a positive reference standard. At concentrations up to 100 μM, the small molecule compound antagonists did not show any cytotoxicity to human LAD-2MC and HTLA cells by cell viability (using trypan blue, data not shown) and MTT assays (data not shown).
[0629] In both assays, the antagonists showed concentration-dependent inhibition of MC degranulation and MRGPRX2 activation with IC 50 In the millimolar concentration range (Table 3), it is noteworthy that in the functional MC degranulation assay, compared with genistein (IC 50 ; 30.32 μM), GE1109 (IC 50 ; 9.87 μM) and GE1111 (IC 50 ; 4.70 μM) showed significant inhibitory activity. However, in contrast, the antagonist GE0119 (IC 50 ; 25.49 μM) and GE1110 (IC 50 ; 23.42 μM) showed inhibitory activity comparable to genistein in MC degranulation. The basal level of MC degranulation was not altered by graded concentrations of the small molecule compound antagonists, indicating no inherent agonist activity. In the receptor activation assay, GE1109 and GE1111 showed IC values of 7.14 μM and 9.42 μM, respectively. 50 , while the IC of genistein 50 31.70 μM. Moreover, to verify the MRGPRX2-dependent effects of fixed concentrations of C48 / 80 and small molecule compound antagonists, mock-transfected HTLA cells were treated with C48 / 80 and graded concentrations of antagonists. No luminescent response was recorded in these cells, indicating that the small molecule compound antagonists have MRGPRX2-dependent activity. GE0117, GE1109 and GE1111 showed potent antagonistic activity in both MC degranulation and MRGPRX2 activation assays.
[0630] Table 3: ICs of novel small molecule compound antagonists calculated by human MC degranulation and MRGPRX2 activation assays 50 concentration
[0631]
[0632] Small molecule antagonists of intracellular Ca 2+ Evaluation of the role of flux
[0633] MRGPRX2 activation leads to intracellular Ca 2+ The rapid increase in flux decays very slowly and is preceded by a decrease in intracellular Ca 2+ Compared with other GPCRs, MRGPRX2 induces a sustained Ca 2+ The flux response is unique because most other GPCRs induce transient Ca 2+ The response, due to its rapid desensitization and internalization, returned to baseline almost immediately. 2+ To investigate the effect of flux activation, LAD2MCs were treated with different antagonist concentrations and subsequently stimulated with C48 / 80 and Ca2+ was measured. 2+ Small molecule antagonists do not induce Ca 2+ Flux (data not shown). C48 / 80 treatment induced significant ( #### P<0.0001)Ca 2+ Antagonists GE0117, GE0118, GE0119, GE1109, GE1110 and GE1111 showed significant Ca flux. 2+ The concentration-dependent decrease in flux ( Figure 7 ). Among them, GE0117, GE1109, GE1110 and GE1111 showed high efficacy at all three concentrations (12.5 μM, 25 μM and 50 μM, ****P<0.0001). Genistein was used as a reference standard and showed significant (**P<0.001) Ca 2+ The flux is reduced. 2+ Flux assays showed potent antagonistic activity against early MC activation. 2+ entry, SOCE), reported that stromal interaction molecule 1 (STIM1) is involved in the activation of MRGPRX2; without being bound by any theory, the antagonist may exert its effect by modulating the activity of SOCE-STIM1 in MCs.
[0634] Dose response curves (EC50 & E50) of small molecule antagonists to compound 48 / 80 by MC degranulation assay and MRGPRX2 activation assay max )
[0635] C48 / 80 activated MCs via MRGPRX2 in a dose-dependent manner; dose-dependent activation of MCs was measured by MC degranulation assay and MRGPRX2 activation assay. To compare the efficacy of all small molecule compound antagonists, human LAD2 MC cells and MRGPRX2-transfected HTLA cells were treated with a fixed concentration (10 μM) of antagonist followed by graded concentrations of the agonist C48 / 80 ( Fig. 8A and 8B ). Compared with genistein, antagonists GE0117, GE1109 and GE1111 significantly antagonized C48 / 80-induced MC degranulation and MRGPRX2 activation, as shown by changes in EC50 and Emax (Table 4).
[0636] Table 4: EC values of the dose-dependency curve (DRC) of C48 / 80 calculated for small molecule antagonists as determined by human MC degranulation and MRGPRX2 activation assays 50 and E max Changes
[0637] In the MC degranulation assay of C48 / 80, GE0117, GE1109 and GE1111 increased the EC of C48 / 80 by 50 from 4.61 μM to 8.97 μM, 11.38 μM and 20.85 μM, and the E of C48 / 80 max Reduced by 29.56%, 20.93% and 72.75 ( Fig. 8A and 8B and Table 4). In addition, in the receptor activation assay, the antagonists GE0117, GE1109 and GE1111 50 and E max Showed good efficacy ( Fig. 8A and 8B and Table 4).
[0638] Evaluation of the effects of small molecule antagonists on human monocyte chemoattractant protein-1 and prostaglandin D2 levels
[0639] MC activation involves the induction of Ca 2+Small molecule compound antagonists (such as GE0117, GE1109 and GE1111) have an inhibitory effect on the early stage of MC activation (MC degranulation and Ca flux and degranulation) and the late stage of inducing the production and release of inflammatory chemokines or cytokines. 2+ To test whether the potent antagonists GE0117, GE1109, and GE1111 could modulate the late phase of MC activation, the release and production of monocyte chemoattractant protein-1 (MCP-1) and prostaglandin D2 (PGD2) were examined. C48 / 80 activated human LAD2 MCs and increased the production of MCP-1 and PGD2 compared to basal levels ( #### P < 0.0001)( Fig.9A and 9B ). MCP-1 plays a role in recruiting other inflammatory cells such as monocytes, neutrophils, and lymphocytes, and induces chemotaxis through the activation of G protein-coupled receptors. PGD2 is an important prostaglandin that is primarily produced by MCs in response to allergic or inflammatory stimuli. PGD2 production begins with the release of arachidonic acid from membrane phospholipids by phospholipase A2 in response to inflammatory stimuli. PGD2 plays a role in inducing vasodilation and increasing permeability in several allergic inflammatory diseases. Compared with the C48 / 80 control, treatment of MCs with the antagonists GE0117 or GE1111 significantly inhibited the release of MCP-1 at all tested concentrations (12.5 μM, *P<0.05; 25 μM, **P<0.01; and 50 μM, ***P<0.001), while GE1109 showed significant activity only at 25 μM and 50 μM (*P<0.05). The experimental results showed that small molecule compound antagonists have potent activity in inhibiting the release of pre-stored inflammatory mediators (MCP-1) and de novo synthesized inflammatory mediators (PGD2), expanding their therapeutic role in the treatment of allergic and inflammatory diseases with MC activation.
[0640] Example 3. Compounds show antiallergic activity in animal models.
[0641] Materials and methods
[0642] Local allergic / pseudoallergic activity in vivo
[0643] Young adult male mice (C57 / BL / 6N, 6-8 weeks old, n=6 / group) are used to measure local allergic activity by measuring the Evans blue tissue exudation in the claw tissue and ear tissue. Animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR) (animal ethics approval number CULATR 5125-19) in teaching and research. Mice were anesthetized by intraperitoneal injection of ketamine and xylazine, and the claw thickness was measured using a vernier caliper. Antagonists (GE0117, GE1109 and GE1111) at a dose of 5 mg / kg body weight were injected by intraperitoneal injection, followed by a tail vein injection of 50 μL of 12.5% Evans blue in saline (regardless of body weight). Thirty minutes later, C48 / 80 (10 μL, 30 μg / ml) was injected into one claw and ear, while saline was injected into other claws and ears as negative controls. Fifteen minutes later, the claw and ear tissues were photographed and the claw thickness was measured again to calculate the % increase in claw thickness. The mice were euthanized by cervical dislocation under anesthesia, and the collected claw and ear tissues were dried at 50°C for 24 hours and weighed separately. Evans blue was extracted with formamide (500 μL / tissue) by incubation at 50°C for 24 hours. The supernatant was aliquoted into 96 well plates (200 μL / well, in duplicate), and OD was measured at 595nm using a Victor 4X microplate reader (PerkinElmer).
[0644] Absorbance values were normalized per gram dry weight of each paw tissue to quantify Evans blue extravasation.
[0645] Systemic allergic activity in vivo
[0646] Animals (C57 / BL / 6N, 6-8 weeks old, n=6-8 / group) were transported to the surgical area one day before injection to reduce stress. Antagonists (GE0117, GE1109 or GE1111) or vehicle were injected intraperitoneally, and mice were kept in cages for 30 minutes. 8mg / kg C48 / 80 was injected intraperitoneally 30 minutes after injection of saline (negative control). According to AAALAC guidelines, the volume of intraperitoneal injection is 10ml / kg body weight. The injection site was wiped with cotton soaked in 70% alcohol, and mice were placed in separate cages, one mouse per cage. The core body temperature was measured with an infrared non-contact thermometer every hour before injection (basal) and after injection. At the same time, the allergic symptoms / severity of mice were monitored after injection of C48 / 80 and scored from 0-5 for 1 hour or until death, whichever comes first. Briefly, the scoring system is as follows: 0, no symptoms; 1, scratching and rubbing around the nose and head; 2, periocular and perioral edema, diarrhea, pilar erecti, decreased activity and / or decreased activity with increased respiratory rate; 3, panting, dyspnea, cyanosis around the mouth and tail; 4, no activity or trembling, convulsions after stimulation; 5, death. The core body temperature and allergy score were plotted using Graph Pad Prism.
[0647] Histological analysis
[0648] Mice were anesthetized with ketamine / xylazine and injected intraperitoneally with antagonists (GE0117, GE1109 and GE1111) at a dose of 5mg / kg body weight. After 30 minutes, C48 / 80 (10 μL, 30 μg / ml) and saline (as negative control) were injected into the ear. After 15 minutes, mice were killed, the injection site of the ear was sliced, washed with PBS, and fixed with 10% buffered formalin for 24 hours. After 24 hours, ear tissue was dehydrated at 4°C in graded concentrations of ethanol (30%, 50% and 70% ethanol per 24 hours). Subsequently, tissue was processed in an automatic tissue processor (Leica ASP300) and embedded in paraffin using an embedding center (Embedding Centre) (Leica EG1150). Paraffin-embedded tissue was sliced with 5 μM size using a fully automatic microscope slicer (Leica RM2265). The tissue sections were stained with H&E using an automated tissue section stainer (LeicaST5020) using a standard staining procedure. After staining, the slides were dried under a fume hood and fixed with DPX. For MC detection, Toluidine blue O staining was performed on the ear tissue of the sections according to available online protocols (http: / / www.ihcworld.com / _protocols / special_stains / toluidine_blue.htm). Images were captured at 10 times and 20 times magnification using a Nikon Eclipse Ni-U upright microscope and a Nikon DS-Ri2 microscopic camera (Nikon Corporation, Tokyo, Japan).
[0649] Statistical analysis
[0650] Unless otherwise specified, data are presented as mean ± SEM of at least three independent experiments. Plots were made using Prism 7.0 software (GraphPad Software Inc.). Data were analyzed using analysis of variance (ANOVA), two-tailed test, and Tukey's multiple comparison test. P < 0.05 values were considered significant.
[0651] result
[0652] Evaluation of potent small molecule antagonists in an in vivo mouse model of localized allergic / pseudoallergic reactions
[0653] MRGPRB2 is the mouse orthologous receptor of human MRGPRX2, showing an agonistic response to C48 / 80 similar to its human counterpart. In vitro experiments have verified the efficacy of small molecule compound antagonists. Next, the in vivo mouse model of local pseudoallergic reaction induced by C48 / 80 was tested. This model is a widely used animal model for evaluating the activity of drugs (agonists / antagonists) on pseudoallergic reactions induced by MRGPRB2 / MRGPRX2. Evans blue dye was injected intravenously to visualize vascular permeability and quantify exudation / edema. Mice treated with vehicle control or antagonist treatment were injected with normal saline or C48 / 80 (5 mg / kg body weight, intraperitoneal injection) in their respective ears and claws. Paw thickness and Evans blue exudation (an indicator of MC degranulation) were assessed. Genistein was used as a positive control. Significant increases in paw thickness ( FIG. 10A ; paw images not shown) and Evans blue dye extravasation (indicative of vascular leakage) were observed in the ears and paws of C48 / 80-treated mice compared to saline-treated mice (###p<0.001) ( Fig. 10B and Fig.11 ; paw and ear images not shown). However, this response was significantly reduced in the antagonist-treated mice. The small molecule compound antagonists GE0117 and GE1111 significantly (***P<0.001) attenuated the increase in paw thickness and Evan's blue dye extravasation compared with C48 / 80 mice ( Fig. 10A and 10B ). GE1109 and genistein also showed significant (*P<0.05) antagonistic activity compared with C48 / 80 mice. Among them, GE0117 and GE1111 showed potent antagonistic activity compared with genistein. The C48 / 80-induced pseudoallergic mouse model represents the acute phase of MC reaction (degranulation) due to its short duration and acute nature. The accumulation of vascular fluid in the paw tissue is due to the release of MC mediators, leading to vasodilation and vascular leakage. Therefore, the reduction in paw edema observed after antagonist treatment may be achieved by inhibiting MC activation. The in vivo results are consistent with the in vitro findings, showing the therapeutic potential of small molecule compounds for local allergic reactions.
[0654] Evaluation of potent small molecule antagonists in an in vivo systemic allergy mouse model
[0655] Anaphylactic shock is a sudden, life-threatening systemic allergic reaction characterized by hypothermia, scratching, edema, respiratory distress, etc., which can occur within minutes after contact with allergens. Monitor the body temperature and allergic symptoms of mice for 1 hour or until death. After 30 minutes of vehicle and antagonist / genistein treatment (5 mg / kg body weight, intraperitoneal injection), mice were injected with C48 / 80 (8 mg / kg body weight, intraperitoneal injection). Genistein was used as a positive control. In animal models of systemic anaphylaxis, the endpoint is death because it has a sudden and fatal nature and may lead to death. However, no deaths were observed in all experimental groups 1 hour after C48 / 80 injection. Compared with saline-treated mice, body temperature was significantly reduced 10 minutes after injection of C48 / 80 in the C48 / 80 control group (##p<0.01). The maximum decrease in body temperature in the C48 / 80-treated group occurred at 20 minutes (#####p<0.0001), while there was no change in body temperature in the saline-treated group. The small molecule compound antagonists GE1109 (*p<0.05) and GE1111 (*p<0.01) reversed the C48 / 80-induced changes in body temperature at 30 minutes. At 35 minutes, all antagonist treatment groups GE0117 (*p<0.05), GE1109 (**p<0.01), GE1111 (****p<0.0001) and genistein (*p<0.05) significantly reversed the changes in body temperature in the C48 / 80-treated group (Figure 12A). In addition, compared with saline-treated mice, C48 / 80-treated mice showed severe allergic symptoms (wheezing, dyspnea and cyanosis around the mouth, and no activity after stimulation) ( Fig. 12B ). The GE1111 (**p<0.01) treatment group restored the severity of hypothermia and allergic symptoms induced by compound 48 / 80. The other antagonist treatment groups showed fewer allergic symptoms, but there was no significant difference from the C48 / 80 treatment group mice ( Fig. 12B ).
[0656] Evaluation of the effects of potent small molecule antagonists on histological changes and MC degranulation in vivo
[0657] To evaluate the effects of small molecule compound antagonists on C48 / 80-induced histological changes and MC degranulation in vivo, ear tissues were subjected to H&E staining and toluidine blue staining, respectively. In the H&E ear staining of the vehicle + C48 / 80 experimental group, mice in the experimental group treated with the vehicle showed more inflammation (thickness) and cellular infiltration. The degree of inflammation and infiltration in the experimental mice treated with the antagonist was reduced compared with the C48 / 80-treated group (images not shown). To evaluate the in vivo antagonistic effect, C48 / 80-induced MC degranulation in ear tissue was studied. The number of degranulated MCs and non-degranulated MCs in 20x magnified ear sections of mice in each experimental group was measured. Degranulated MCs are distinguished from non-degranulated cells by the reduced intensity of toluidine blue staining, and the cytoplasmic granules are dispersed. Although there was no significant difference in the total number of MCs in the experimental group mice treated with the vehicle and antagonist (data not shown), the percentage of degranulated MCs in the C48 / 80-treated group was significantly higher ( #### p<0.0001). Compared with the C48 / 80 treatment group, GE1107 ( ** p<0.01), GE1109( ** p<0.01) and GE1111( **** p<0.0001) treatment reduced MC degranulation ( Fig.13 ; images not shown). These histological results validate the potential of small molecule antagonists in inhibiting MC-induced pseudoallergic inflammation in vivo.
[0658] In summary, small molecule compound antagonists for the treatment of non-IgE MRGPRX2-mediated pseudoallergic reactions have been identified based on computational and experimental pharmacological approaches. The results show that small molecule compound antagonists, especially GE0117, GE1109 and GE1111, are potent candidate drugs with inhibitory activity on MRGPRX2-mediated MC degranulation, calcium influx, inflammatory cytokines, angioedema, inflammation and systemic allergic reactions. Given that MC-MRGPRX2 activation plays a role in the etiology of pseudoallergic reactions to several FDA-approved drugs, endogenous and exogenous peptides, and asthma-related chronic inflammation, the small molecule compound antagonists developed herein can be used as treatment options for these conditions.
[0659] References
[0660] Solensky and Khan,Annals of allergy,asthma&immunology,2010.105 (4):p.259-273.
[0661] Porebski,G.,et al.,Frontiers in immunology,2018.9:p.3027.
[0662] Yuan,F.,et al.,Biomedicine&Pharmacotherapy,2021.137:p.111323.
[0663] Navinés-Ferrer,A.,et al.,Scientific reports,2018.8(1):p.1-11.
[0664] Gell,P.,Clinical aspects of immunology,1963:p.317-337.
[0665] Rajan,T.,TRENDS in Immunology,2003.24(7):p.376-379.
[0666] et al.,Acta dermatovenerologica Croatica,2009.17(1):p.0-0.
[0667] He,S.-h.,et al.,Acta Pharmacologica Sinica,2013.34(10):p.1270-1283.
[0668] Krystel-Whittemore,M.,et al.,Frontiers in immunology,2016.6:p.620.
[0669] Atanaskovic-Markovic,M.,et al.,Pediatric Allergy and Immunology,2019.30(3):p.269-276.
[0670] Ben-Shoshan and Clarke,Allergy,2011.66(1):p.1-14.
[0671] Kumar,M.,et al.,Molecules,2020.25(5):p.1028.
[0672] Ding,Y.,et al.,International immunopharmacology,2019.66:p.185-197.
[0673] Callahan,B.N.,et al.,Frontiers in Immunology,2020.11:p.703.
[0674] Bulfone-Paus,S.,et al.,Trends in immunology,2017.38(9):p.657-667.
[0675] Subramanian,H.,et al.,Journal of Allergy and Clinical Immunology,2016.138(3):p.700-710.
[0676] Motakis,E.,et al.,Blood,2014.123(17):p.e58-e67.
[0677] McNeil,B.D.,et al.,Nature,2015.519(7542):p.237-241.
[0678] Dong,X.,et al.,Cell,2001.106(5):p.619-632.
[0679] Demoly,P.,et al.,Allergy,1999.54(5):p.500-506.
[0680] Ogasawara,H.,et al.,Journal of leukocyte biology,2019.106(5):p. 1069-1077.
[0681] Kühn,H.,et al.,Journal of Allergy and Clinical Immunology,2020.
[0682] Babina,M.,Itch,2020.5(2):p.e32.
[0683] Berman,H.M.,et al.,Nucleic Acids Res,2000.28:p.235-242.
[0684] Lansu,K.,et al.,Nature chemical biology,2017.13(5):p.529-536.
[0685] Reddy,V.B.,et al.,Journal of Allergy and Clinical Immunology,2017.140(6):p.1726-1728.
[0686] Trott,O.and A.J.Olson,Journal of computational chemistry,2010.31(2):p.455-461.
[0687] Read,G.W.,et al.,Journal of medicinal chemistry,1973.16(11):p. 1292-1295.
[0688] Aridor,M.,et al.,The Journal of cell biology,1990.111(3):p.909-917.
[0689] Bueb,J.-L.,et al.,Mol Pharmacol,1990.38(6):p.816-822.
[0690] Mousli,M.,et al.,Immunology letters,1990.25(4):p.355-357.
[0691] Sunseri,and Koes,Nucleic acids research,2016.44(W1):p. W442-W448.
[0692] Hughes,J.P.,et al.,British journal of pharmacology,2011.162(6):p.1239-1249.
[0693] Lipinski,C.A.,et al.,Advanced drug delivery reviews,1997.23(1-3):p.3-25.
[0694] Kroeze,W.K.,et al.,Nature structural&molecular biology,2015.22(5):p.362-369.
[0695] Subramanian,H.,et al.,Journal of Biological Chemistry,2011.286(52):p.44739-44749.
[0696] Occhiuto,C.J.,et al.,Frontiers in immunology,2020.10:p.3143.
[0697] Ferguson,S.S.,Pharmacological reviews,2001.53(1):p.1-24.
[0698] Arima,M.and T.Fukuda,The Korean journal of internal medicine, 2011.26(1):p.8.
[0699] Castellani,M.,et al.,2009,SAGE Publications Sage UK,London, England.
[0700] Jimenez-Rodriguez,T.W.,et al.,Journal of asthma and allergy,2018.11:p.121.
[0701] Yoon,T.J.,et al.,International immunopharmacology,2013.15(4):p. 666-670.
[0702] Che,T.,et al.,Cell,2018.172(1-2):p.55-67.e15.
[0703] Singh,K.,et al.,Plos one,2016.11(3):p.e0149359.
[0704] Webb,B.and A.Sali,Current protocols in bioinformatics,2016.54(1):p.5.6.1-5.6.37.
[0705] Prisant,M.,et al.,Proteins,2003.50:p.437-450.
[0706] Hanwell,M.D.,et al.,Journal of cheminformatics,2012.4(1):p.17.
[0707] Dallakyan,S.and A.J.Olson,Chemical biology,2015,Springer.p. 243-250.
[0708] Ding,Y.,et al.,Computational biology and chemistry,2016.64:p. 403-413.
[0709] Mashiach,E.,et al.,Nucleic acids research,2008.36(suppl_2):p. W229-W232.
[0710] Schrodinger,L.,Version,2010.1(5):p.0.
[0711] Release,S.,Maestro-Desmond Interoperability Tools, NewYork,NY,2017.
[0712] Biovia,D.S.,Discovery studio modeling environment,2017,Release.
[0713] Daina,A.,et al.,Scientific reports,2017.7(1):p.1-13.
[0714] Lipinski,C.A.,Journal of pharmacological and toxicological methods,2000.44(1):p.235-249.
[0715] M.,et al.,Current Protocols in Immunology,2010.90(1):p.7.37.1-7.37.12.
[0716] Kroeze,WK,et al.,Nature Structural&Molecular Biology,2015.22(5):p.362.
[0717] Slater,T.,et al.,Biochemistry and Biophysics Acta,1963.77:p.383-393.
[0718] Alley,MC,et al.,Cancer Research,1988.48(3):p.589-601.
[0719] Shin,T.,et al.,Journal of Ethnopharmacology,2001.74(2):p.133-140.
[0720] Li,X.-M.,et al.,Journal of Allergy and Clinical Immunology, 2000.106(1):p.150-158.
Claims
1. A compound having the following structure: in, X' is C or N; Each occurrence of R3 is independently hydrogen, straight chain C1-C 10 Alkyl, branched C3-C 10 Alkyl, cyclic C3-C 10 Alkyl, aldehyde, oxo, hydroxyl or carboxyl; R4 is independent each time it appears R5 to R 10 Independently hydrogen, straight chain C1-C 10 Alkyl, branched C3-C 10 Alkyl or cyclic C3-C 10 alkyl.
2. A compound having the following structure:
3. Pharmaceutical preparations, including: One or more compounds of claim 1 or 2; and a pharmaceutically acceptable excipient, The one or more compounds are in an effective amount to prevent or treat pseudoallergy, pseudoallergic disease or pseudoinflammatory disease in a subject, or to treat or alleviate one or more symptoms associated with pseudoallergy, pseudoallergic disease or pseudoinflammatory disease.
4. The pharmaceutical formulation of claim 3, further comprising a second active agent.
5. The pharmaceutical formulation of claim 3, further comprising more than one second active agent.
6. The pharmaceutical formulation of claim 4 or 5, wherein the second active agent is an anti-allergic agent or an anti-inflammatory agent or a combination thereof.
7. A method for preparing the compound of claim 1, comprising (i) mixing a reactant mixture with a catalyst to form a reaction mixture, wherein the reactant mixture comprises a first reactant, a second reactant, and a solvent; and (ii) heating the reaction mixture at a suitable temperature and for a period of time sufficient to form a product comprising a compound of claim 1, wherein step (i) is performed before step (ii) or simultaneously with step (ii), in, The first reactant has a structure shown in the following formula: in, X' is C or N; Each occurrence of R3 is independently hydrogen, straight chain C1-C 10 Alkyl, branched C3-C 10 Alkyl, cyclic C3-C 10 Alkyl, aldehyde, oxo, hydroxyl or carboxyl; R 11 is halogen, dinitrogen, dialkyl ether, perfluoroalkyl sulfonate, toluene sulfonate, mesylate, sulfonate, alcohol, nitrate, phosphate, inorganic ester, thioether, amino, carboxylate, phenoxide, hydroxide, alkoxy, amide, hydride, arsenide or alkyl, or R 11 Has the structure of Formula XIV: Where R 12 Each occurrence is independently hydrogen or C1-C 10 Alkyl, and The second reactant has a structure shown in the following formula: Among them, R4 appears independently each time R5 to R 10 Independently hydrogen, straight chain C1-C 10 Alkyl, branched C3-C 10 Alkyl or cyclic C3-C 10 alkyl, R 13 is a triflate or has the structure of Formula XIV.
8. The method of claim 7, wherein the solvent is water, dioxane, dimethoxyethane, 2-methyltetrahydrofuran, cyclopentyl methyl ether, tetrahydrofuran, tert-butyl methyl ether or dichloromethane or a combination thereof.
9. The method of claim 7, wherein the catalyst is PdCl2(dppf), PdCl2(dppf)DCM complex, Tetrakis, PdCl2(PPh3)2, XPhos Pd G3 or Pd(OAc)2 / PPh3 or a combination thereof.
10. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 50°C to 150°C.
11. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 60°C to 150°C.
12. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 70°C to 150°C.
13. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 80°C to 150°C.
14. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 50°C to 140°C.
15. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 50°C to 120°C.
16. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 70°C to 120°C.
17. The process of claim 7, wherein in step (ii), the reaction mixture is heated at a temperature in the range of 80°C to 120°C.
18. The process of claim 7, wherein in step (ii), the reaction mixture is heated at 100°C.
19. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 1 hour.
20. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 2 hours.
21. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 3 hours.
22. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 4 hours.
23. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 5 hours.
24. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 6 hours.
25. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 8 hours.
26. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of at least 10 hours.
27. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of up to 20 hours.
28. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of up to 7 hours.
29. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of up to 16 hours.
30. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of time ranging from 1 hour to 7 hours.
31. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of 2 hours to 16 hours.
32. The process of claim 7, wherein in step (ii), the reaction mixture is heated for a period of 2 hours to 15 hours.
33. The method of claim 7, further comprising mixing the first reactant, the second reactant, and the solvent to form the reactant mixture prior to step (i), purging the reactant mixture with an inert gas prior to step (ii), stirring the reaction mixture during step (ii), and / or purifying the product containing the compounds.
34. Use of the pharmaceutical preparation of claim 3 in the preparation of a medicament for preventing or treating pseudoallergic reactions, pseudoallergic diseases and / or pseudoinflammatory diseases, or treating or alleviating one or more symptoms associated with pseudoallergic reactions, pseudoallergic diseases and / or pseudoinflammatory diseases in a subject in need thereof, wherein: The pharmaceutical formulation is administered to the subject one or more times.
35. The use of claim 34, wherein Only a single administration of the pharmaceutical formulation is performed, wherein the pharmaceutical formulation comprises an effective amount of the compound to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage and / or prevent or reduce MC degranulation in the subject.
36. The use of claim 34, wherein The pharmaceutical formulation is administered to the subject more than once, wherein after all administrations, an effective amount of the compound to prevent or reduce inflammation, prevent or reduce allergic symptoms, prevent or reduce tissue damage and / or prevent or reduce MC degranulation in the subject is administered to the subject.
37. The use of claim 34, wherein the subject is a mammal.
38. The use of claim 34, wherein the pharmaceutical formulation is administered by oral administration, parenteral administration, inhalation, mucosal administration, topical administration, or a combination thereof.
